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ABSTRACT 
 
 
UNDERSTANDING ELEMENTS INVOLVED IN ACTIVE RACIAL AND ETHNIC 
MINORITY RECRUITMENT PRACTICES FOR BIOPHARMACEUTICAL-
SPONSORED CLINICAL TRIALS: 
A SOCIO-ECOLOGICAL QUALITATIVE INQUIRY 
by 
REBECCA RAE JOHNSON 
Seton Hall University 
2020 
Dissertation Chair: Terrence Cahill, Ed.D., FACHE 
 
 
Inequitable participation in clinical trials continues to be a problem, and trial populations 
do not always reflect the demographics of the population that the investigational product will 
ultimately be treating. Because genetic differences between racial and ethnic groups affect the 
safety and efficacy of new treatments, it is important that standard of care decisions are made 
based on a representative population. The purpose of this study is to understand the socio-
ecological elements that are involved in the active implementation of racial and ethnic minority 
recruitment practices for biopharmaceutical-funded trials in the United States. This general 
qualitative study was both descriptive and exploratory in nature and utilized semi-structured, in-
depth interviews for data collection. The socio-ecological model was utilized as the conceptual 
framework guiding this study (McLeroy, Bibeau, Stecker, & Glanz, 1988). The interview guide 
was designed to explore the perceptions, practices and experiences of 15 clinical research site 
professionals related to recruiting racially and ethnically diverse trial participants. Data analysis 
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utilized a coding process in which data were coded inductively. Codes were classified according 
to the socio-ecological model. Following data analysis, 20 themes emerged from information 
pertaining to the actual implementation of minority recruitment practices. These 20 themes 
represent each level of the socio-ecological model and provide explanations for intrapersonal, 
interpersonal, organizational, community and policy components. A holistic view that facilitates 
a comprehensive understanding of effective minority recruitment practices is offered after 
considering the interaction of the components at all levels of the socio-ecological model. These 
multi-faceted findings reveal that an ecological perspective offers insight into improving access 
to clinical trials by focusing on environmental change initiatives, rather than individual change 
on a patient level. This study’s findings offer practical guidance for the implementation of 
change initiatives in minority recruitment practices at research sites. The results of this study 
demonstrate that environmental change can provide a premise for improving access to clinical 
trials among minority populations.  
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Chapter I
 
INTRODUCTION 
 
 
Currently, racial and ethnic minority populations are underrepresented as participants in 
most clinical trials (CISCRP, 2017; Diehl et al., 2011; Duda et al., 2011; Killien et al., 2000; 
Martin, Negron, Balbierz, Bickell, & Howell, 2013; Murthy, Krumholz, & Gross, 2004; The 
Society for Women’s Health Research & FDA, 2011). Aggravated by the fact that health 
disparities also disproportionately affect racial and ethnic minorities (USHHS, Centers for 
Disease Control and Prevention [CDC], 2011a; USHHS, CDC, 2011b), clinical trial results need 
to be generalizable to a wider population that includes racial and ethnic minority groups, women, 
and the elderly. To gain insight into improving health outcomes, it is imperative to have equal 
representation of all members of the applicable population subgroups represented in clinical 
trials. Many known barriers to minority recruitment into clinical trials contribute to this problem, 
yet successful strategies used in biopharmaceutical-sponsored trials to address those barriers are 
not documented in the literature. Additionally, it is important to understand how research site 
staff and organizational characteristics may play a role in the successful recruitment of these 
underrepresented populations. The purpose of this study is to explore the involvement of 
physical and social environmental elements when investigator sites actively focus on minority 
recruitment when conducting biopharmaceutical sponsored clinical trials. 
Background of the Problem 
Researchers conduct clinical trials to improve the standard of care for diseases and 
survival rates and health outcomes in patients. These trials are designed to evaluate the safety 
and efficacy of new therapies and to provide scientific evidence in support of decisions heath 
care practitioners must make about the care of all affected patients. This includes how new 
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therapies may affect women and members of various minority groups differently. Demographic 
profiles of clinical trial participants need to be representative of the disease prevalence in order 
for the results to be generalized to demographic subgroups (Diehl et al., 2011; Duda et al., 2011; 
USHHS, NIH, 2001; USHHS, NHLBI, 2011). In particular, it is important to test the efficacy 
and safety of potential new therapies across all racial and ethnic groups since genetic differences 
occur amongst various demographic populations. This leads to variations in drug metabolism and 
toxicity within different racial and ethnic groups (Hershman et al., 2003; Rotger, Csajaka, & 
Telenti, 2006). For example, while angiotensin-converting enzyme (ACE) inhibitors have been 
found to be effective in decreasing blood pressure in both African American and white patients 
with hypertension, African Americans respond less well than white patients to such treatments 
(Cohn et al., 2004). The first race-specific drug, BiDil® (isosorbide dinitrate and hydralazine 
hydrochloride), was approved by the Food and Drug Administration (FDA) in 2005 for the 
treatment of heart failure in African American patients when added to standard therapy. When 
analyzing data from clinical trials, researchers determined that African American and white 
patients had a different response to BiDil, with a treatment effect apparent in African American 
patients only (Brody & Hunt, 2006; Temple & Stockbridge, 2007). Additionally, a clinical trial 
examining the use of gefitinib in non–small-cell lung cancer was conducted. The investigators 
found through racial and ethnic molecular profiling that gefitinib works better than the standard 
of care in the treatment of patients with a specific mutation that occurs more frequently in Asian 
populations (Chen, Lara, Dang, Paterniti, & Kelly, 2014; Mok et al., 2009; Paez et al., 2004). 
Therefore, it is imperative that there is adequate participation in clinical trials of patients from 
racial and ethnic minorities so treatment effects are tested outside of adult white males, who 
represent the majority of clinical trial participants (CISCRP, 2017; Killien et al., 2000; The 
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Society for Women’s Health Research & FDA, 2011). More diverse representation in clinical 
trials ensures that study results can be of benefit to a wider population through the use of 
evidence-based medicine. 
Contributing to the problem.  
Drug development process. Several factors contribute to the lack of diversity in clinical 
trial participation. One probable contributor is the lengthy drug development process and the cost 
of bringing a drug to market (USHHS, OIG, 2000). The drug development process takes 
approximately 10 to 15 years from discovery through development (PhRMA, 2016, April). The 
average cost for each successful drug that goes to market is approximately $2.6 billion dollars 
(DiMasi, Grabowski, & Hansen, 2016). The drug development process is highly regulated. It 
begins with a discovery process where scientists choose a molecule to target a disease, find a 
drug candidate and conduct extensive laboratory tests and studies on animals to determine if the 
potential drug is safe to test in humans. This discovery process typically takes between 3 and 6 
years. If during the discovery process the researchers deem the drug safe and effective for testing 
in humans, the drug manufacturer must file an Investigational New Drug (IND) application with 
the FDA and submit their proposed clinical trial to the Institutional Review Board (IRB). Once 
approval is received, the manufacturer can then begin testing the safety and efficacy of the drug 
on humans through clinical trials (PhRMA, 2016, April). The drug must be tested in three phases 
of clinical trials before the manufacturer is able to submit a New Drug Application (NDA) to the 
FDA requesting approval to market the drug. During the Phase I clinical trial, researchers 
determine the safety, pharmacokinetics and pharmacodynamics of the drug in a small group 
(typically less than 100) of healthy volunteers. If researchers deem the drug safe for humans, 
they then conduct a Phase II trial. Researchers administer the drug to a group of 100 to 500 
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patients with the disease or condition for which the drug is being developed and gather additional 
safety data, examine side effects, determine the dosing strength, as well as determine if the drug 
is working by the expected mechanism of action. If the administration of the drug results in 
improvements in the condition or disease, the drug is then tested with a larger group of people 
with the disease (1,000 to 5,000 patients) to obtain statistically significant data about the safety, 
efficacy, and benefit versus risk of use of the drug. The three phases of clinical trials generally 
take 6 to 7 years for completion. Once the trials are complete and the drug is determined safe and 
effective for use in humans, the manufacturer submits an NDA to the FDA. The FDA takes 
between 6 months and 2 years to review the preclinical and clinical findings, proposed labeling, 
and manufacturing plans before they approve the drug for use in patients. Oftentimes, the FDA 
requires manufacturers to conduct Phase IV studies to evaluate long-term safety or to determine 
how the drug affects a certain subgroup of patients (PhRMA, 2016, April; USHHS, NIH, 2013a). 
Clinical trials play a key role in bringing new drugs to market (USHHS, OIG, 2000). 
Several trends in the biopharmaceutical industry are contributing to the need for completing 
clinical trials in the shortest time possible. There’s been an increase in pharmaceutical 
manufacturer’s research and development (R&D) activities. Combined with the lengthy and 
costly drug development process, biopharmaceutical manufacturers need to get their drugs to 
market quickly. Delays in clinical trial completion result in delays in getting the product to 
market. Every day that a drug is delayed in getting to market results in more than $1.4 million 
dollars of potential loss in future sales (assuming projected annual sales of $500 million). 
Further, clinical trial delays increase the cost of clinical development (IMS Health, 2012; 
Kermani & Bonacossa, 2003; USHHS, OIG, 2000). One of the critical factors in delaying 
clinical trials is not being able to recruit the necessary number of appropriate participants within 
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the study timeframe. As a result, 80% of trials are delayed due to difficulties in enrollment 
(Clinical Trial Arena, 2012; IOM, 2012). For example, recruitment goals were not met in time 
for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT), resulting in the need to double the amount of investigator sites and extend the 
recruitment period 1½ years and the follow-up period by an additional year in order to achieve 
sufficient power (Pressel et al., 2001). Furthermore, half of all research sites under-perform and 
only enroll between 0 and 1 patients: 20% fail to enroll a single patient and another 30% fewer 
patients than expected. Overall, the majority of patients (70%) are enrolled by only 30% of 
research sites (Clinical Trials Arena; 2012; IOM, 2012; PhRMA, 2015 March). As a result, 
sponsors are looking for rapid recruitment and gauge a site’s recruitment ability during the site-
selection process to find investigator sites that are high performers and will recruit patients 
quickly (USHHS, OIG, 2000). This results in a focus on rapid enrollment and not the 
prioritization of enrolling study participants in proportion with the disease prevalence being 
studied. 
Policy and regulation on clinical trial enrollment. Another factor contributing to the 
problem of underrepresentation of minorities in clinical trials is related to policy. In an effort to 
address this challenge, the National Institutes of Health (NIH), the largest government funding 
body for clinical trials, instituted the Revitalization Act of 1993, which mandates the inclusion of 
women and minority participants in clinical trials supported or funded by the NIH. As part of this 
policy, the NIH is obligated to conduct or support outreach programs to recruit women and 
members of minority groups as participants in clinical research (USHHS, NIH, 2001). The NIH’s 
National Heart, Lung, and Blood Institute (NHLBI) further requires investigators to recruit 
minorities in the study population in the same proportions as in the U.S. population having the 
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disease entity being studied. When the prevalence of the disease being studied is unknown, the 
NHLBI mandates that minority groups be represented in proportions equal to their representation 
in the total U.S. population. However, the NHLBI does allow principal investigators (PIs) 
seeking funding to justify why they have planned for limited diversity when these mandates are 
not met (USHHS, NHLBI, 2011). It is also important to note that the majority of government-
funded trials are epidemiologic and behavioral studies and are not designed to test investigational 
treatments (Getz, 2010). Although the NIH has established a policy to enforce diverse 
representation in clinical trials supported or funded by the NIH, this policy does not apply to 
industry-sponsored studies. The majority of clinical trial sponsors provide details on the 
demographic profiles of the participants in their NDAs, but the FDA has recently recognized 
improvements are still needed and enacted the Food and Drug Administration Safety and 
Innovation Act (FDASIA) in 2012. Section 907 of the FDASIA, “Reporting of Inclusion of 
Demographic Subgroups in Clinical Trial and Data Analysis in Applications for Drugs, 
Biological Products, and Devices,” sets forth requirements for reporting to Congress the extent to 
which clinical trial participation by demographic subgroups, including sex, age, race, and 
ethnicity, is included in NDAs that are submitted to the FDA. Section 907 of the FDASIA also 
requires an analysis of the extent to which the inclusion of safety and effectiveness data by 
demographic subgroups is included in product labeling (Food and Drug Administration Safety 
and Innovation Act, 2012). The FDA has developed an action plan as part of the FDASIA to be 
rolled out over the next several years in an attempt to encourage diverse participation in 
biomedical research (USHHS, FDA, 2014). While the efforts of “The FDA Action Plan to 
Enhance the Collection and Availability of Demographic Subgroup Data” encourage inclusion of 
minorities in clinical trial research, it is not mandated, though it includes an initiative to improve 
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the availability and transparency of reporting to the public the demographic composition by 
subgroup in clinical trials for FDA-approved medical products (USHHS, FDA, 2014). Since 
2015, this information is publically available in the Center for Drug Evaluation and Research’s 
(CDER’s) Drug Trial Snapshots Summary Report (USHHS, FDA, 2019). Unfortunately, post-
hoc subgroup analyses conducted on clinical trial data to ascertain differential responses to an 
investigational medication based on race typically cannot be conducted because the sample size 
of the minority participants is often too low to achieve adequate power (Cooper & Psaty, 2005). 
The FDA’s August 2013 report, “Collection, Analysis, and Availability of Demographic 
Subgroup Data for FDA-Approved Medical Products,” includes an analysis of demographic 
subgroup data provided in NDAs during 2011. The report noted that while approximately half of 
the applications included race subset data in labeling, only a few included efficacy and safety 
subset analyses. Furthermore, the analysis of subgroup data reveals that racial subgroups are 
underrepresented and race composition is not always consistent with disease prevalence in the 
US population. For example, while more than 13% of African American adults has diabetes, 
only 2% of study participants in the type 2 diabetes mellitus (T2DM) studies included in the 
report are African American. Similar to the findings by Cooper and Psaty (2005), the inclusion 
of patient subgroup data did not provide sufficient data for meaningful analysis or to detect 
effects in different subgroups because of low sample size limitations (USHHS, FDA, 2013; 
USHHS, FDA, 2014). These findings also are confirmed by a literature review conducted by 
Chen, Lara, Dang, Paterniti, and Kelly (2014). Chen et al. (2014) found that between 1.5% and 
57% of clinical trial publications report their study sample by race and ethnicity; however, a 
much lower percentage include an analysis of results by racial or ethnic subgroups.  
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Recent public policy initiatives encourage inclusion of racially and ethnically diverse 
populations in industry-funded clinical trials. In 2016, the FDA issued guidance for industry for 
the “Collection of Race and Ethnicity Data in Clinical Trials.” Within this guidance, the FDA 
states their expectations that “sponsors enroll participants who reflect the demographics for 
clinically relevant populations with regard to age, gender, race and ethnicity. A plan to address 
inclusion of clinically relevant subpopulations should be submitted for discussion to the Agency 
at the earliest phase of development and, for drugs and biologics, no later than the end of the 
phase 2 meeting” (USHHS, FDA, 2016, p. 3). For clarity, this guidance by the FDA does not 
issue a mandate but does provide expectations regarding trial enrollment. In addition, in 
fulfillment of a stipulation within the FDA Reauthorization Act of 2017 (FDARA) regarding 
expanded access, in 2019 the FDA issued draft guidance for industry, “Enhancing the Diversity 
of Clinical Trial Populations—Eligibility Criteria, Enrollment Practices, and Trial Designs.” The 
primary focus of this guidance is to broaden eligibility criteria in clinical trials to better reflect 
the population most likely to receive the drug. For example, patients with concomitant illnesses 
generally are excluded from participation based on the inclusion and exclusion criteria set forth 
by the researchers (USHHS, FDA, 2019 June). 
Statement of the Problem 
Despite efforts of the NIH Revitalization Act of 1993 (2001) and FDASIA (2012), 
disparities exist in clinical trial participation with African Americans, Asian Americans and 
Hispanic/Latino Americans underrepresented in most studies (Chen, Lara, Dang, Paterniti, & 
Kelly, 2014; CISCRP, 2017; Diehl et al., 2011; Duda et al., 2011; Martin, Negron, Balbierz, 
Bickell, & Howell, 2013; The Society for Women’s Health Research & FDA, 2011). 
Historically, both non-minority and minority women have been underrepresented in clinical 
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research studies (Bennett, 1993; Killien et al., 2000; Murthy, Krumholz, & Gross, 2004). This is 
a significant problem because minority women are disproportionately affected by disease 
(USHHS, NIH, NCI, 2019; USHHS, Healthy People 2020, 2014). Participation disparities are 
evident in both government-funded and industry-funded trials. The literature varies with regards 
to minority participation in government-funded clinical trials. Some sources indicate that overall 
minority enrollment in NIH-funded studies is closely proportional to the US population 
(CISCRP, 2017; NIH, 2013c; The Society for Women’s Health Research & FDA, 2011). In fact, 
the NIH (2013c) reports that 36% of minorities were enrolled in government-funded clinical 
research in 2012. According to the US Census Bureau (2012), minorities represented 37% of the 
US population at that time. However, there are also several examples of government-funded 
trials in which minorities are underrepresented, despite the fact that the majority of NHLBI PIs 
with active studies believe it is important to include racial and ethnic minority groups as 
participants in their research (Corbie-Smith, Durant, & St. George, 2006). For example, in 2005, 
Fisher et al. (2005) conducted a government-funded trial to assess the effect of tamoxifen as a 
preventive therapy for breast cancer in 13,388 patients. Of these patients, 96.5% of the 
participants were white, whereas only 3.5% were African American or an unspecified minority. 
Furthermore, in a 2004, Murthy, Krumholz, and Gross (2004) conducted a clinical trial that 
analyzed enrollment in National Cancer Institute (NCI)-funded trials. They concluded that fewer 
Hispanics and African Americans participate in cancer clinical trials as compared with the 
percentage of cancer incidence among those populations in the United States. This is further 
confirmed by a 2010 Institute of Medicine (IOM) report, which stated that almost 90% of clinical 
trial participants enrolled into publically funded NCI clinical trials prior to 2006 were white 
when comparing enrollment by race. Furthermore, 8% of the NCI trial participants were African 
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American and less than 3% were Asian American (IOM, 2010). Enrollment by ethnicity prior to 
2006 was 94.4% non-Hispanic white and 5.6% Hispanic. Enrollment of minority populations 
into NCI clinical trials improved slightly in 2013 with 25% minority participation, yet these trials 
are still falling short of enrollment that is representative of the US population (National 
Academies of Sciences, Engineering, and Medicine, 2016). Chen et al. (2014) also found that 
only 1% of NCI-sponsored clinical trials focus primarily on racial or ethnic minority populations. 
Instead, the focus is placed on cancer types and not the populations who are disproportionately 
affected by those cancers. 
Racial and ethnic minorities are underrepresented in most industry-sponsored studies, as 
well. For example, in a 2006 study sponsored by the pharmaceutical manufacturer 
GlaxoSmithKline comparing the efficacy of different treatments in recently diagnosed type 2 
diabetes patients, 88% of the trial participants were white. Yet, more than 13% of African 
American adults as well as 13% of Hispanic adults are diagnosed with diabetes (Viberti et al., 
2006; USHHS, CDC, 2020). Additionally, according to the 2019 CDER Drug Trial Snapshots 
Summary Report in which 48 newly approved drugs were reviewed, 72% of the trial participants 
on average were white. Of note, these were global trials and only 40% of the demographic data is 
based on US participation (USHHS, FDA, 2019). Overall, 83% of domestic industry-funded trial 
participants are non-Hispanic white, considerably greater than the proportion of the US 
population that they represent (CISCRP, 2017; The Society for Women’s Health Research & 
FDA, 2011; US Census Bureau, 2012). Speakers participating in the “Dialogues on Diversifying 
Clinical Trials” workshop convened by the Society for Women’s Health Research and the FDA 
(2011) highlighted the under-representation of minorities in clinical trials. Clinical trials have 
representation from 1% of the Hispanic population, yet 16% of the US population was Hispanic 
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at that time. African Americans comprise 5% of clinical trial participants, much less than the 
12% of the US population they represented at the time (Coakley et al., 2012; The Society for 
Women’s Health Research & FDA, 2011). Asian Americans are also underrepresented in clinical 
trials. Kwiatkowski, Coe, Bailar, and Swanson (2013) conducted a systematic review of both 
federally funded and industry funded clinical trials and reported that among the cancer treatment 
clinical trials that reported on race and ethnicity between 2001 and 2010, 3% of trial participants 
were Asian American. This is a dramatic increase from 1990-2000 when only 0.04% of cancer 
treatment trial participants were Asian American, yet, according to the US Census Bureau 
(2019), 6% of the US population is Asian. These facts indicate that clinical trial participation is 
not representative of the US population or the prevalence of the disease being studied. 
The biopharmaceutical industry is currently the largest funder of drug R&D, and as of 
2008, accounted for 90% of all spending on clinical trial testing of investigational drugs and 
devices in the United States (Getz, 2010; PhRMA, 2016 April). Members of Pharmaceutical 
Researchers and Manufacturers of America (PhRMA) alone invested nearly $80 billion in R&D 
in 2018 (PhRMA, 2019). Since 2006, there has been a 43% increase in industry-sponsored trials, 
while at the same time a 24% decrease in NIH-funded studies (Ehrhardt, Appel, & Meinert, 
2015; Johns Hopkins Bloomberg School of Public Health, 2015). Industry researchers conducted 
more than 6,000 clinical trials in the United States in 2013, whereas the NIH provided funding 
for just over 1,000 trials that same year (Ehrhardt, Appel, & Meinert, 2015; PhRMA, 2015 
March; USHHS, NIH, 2018, June). Therefore, a significant majority of clinical trials are 
sponsored by the biopharmaceutical industry and, as such, investigators are not mandated to  
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include participation from diverse populations. Accordingly, this study addresses the 
underrepresentation of racial and ethnic minority populations enrolled in clinical trials sponsored 
by the biopharmaceutical industry. 
Purpose of the Study  
While the underrepresentation of racial and ethnic minority participants in industry-
funded clinical trials is a problem, historically, there have been occasions of successful 
enrollment of diverse populations. Notably, NitroMed, Inc., a privately held pharmaceutical 
company that is no longer in existence (businesswire, 2008; Mitchell et al., 2011), successfully 
enrolled 1,050 African American participants into their African American Heart Failure Trial (A-
HeFT). The participating sites actively recruited only African Americans. However, the specific 
recruitment strategies leading to the successful recruitment of this minority group are not 
discussed in the literature, nor are details on recruitment strategies related to any other industry-
related trial recruiting minority participants discussed in the literature. The purpose of this study 
is to understand the socio-ecological elements that are involved in the active implementation of 
racial and ethnic minority recruitment practices for biopharmaceutical-funded trials in the United 
States.  
Conceptual Framework 
A conceptual framework to view phenomena enables a systematic exploration of 
situations in order to better understand and explain the dynamics of events (USHHS, NIH, NCI, 
2005). The conceptual framework used as a lens for this study is the socio-ecological model 
(McLeroy, Bibeau, Stecker, & Glanz, 1988). Describing the study of an organization as a system 
helps to better understand the applicability of the socio-ecological model for this study. Aristotle 
claimed that “the whole was more than the sum of its parts” and that knowledge is derived from 
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understanding of “the whole.” This worldview laid the foundation for the organization of general 
systems theory by Ludwig von Bertalanffy in which he recognized that investigating single parts 
and processes cannot provide a complete explanation of phenomena. Rather, the ensemble of the 
components and the relations existing between their interactions must be understood in order to 
derive the properties and modes of action of higher levels from their components (von 
Bertalanffy, 1950; von Bertalanffy, 1972).  
Systems can be defined as either open or closed. In an open system, there is an inflow 
and outflow of energy to the environment, resulting in a change to the components. An open 
system moves towards a steady state through the continuous inflow and outflow of energy with 
the environment. In contrast, there is no energy exchange from the environment in closed 
systems and eventually a state of equilibrium is reached. The biggest difference between open 
and closed systems is characterized by the concept of equifinality. In an open system, an end 
state can be reached by many potential means, meaning that similar results can be achieved with 
different initial conditions and in different ways. Whereas closed systems cannot behave 
equifinally because the final state of the system is dependent on the initial components, which 
lead to the same final result (Katz & Kahn, 1978; von Bertalanffy, 1950). 
General systems theory initially was applied to biology but now extends to several other 
disciplines, including social sciences. The principles of general systems theory apply to all 
systems, defined as “a set of elements standing in interrelation among them and with the 
environment” (von Bertalanffy, 1972, p. 417). Systems can be distinguished as being real, 
conceptual or abstract. From a social science perspective, organizations are considered systems 
(Foster –Fishman, Nowell, & Yang, 2007; Katz & Kahn, 1978). Organizations are categorized as 
real systems, that is, entities that can be inferred by observation and exist independently of an 
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observer. However, many of the interactions between the component elements of the 
environmental landscape that the organization is part of are conceptual constructs. General 
systems theory provides a way of seeing this organized whole through the dynamic interaction of 
multiple factors, which von Bertalanffy suggests were previously overlooked (1950, 1972). In 
fact, according to open systems theory, environmental influences are necessary social system 
components. Therefore, to understand an organization, its environmental influences must also be 
considered (Katz & Kahn, 1978). 
A system can be viewed as a hierarchy composed of the system itself, components of the 
system (subsystems) and the larger system surrounding the system (supra-system). Each level of 
the system is influenced by and influences other parts of the system within the hierarchy. When 
using a systems perspective, it is up to the researcher to define the hierarchy of systems, 
considered to be the “whole,” including the relationship between the system, subsystems and 
supra-system (Benko & Sarvimaki, 2000). When using a systems perspective, real-world 
complexities are viewed as whole entities embedded in context. Thinking holistically of a system 
as a whole with both interconnected and interdependent parts is essential with systems theory 
because a change in one part leads to changes in other parts and the system itself. As such, a 
system as a whole cannot be understood by isolating different parts of the system. Instead, 
synthetic thinking is used to better understand the interactions of its parts, not the actions of its 
parts taken separately (Patton, 2002). This allows for simultaneous analyses of relationships on 
and between different system levels (Benko & Sarvimaki, 2000). The context for human actions 
in organizations can be examined and better understood using a systems perspective, since a 
system change is necessary to change an individual within the system.  
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A system needs to be understood in its natural ecosystem, considering the ecological, 
cultural, political, economic and policy environments of which the system is a part. 
Organizations are social systems that consist of the patterned activities of individuals and should 
be studied in the context of their environment relations, both the social and physical environment 
within the organization, as well as the environment the organization is a part of (Katz & Kahn, 
1978; McLaren & Hawe, 2005; Patton, 2002). An ecological perspective includes a 
comprehensive context of the environment, including physical, social, cultural and historical 
aspects, as well as the attributes and behaviors of people within this environment. Social ecology 
offers a perspective for understanding these interrelations, stressing the multiple dimensions, 
levels and complexity of situations within the corresponding environment. Specifically, a socio-
ecological model uses systems thinking in trying to understand the interacting and 
interdependent elements that form a whole (McLaren & Hawe, 2004; Stokols, 1992).  
A socio-ecological model is a conceptual framework that focuses on the 
interrelationships between individuals and their social and physical environment under the 
premise that behavior is both affected by and affects the environmental system of which it is a 
part. The ecological environment is a nested arrangement of structures that can affect and be 
affected by individual and organizational behavior at multiple levels (Bronfenner, 1977; 
McLeroy, Bibeau, Stecker, & Glanz, 1988; Trickett, 2009). These levels of influence are 
(McLeroy et al., 1988): 
1. Intrapersonal factors: characteristics of an individual such as knowledge, attitudes, 
behavior, self-concept and skills 
2. Interpersonal factors: social network and social support systems, including family, friends 
and work group 
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3. Organizational factors: social institutions with organizational characteristics and rules 
and regulations for operation 
4. Community factors: relationships among organizations, institutions and informal 
networks within defined boundaries, including face-to-face primary groups to which an 
individual belongs. This includes family, social networks, churches and neighborhoods, 
all of which may be sources of social identity and influence the community’s norms and 
values, as well as individual beliefs and attitudes. This also includes relationships among 
organizations as a means to influence community awareness 
5. Public policy: local, state, and national laws, policies and procedures 
Application of a socio-ecological model. Grounds for using a socio-ecological model 
have been made for developing effective health promotion programs for overcoming public 
health problems. Most public health challenges are too complex to be understood using a single 
level of analysis and, therefore, require a comprehensive approach that includes individual, 
organizational, cultural, community and regulatory levels (Stokols, 1996). Historically, the 
socio-ecological model has been used for understanding individual behavior in an effort to 
develop behavior change interventions targeted at individuals and delivered through health 
promotion programs (ACHA, 2016; Baert, Gorus, Calleeuw, DeBacker, & Bautmans, 2016; 
Daley at al., 2011; Holt, Rung, Leon, Firestein, & Krousel-Wood, 2014; Mahadevan et al., 2014; 
McLeroy, Bibeau, Stecker, & Glanz, 1988; Sword, 1999). Applications of the socio-ecological 
model also have been documented in the clinical trial literature, primarily as a framework for 
identifying and addressing barriers to and facilitators of clinical trial participation (Chakrapani, 
Newman, Singhal, Jerajani, & Shunmugam, 2012; Elder et al., 2007; Frew et al., 2014; Salihu, 
Wilson, King, Marty, & Whiteman, 2015; Wallington et al., 2016; Wells & Zebrack, 2008). 
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Healthy People 2020 recognizes that the interrelationships between biological, social, economic 
and environmental factors influence the ability of individuals and communities to progress 
towards the achievement of meeting the objectives set forth for eliminating health disparities 
(USHHS, Healthy People 2020, 2020b). 
Much of the wide application of the socio-ecological model used for developing health 
promotion programs focuses on analyzing behavior change strategies on an individual level in an 
effort to change individuals (Stokols, 1992). However, human behavior is influenced by the 
environmental system of which it is a part. Instead of focusing on individual behavior change, 
the focus should be on changing the social and physical environment that reinforces unhealthy 
behaviors; therefore, change may be needed at the organizational and environmental levels 
(McLeroy, Bibeau, Stecker, & Glanz, 1988; Stokols, 1992). Accordingly, the socio-ecological 
model also is used to create health promotion initiatives that focus on changing the 
environmental system in order to create an environment that promotes healthy behavior (Glanz 
& Mullis, 1988; Monahan & Scheirer, 1988; Moore, Murphy, Tapper, & Moore, 2010). One 
such program strived to create opportunities for the general population to follow a healthy diet. 
While the goal of the program initiatives was population health, the researchers used an 
environmental approach to target the multiple levels of an ecological model that would impact 
population access to following a healthy diet, rather than targeting individual behavioral factors 
(Glanz & Mullis, 1988). Moore, Murphy, Tapper, and Moore (2010) investigated how the 
availability of food at lunchtime in primary schools was influenced by different socio-ecological 
levels, including national policy, Local Education Authority policy, priorities and practices of 
catering staff within each school, as well as the social interactions between the catering staff and 
children. Interviews were held at an organizational level with the Local Education Authority and 
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primary school catering managers to better understand influencers at multiple levels of the socio-
ecological framework. Monahan and Scheirer (1988) also used a social ecological approach to 
demonstrate that by considering a multitude of factors and sources of influence at different 
levels, state health department dental offices could successfully act as linking agents in the 
adoption of a fluoride mouth rinse program at an organizational level (public schools).  
Improving population health by implementing health promotion programs through the 
influence of social and environmental changes acting synergistically at multiple levels of a socio-
ecological framework provides a premise for exploring ways to promote participation of 
minorities into clinical trials using socio-ecological elements. Hawe, Shiell and Riley (2009) 
suggested that a public health prevention program be viewed as an intervention within the 
ecological system in which it was introduced. In doing so, the intervention should be viewed in 
the context of the setting in which it was introduced (Hawe, Shiell & Riley, 2009). Glanz and 
Mullis (1988), Moore, Murphy, Tapper, and Moore (2010) and Monahan and Scheirer (1988) all 
shared an alternative approach to improving population health by understanding the multiple 
levels of influence that impact providing access to the intervention. Similar to the approaches 
described in the literature by these authors, the socio-ecological model could guide a better 
understanding of the elements involved in overcoming the problem of underrepresentation of 
minorities in clinical trials. Specifically, if we view minority recruitment practices as a health 
promotion intervention to improve minority access to participate in clinical trials, clinical 
research staff could be viewed as the linking agent providing the vehicle for increasing minority 
participation. The socio-ecological model could then be used to explore how the behavior and 
practices of individuals involved in clinical research who actively recruit minority participants 
into clinical trials are influenced by and influence environmental elements. This would offer a 
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better understanding of the contextual factors that promote an environment inviting clinical trial 
participation among minorities. Understanding the multiple levels of influencers on the 
successful implementation of minority recruitment practices would help researchers provide 
opportunities for minority populations to participate in clinical trials in the future by increasing 
access to trials. 
 
 
 
Figure 1. Application of a socio-ecological model when viewing minority recruitment practices 
as a health promotion intervention. Adapted from McLeroy, Bibeau, Steckler, & Glanz, 1988.  
 
Using a socio-ecological model to explore from a provider perspective the 
interrelationships between individuals who are involved in clinical research and who actively 
recruit minority participants and environmental elements specific to recruiting minority 
participants into clinical trials will help frame an approach to increase minority participation. In 
literature reviewed, no studies were found that explored minority participation in clinical trials 
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using a socio-ecological model from a provider perspective. Delivery of care from the service 
provider viewpoint is determined by multiple factors operating within the socio-ecological 
framework.  Healthcare utilization is understood more wholly when utilizing a socio-ecological 
approach (Daley et al., 2011; Sword, 1999). We can assume from this that similar to 
understanding delivery of care from a service provider perspective, we can also understand 
minority recruitment from a service provider perspective under the realm of a socio-ecological 
model.  
Research Question 
 There is one overarching research question guiding this study:  
What are the socio-ecological elements that are involved in the active implementation of 
racial and ethnic minority recruitment practices for biopharmaceutical-funded trials in the United 
States? 
Utilizing the socio-ecological model as a framework, the five sub-questions address 
different components of the model to support the overarching research question: 
1. How are intrapersonal site staff elements involved in the active implementation of 
minority recruitment practices for biopharmaceutical-funded trials in the United 
States?  
2. How are interpersonal site staff elements involved in the active implementation of 
minority recruitment practices for biopharmaceutical-funded trials in the United 
States?  
3. How are organizational elements involved in the active implementation of minority 
recruitment practices for biopharmaceutical-funded trials in the United States? 
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4. How are community elements involved in the active implementation of minority 
recruitment practices for biopharmaceutical-funded trials in the United States? 
5. How are policy elements involved in the active implementation of minority 
recruitment practices for biopharmaceutical-funded trials in the United States?  
Significance of the Study 
The minority population residing in the United States is continually growing, and, in fact, 
minorities are expected to be in the majority by 2044. Additionally, the Hispanic population is 
expected to grow from 17% of the population in 2014 to 29% of the population by 2060. 
Meanwhile, the non-Hispanic white population is projected to drop from 62% in 2014 to 44% by 
2060. The African American population is expected to grow from 13% in 2014 to 14% by 2060 
and the Asian population will nearly double; it is projected to grow from 5% in 2014 to 9% of 
the US population by 2060 (US Census Bureau, 2015). Based on these projections, the 
composition of the US population is drastically changing and, if these projections hold true, we 
will have two main population groups in 2060 (Hispanic and non-Hispanic white).  
The Healthy People 2020 goals include achieving health equity, eliminating disparities, 
and improving the health of all population groups (USHHS, Healthy People 2020, 2020b). 
Despite the goals of Healthy People 2020 and other such initiatives, health disparities still exist 
and disproportionately affect members of racial and ethnic minority populations. In fact, 
minorities have the highest rates of incidence and mortality of chronic disease (USHHS, CDC, 
2009), and minority women are disproportionately affected by disease (USHHS, CDC, 2011a). 
According to the Racial and Ethnic Approaches to Community Health across the U.S. (REACH 
U.S.) Risk Factor Survey results, residents of minority communities have a lower socioeconomic 
status, more barriers to healthcare access, and greater risks for and burden of diseases compared 
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with the general populations living in non-minority communities (USHHS, CDC, 2011a). Health 
disparities among minority populations not only apply to differences in disease prevalence, but 
also to the severity and rate of progression of disease (Ejiogu et al., 2011; USHHS, CDC, 
2013a). Several examples of disease-specific healthcare disparities include:  
• Healthy People 2020 includes objectives to reduce the prevalence of hypertension 
among adults to 26.9% and increase blood pressure control among adults with 
hypertension to 64.1% (USHHS, Healthy People 2020, 2020c). However, the rate of 
controlled blood pressure is lower among Hispanics (34.4%) and non-Hispanic blacks 
(42.5%) than non-Hispanic whites (52.6%) (USHHS, CDC, 2013a). 
• When looking at coronary heart disease (CHD), the Morbidity and Mortality Weekly 
Report (MMWR) reported that death rates from CHD and stroke are declining, but 
there are still disparities in the rate of death from these events in racial and ethnic 
groups (USHHS, CDC, 2013a). 
• Cardiovascular disease (CVD) is the leading cause of death in the United States and 
non-Hispanic black adults are at least 50% more likely to die prematurely of stroke or 
heart disease then non-Hispanic whites (USHHS, CDC, 2013a). 
• Adult diabetes is also higher among Hispanic and non-Hispanic blacks than among 
non-Hispanic whites. (USHHS, CDC, 2013a). For example, more than 13% of 
Hispanic adults in the United States have type 2 diabetes, compared with 7.9% of 
non-Hispanic white adults (USHHS, CDC, 2020).  
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• Older blacks and Hispanics are disproportionately more likely to have Alzheimer’s 
disease than whites. In fact, older blacks are twice as likely and older Hispanics are 
one and one half times as likely than older whites to suffer from the disease 
(Alzheimer’s Association, 2020). 
• Overall cancer incidence is highest among African Americans compared with all 
other racial and ethnic groups, and the death rate from cancer is higher for African 
Americans than for whites. The higher incidence and death rates of cancer among 
African Americans (and Hispanics) can be contributed to lack of medical coverage, 
unequal access to healthcare services and cancer treatments, lower socioeconomic 
status and barriers to screening (USHHS, NIH, NCI, 2019). 
o Although the incidence rate of breast cancer is similar in African American 
and white women, African American women are most likely to die from the 
disease (USHHS, NIH, NCI, 2019). 
o American Indian/Alaska Native and Hispanic women experience the highest 
cervical cancer incidence rates, yet African American women have the highest 
death rates from cervical cancer compared with all other racial and ethnic 
groups (USHHS, NIH, NCI, 2019). 
o Similarly, due to genetic factors, African American men are more than twice 
as likely than white men to die from prostate cancer (USHHS, NIH, NCI, 
2019). 
o African American men have the highest incidence and death rates for lung 
cancer (USHHS, NIH, NCI, 2019). 
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Not only do health disparities cause greater risk for disease, disparities in healthcare 
access and quality create an additional cost burden on the system. According to a study by the 
Joint Center for Political and Economic Studies, “eliminating health inequalities for minorities 
would have reduced indirect costs associated with illness and premature death by more than $1 
trillion between 2003 and 2006…and reduced direct medical care expenditures by $229.4 billion 
for the years 2003 to 2006 ” (LaVeist, Gaskin, & Richard, 2009).  
Despite the fact that the United States has a growing minority population that faces a 
disproportionate rate of healthcare disparities, minority populations are significantly 
underrepresented in industry-funded clinical trials. As previously discussed, 83% of industry-
funded clinical trial participants are non-Hispanic white, leading to a pool of trial participants 
who are not representative of the US population or the disease being studied (Bennett, 1993; 
CISCRP, 2017; Coakley et al., 2012; Cooper & Psaty, 2005; Diehl et al., 2011; Duda et al., 
2011; Killien et al., 2000; Martin, Negron, Balbierz, Bickell, & Howell, 2013; Murthy, 
Krumholz, & Gross, 2004; The Society for Women’s Health Research & FDA, 2011; USHHS, 
FDA, 2013; USHHS, FDA, 2014; US Census Bureau, 2015). One reason leading to this problem 
is that 90% of clinical trial funding testing investigational medicines and devices in the United 
States is through industry and, as such, a significant majority of clinical trials do not mandate 
diverse participation (Getz, 2010; PhRMA, 2016 April; USHHS, FDA, 2014). 
This is especially important with the implementation of the Affordable Care Act (ACA). 
It was expected that many of the 46 million previously uninsured nonelderly Americans would 
have access to healthcare and prescription medicines as a result of the ACA, a majority of which 
were expected to be minority populations, especially Hispanics (The Henry J. Kaiser Family 
Foundation [KFF], 2013a; KFF, 2013b; KFF, 2019). In 2010 when the ACA was signed into 
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law, approximately 50 million nonelderly Hispanics were residing in the United States. Prior to 
the ACA, 33% of nonelderly Hispanic individuals did not have health insurance, making this 
group of more than 15 million people the highest uninsured minority racial or ethnic group 
within the United States (KFF, 2020). It was expected that the majority of these uninsured 
individuals and families would have access to healthcare as a result of the ACA (KFF, 2013a). 
As of 2016, over 19 million uninsured people gained coverage under the ACA. There was a 
greater decline in the uninsured rate among African Americans and Hispanics than among whites 
(KFF, 2019). The result is that minorities increasingly have access to prescription medications 
primarily tested on adult white males (Killien et al., 2000). While significant progress has been 
made, there are still healthcare coverage disparities. According to the Kaiser Family Foundation 
(2020), 19% of nonelderly Hispanics and 11.5% of nonelderly African Americans remain 
uninsured, compared with 7.5% of nonelderly whites.  
Given the growing minority population in the United States, coupled with the 
disproportionate rate of lack of healthcare access and healthcare disparities, it is important to 
understand how new medications may affect various populations. The current rate of minority 
participation in clinical trials does not allow for understanding genetic differences in treatment 
(Cooper & Psaty, 2005; USHHS, FDA, 2013; USHHS, FDA, 2014; Hershman et al., 2003; 
Rotger, Csajaka, & Telenti, 2006). There are differences in drug metabolism and toxicity in 
diverse racial and ethnic groups (Brody & Hunt, 2006; Cohn et al., 2004; Hershman et al., 2003; 
Rotger, Csajaka, & Telenti, 2006; Temple & Stockbridge). Therefore, there is an unmet need for 
evidence-based treatments that are relevant for all applicable populations. 
In summary, public health is “the science and art of promoting health, preventing disease 
and prolonging life through the organized efforts of society.” This includes creating supportive 
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environments for health (WHO, 1998). Sallis, Bauman, & Pratt (1998) recommend 
environmental and policy interventions based on ecological models as a potential means to 
influence health behavior at a population level. Using the socio-ecological model to structure 
public health behavior change initiatives targeting the environmental system in order to create an 
environment that promotes healthy behavior have proven successful (Glanz & Mullis, 1988; 
Monahan & Scheirer, 1988; Moore, Murphy, Tapper, & Moore, 2010). 
To achieve the Healthy People 2020 goals of eliminating health disparities, several 
objectives need to be met. One Healthy People 2020 imperative is to improve access to quality 
healthcare services, by increasing the proportion of people who receive appropriate evidence-
based clinical preventive services (USHHS, Healthy People 2020, 2020d). Without testing 
medications on those who ultimately will be prescribed them creates a dilemma in that minority 
populations are not receiving quality healthcare or evidence-based services when genetic 
differences in drug metabolism are not accounted for. A lack of a diverse representation in 
industry-funded trials means that minority populations need to be better represented (USHHS, 
FDA, 2014). Given the disparities in minority enrollment into industry-funded trials, it is clear 
that industry just has not been able to address this need appropriately. Examples in the literature 
of successful recruitment of minorities into NIH-funded studies, which will be discussed in the 
next chapter, provide optimism that parity in trial participation can be achieved. Obtaining 
perspectives from industry-funded clinical research staff members who specifically focus on 
recruiting minorities will provide other researchers with guidance for accruing minority 
participants. Therefore, this study will address this significant health problem of 
underrepresentation of minorities in clinical trials by facilitating a better understanding of 
elements involved with actively recruiting minority participants into industry-funded clinical 
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trials. Additionally, this study will provide unique insights from published studies that relate to 
minority recruitment factors of success involving NIH-funded trials. To the researcher’s 
knowledge, there is no published peer-reviewed data on successful minority recruitment 
strategies involving industry-sponsored trials. 
Operational Definitions 
The following definitions are important to understanding this study: 
1. Health disparity is defined as “a particular type of health difference that is closely 
linked with social, economic and/or environmental disadvantage. Health disparities 
adversely affect groups of people who have systematically experienced greater 
obstacles to health based on their racial or ethnic group; religion; socioeconomic 
status; gender; age; mental health; cognitive, sensory, or physical disability; sexual 
orientation or gender identity; geographic location; or other characteristics 
historically linked to discrimination or exclusion” (USHHS, Healthy People 2020, 
2020a).  
2. Minority is defined as a race and ethnicity other than non-Hispanic white (United 
States Census Bureau, 2011). 
3. “Hispanic” or “Latino” refers to “a person of Cuban, Mexican, Puerto Rican, South or 
Central American, or other Spanish culture or origin regardless of race” (United 
States Census Bureau, 2011).  
4. Informed consent is defined as a “person’s voluntary agreement, based upon adequate 
knowledge and understanding, to participate in human subjects research or undergo a 
medical procedure” (USHHS, NIH, 2013b). 
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5. Health literacy is defined as “the degree to which an individual has the capacity to 
obtain, communicate, process and understand basic health information and services to 
make appropriate health decisions” (USHHS, CDC, 2019).  
6. Betancourt, Green, Carrillo and Ananeh-Firempong (2003) define cultural 
competence in health care as “understanding the importance of social and cultural 
influences on patients’ health beliefs and behaviors; considering how these factors 
interact at multiple levels of the health care delivery system; and, finally, devising 
interventions that take these issues into account to assure quality health care delivery 
to diverse patient populations.” Specific to research centers, “cultural competence 
requires that they have a defined set of values and principles and demonstrate 
policies, structures, practices, behaviors and attitudes that enable them to work 
effectively cross-culturally” (Wallington et al., 2016). 
7. Clinical trial is defined as “a research study in which one or more human subjects are 
prospectively assigned to one or more interventions (which may include placebo or 
other control) to evaluate the effects of those interventions on health-related 
biomedical or behavioral outcomes.” Biomedical clinical trials of an experimental 
drug, treatment, device or behavioral intervention may proceed through four phases: 
• Phase I. Investigators test a new biomedical intervention in a small group of 
[healthy volunteers] (e.g., 20-80) for the first time to determine efficacy and 
evaluate safety (e.g., determine a safe dosage range and identify side effects). 
• Phase II. Investigators study the biomedical or behavioral intervention in a larger 
group of people (several hundred) to determine efficacy and further evaluate 
safety. 
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• Phase III. Investigators determine efficacy of the biomedical or behavioral 
intervention in large groups of people (from several hundred to several thousand) 
by comparing the intervention to other standard or experimental interventions, as 
well as monitor adverse effects and collect information that will allow the 
interventions to be used safely. 
• Phase IV. These studies are conducted after the intervention has been marketed 
and are designed to monitor the effectiveness of the approved intervention in the 
general population and to collect information about any adverse effects associated 
with widespread use (USHHS, NIH, 2013a). 
8. Principal Investigator (PI) is defined as the individual who is responsible and 
accountable for conducting the clinical trial. The PI assumes responsibility for 
analyzing the research data and reporting results (USHHS, NCI, n.d.). 
9. Study Coordinator is defined as a specialized research professional who supports, 
facilitates and coordinates the daily clinical trial activities under the direction of the 
PI (Washington University in St. Louis, 2009). 
10. US biopharmaceutical industry: companies engaged in researching, developing, 
manufacturing and marketing drugs and biologics for human or veterinary use. Both 
pharmaceutical and biopharmaceutical manufacturers are classified as 
biopharmaceutical companies (United States Department of Commerce, 2016; United 
States Department of Commerce, 2020). 
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11. Health promotion: “the process of enabling people to increase control over, and to 
improve their health,” (World Health Organization [WHO], 1998); health promotion 
is further defined by WHO, indicating that it moves beyond the focus on individual 
behavior towards a wide range of social and environmental interventions.  
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Chapter II
 
LITERATURE REVIEW 
 
 
 Findings from the literature search demonstrate that recruiting a representative number 
of racial and ethnic minority participants into clinical trials continues to be a challenge, 
especially in biopharmaceutical-sponsored trials (Baquet, Commiskey, Mullins, & Mishra, 2006; 
CISCRP, 2017; Diehl et al., 2011; Duda et al., 2011; Killien et al., 2000; Mak, Law, Alvidrez, & 
Perez-Stable, 2007; Martin, Negron, Balbierz, Bickell, & Howell, 2013; Murthy, Krumholz, & 
Gross, 2004; Simon et al., 2004; The Society for Women’s Health Research & FDA, 2011). 
Furthermore, literature discussing minority recruitment from the perspective of industry-funded 
trials is not available, further contributing to the uniqueness of this study and the need to share 
experiences of those industry researchers who are contributing to minority recruitment with the 
wider research community. Several themes emerged from the literature related to clinical trial 
recruitment trends that further explain the disparities in minority participation and the gaps in the 
literature that this study is addressing. A discussion on the findings from the literature review 
follows.  
Clinical Trial Recruitment Themes 
Clinical trial recruitment disparities. Minorities are not informed of clinical trials or 
asked to participate as often as whites (Baquet, Commiskey, Mullins, & Mishra, 2006; Simon et 
al., 2004). For example, in an analysis comparing independent predictors of clinical trial 
recruitment between respondents who identified themselves as being either African American or 
white, Baquet et al. (2006) found that African Americans were significantly less likely to be 
recruited to a clinical trial than their white counterparts. Simon et al. (2004) had similar findings. 
They found that African American breast cancer patients were half as likely to be offered a 
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clinical trial compared with their white American counterparts (21% and 42%, respectively), and 
only 22% of minority women from other racial groups were offered participation. In their 
analysis, the researchers found that the most common reasons for not being offered clinical trial 
participation were PIs’ perceptions that they were “likely to be ineligible,” “lack of available 
protocols for disease stage,” and “concern about compliance.” African American patients were 
more likely to be considered ineligible than white or other race patients (61% and 53%, 
respectively). The most frequent reasons cited by investigators for why African American 
patients were considered likely to be ineligible and not offered a trial were poor performance 
status and inadequate organ function, whereas white and other race patients were considered 
ineligible because of prior or current treatment, or they were seeking a second opinion only. 
Adams-Campbell et al. (2004) also found that a major reason for excluding African American 
patients from cancer clinical trials was because of existing comorbidities. All of the five patients 
listed by Simon et al. (2004) who were not offered enrollment in a trial because the PI considered 
them likely to be non-compliant were African American. 
The largest magnitude of cancer burden disparities is among racial and ethnic minority 
populations (USHHS, NIH, NCI, 2019). In an analysis conducted by Diehl et al. (2011), the 
researchers found that studies for early-stage cancers were less likely to recruit African 
American and Hispanic American participants. For example, African American and Hispanic 
Americans in an early-stage breast cancer study comprised less than 10% of participants. Two 
advanced-stage breast cancer studies, however, included larger proportions of African American 
and Hispanic American participants (15% and 28%). This suggests a disparity in cancer 
screening and early detection efforts in minority populations, which ultimately decreases the 
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number of minorities who are considered eligible to participate in studies with early-stage 
disease inclusion criteria (Diehl et al., 2011). 
While most clinical trial result publications do not specify enrollment by race and 
ethnicity, of those that do, the majority do not offer enrollment to minority populations. 
Oftentimes, these recruitment disparities lead to a misdirected conclusion that racial and ethnic 
minorities are less willing to participate in clinical trials. For example, Wendler et al. (2006) 
analyzed consent rates by race and ethnicity of those individuals who were actually invited to 
participate in a coronary artery surgery study that enrolled 99% non-Hispanic white patients and 
1% minority patients. Although only 1% of the clinical trial participants were minority patients, 
individuals from minority groups actually agreed to participate at a significantly higher rate than 
non-Hispanic white patients who were asked to participate. 
Clinical trial participation disparities. Baquet, Commiskey, Mullins, and Mishra 
(2006) utilized telephone interviewing to determine attitudes, awareness, and knowledge of 
clinical trials, as well as examine predictors of clinical trial recruitment and participation for 
adults residing in Maryland’s underserved geographic areas. The researchers conducted an 
analysis that compared respondents who self-identified their race as either African American or 
white who were recruited into clinical trials. They looked at nine factors considered as enabling 
factors to clinical trial participation, including reimbursement, insurance coverage, 
transportation, childcare, greater knowledge, time constraints, anonymity, follow-up care and 
additional medical care. For most of these enabling factors, they found that African Americans 
were less likely than their white counterparts to be influenced to participate. Factors contributing 
to clinical trial participation among African Americans and those self-identifying as “other” for 
race included provision of childcare, not having to provide names, and provision of 
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transportation. They also found that those who were African American and of middle income 
(annual income between $15,000-$50,000, as categorized by the authors) were significantly less 
likely to participate in clinical trials. Their findings indicate that the reported low rate of 
recruitment and participation in clinical trials may help to explain the health disparities observed 
among minorities, underserved and rural communities in Maryland (Baquet, Commiskey, 
Mullins, & Mishra, 2006). 
Similarly, a study conducted by Simon et al. (2004) resulted in similar findings related to 
minority participation in clinical trials. They found that the most common reason for both white 
and African American women who were offered participation in a breast cancer trial but didn’t 
enroll was because they refused to participate. However, a small percentage of white women did 
not enroll because they did not meet the study’s eligibility criteria. Conversely, all of the African 
American patients who were offered participation but did not enroll had refused participation. In 
a study analyzing factors influencing enrollment into cancer studies among patients with 
advanced cancer, Jimenez et al. (2013) found that race/ethnicity predicted trial enrollment, with 
white patients more likely to be enrolled.  
Minority interest. Though there are participation disparities in clinical trials, the 
literature also supports the finding that eligible African American and Hispanic American 
patients tend to enroll in clinical trials when given the opportunity (Diehl et al., 2011; Jimenez et 
al., 2013; Simon et al., 2004; Wendler et al., 2006). For example, Simon et al. (2004) did not find 
race to be a significant factor associated with breast cancer clinical trial enrollment among those 
who were offered a clinical trial. This suggests that more minority women may enroll if provided 
an opportunity; however, they are not always given the opportunity (Baquet, Commiskey, 
Mullins, & Mishra, 2006; Diehl et al., 2011; Simon et al., 2004). Albrecht et al. (2008) found 
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that, in general, patients at two NCI centers were not offered a clinical trial 76% of the time, 
even though they were referred as being potentially eligible. Of those patients who were offered 
a clinical trial, 77% actually enrolled. Although separate enrollment rates were not calculated 
based on race, 17% of the study sample was African American patients. Since 13% of the US 
population is African American, trial participation at these two centers was representative of the 
African American population in the United States (US Census Bureau, 2015). Similarly, Adams-
Campbell et al. (2004) found that the enrollment rate among eligible African American cancer 
patients at one cancer center was 60%, indicating a high rate of interest in trial participation in 
this population. In fact, Markman, Petersen, and Montgomery (2008) studied whether there was 
a difference in interest rate among various populations with cancer in learning about cancer 
clinical trials. They found that minority respondents (categorized as African American, Hispanic 
and Asian American) expressed a greater interest than whites in learning about clinical trials. 
Furthermore, Cook, Kosoko-Lasaki, and O’Brien (2005) found that while only 5% of minority 
respondents participating in a survey indicated they were ever asked to participate in a healthcare 
study, 60% responded that they would participate if they were asked.  
While Baquet, Commiskey, Mullins, and Mishra (2006) found that African Americans 
who were recruited to clinical trials were significantly less likely to participate, they also found 
that males from a race other than white or African American were significantly more likely to 
participate in a trial. Diehl et al. (2011) analyzed enrollment data from 10 cancer clinical trials 
and found that African American and Hispanic patients were represented across the trials. 
However, the extent of their participation was not representative of the US population, especially 
among Hispanics. Jimenez et al. (2013) found race and ethnicity to be a significant predictor of 
clinical trial enrollment; specifically, patients who were white were significantly more likely to 
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enroll. However, after controlling for socioeconomic and clinical factors, race and ethnicity was 
no longer associated with trial enrollment. This suggests that minority patients are just as likely 
as white patients to enroll in clinical trials. This finding is substantiated by the “Strategies for 
Ensuring Diversity, Inclusion, and Meaningful Participation in Clinical Trials” workshop 
proceedings in which acclaimed researchers devoted to reducing racial and ethnic disparities in 
healthcare indicated that based on their experiences, minorities are actually just as likely as 
majority populations to participate in clinical trials when given the opportunity (National 
Academies of Sciences, Engineering, and Medicine, 2016). After reviewing records of patient 
screening data for more than 4,500 patients who declined to participate in a cancer clinical trial, 
Langford et al. (2014) found no differences in enrollment, refusal rates, or “not having a desire to 
participate in research” based on race or ethnicity. Based on a study conducted by Wendler et al. 
(2006), there is evidence to suggest that individuals from minority groups are actually more 
willing to participate in clinical or surgical intervention studies than non-Hispanic white patients. 
Wendler et al. (2006) analyzed consent rates of more than 14,000 individuals who were eligible 
and invited to participate in clinical and surgical intervention trials and found that consent rates 
of minority populations were higher than those of non-Hispanic whites. Hispanics in particular 
had statistically significant higher overall consent rates. Additionally, Brooks et al. (2015) found 
that up to 83% of minority patients who were eligible for a clinical trial chose to enroll, while 
only 45% of eligible white patients enrolled.  
Barriers of minority participation. There is an abundance of literature on the barriers 
specific to participation for minorities in clinical trials. In a systematic review conducted by Ford 
et al. (2008), barriers specific to underrepresented populations in clinical trials were categorized 
according to a conceptual model that was used to illustrate factors that were related to enrollment 
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in a clinical trial. To make a decision about enrolling, an individual needs to be aware of the trial, 
as well as be provided with an opportunity to participate. As previously discussed, minorities are 
not made aware of or asked to participate in clinical trials at the same rate as white patients 
(Baquet, Commiskey, Mullins, & Mishra, 2006; Simon et al., 2004). This results in minority 
patients experiencing a lack of awareness and lack of access to trials. Thus, Ford et al. (2008) 
categorized barriers based on awareness, opportunity and decision about participation. The 
socio-ecological model also can be used as a framework for categorizing barriers to minority 
participation, as previously documented in the clinical trial literature (Frew et al., 2014; Salihu, 
Wilson, King, Marty, & Whiteman, 2015; Wells & Zebrack, 2008). It is important to note that 
while the categorization of barriers to minority participation in clinical trials using the socio-
ecological model provides insight into multiple levels of influencers on an individual patient 
level, this is a different application of the socio-ecological model than that which was used to 
guide this study. However, since the utility of this categorization is beneficial for a 
comprehensive understanding, the barriers have been categorized according to the socio-
ecological model as follows: 
Intrapersonal barriers. Barriers to clinical trial participation on an individual patient 
level comprise characteristics of the individual, including demographic characteristics, 
knowledge, attitudes, beliefs and skills (Baquet, Commiskey, Mullins, & Mishra, 2006; Corbie-
Smith, Thomas, Williams, & Moody-Ayers, 1999; Ejiogu et al., 2011; Ford et al., 2008; Ford et 
al., 2013; Martin, Negron, Balbierz, Bickell, & Howell, 2013; McLeroy, Bibeau, Stecker, & 
Glanz, 1988; Roberson, 1994; Simon et al., 2004; Swanson & Ward, 1995). Examples of these 
intrapersonal barriers include:  
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• Demographic characteristics, including being of a racial/ethnic minority descent and 
having a lower socioeconomic status. Socioeconomic barriers at an intrapersonal 
level include cost of participation, lack of transportation and low levels of education 
(Baquet, Commiskey, Mullins, & Mishra, 2006; Ejiogu et al., 2011; Ford et al., 2008; 
Ford et al., 2013; Simon et al., 2004; Swanson & Ward, 1995) 
• Misunderstandings due to health illiteracy and misunderstanding the concept of 
informed consent (Corbie-Smith, Thomas, Williams, & Moody-Ayers, 1999; Cortes, 
Drainoni, Henault, & Paasche-Orlow, 2010; Swanson & Ward, 1995) 
• Awareness barriers, including a lack of knowledge surrounding the need for medical 
research and about what clinical trials are and a lack of awareness of clinical trial 
opportunities (Ejiogu et al., 2011; Ford et al., 2008; Leiter, Diefenbach, Doucette, Oh, 
& Galsky, 2015; Ramirez et al., 2008; Roberson, 1994; Simon et al., 2004) 
• Individual beliefs and attitudes, including: 
o Fear of being used as a guinea pig (Corbie-Smith, Thomas, Williams, & 
Moody-Ayers, 1999; Ford et al., 2008; Ford et al., 2013; Roberson, 1994) 
o Time demands and perceived interference of participation with other personal 
responsibilities (Corbie-Smith, Thomas, Williams, & Moody-Ayers, 1999; 
Ford et al., 2008; Martin, Negron, Balbierz, Bickell, & Howell, 2013) 
o Fear of exportation (Ford et al., 2013) 
o Lack of perceived benefit of participation (Corbie-Smith, Thomas, Williams, 
& Moody-Ayers, 1999; Ejiogu et al., 2011; Ford et al., 2008) 
o Lack of interest (Martin, Negron, Balbierz, Bickell, & Howell, 2013) 
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o Skepticism due to uncertainty or negative connotations of clinical trials 
(Durant et al., 2014) 
o Perceived stresses of burdensome procedures or adverse effects (Ford et al., 
2008) 
Interpersonal barriers. Barriers on an interpersonal level include influences of an 
individual’s social network and social support system, including family, work and friendship 
networks and healthcare providers (McLeroy, Bibeau, Stecker, & Glanz, 1988; Salihu, Wilson, 
King, Marty, & Whiteman, 2015). Interpersonal barriers include: 
• Negative experience of a potential participant’s family member with the healthcare 
system (Ford et al., 2008; Swanson & Ward, 1995) 
• Family concerns about research trials (Ford et al., 2008) 
• Work obligations and an inability to get the time off of work (Ford et al., 2008) 
• Communication barriers, including misunderstandings due to language barriers and 
poor doctor-patient communications (Ford et al., 2008; Ford et al., 2013; Swanson & 
Ward, 1995; Williams & Corbie-Smith, 2006). Additionally, skepticism about trial 
participation is commonly mistaken by research staff as distrust whereas education on 
clinical trials could help to alleviate some concerns of potential participants (Durant 
et al., 2014) 
• Patients’ lack of trust in their physicians (Corbie-Smith, Thomas, Williams, & 
Moody-Ayers, 1999) 
• Cultural differences between researchers and participants (Ford et al., 2013; Williams 
& Corbie-Smith, 2006) 
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• Attitudes of healthcare providers: minority patients are oftentimes not informed of a 
study when their primary physician mistrusts research or perceives limited scientific 
value, perceives their patients as mistrusting research, doesn’t want to commit the 
additional time to explain the study or complete paperwork, and/or objects to 
referring their patients to other physicians conducting a study (Howerton et al., 2007; 
Ramirez et al., 2008; Ramirez et al., 2012; Salihu, Wilson, King, Marty, & 
Whiteman, 2015) 
• Lack of provider awareness about clinical trials (Howerton et al., 2007) 
Organizational barriers. An organization is defined as a social institution with 
organizational characteristics and rules and regulations for operation. Barriers on an 
organizational level include influences of organizations, including the healthcare system, and 
how policies and structures in place within organizations and the healthcare system influence an 
individual’s behavior (McLeroy, Bibeau, Stecker, & Glanz, 1988; Salihu, Wilson, King, Marty, 
& Whiteman, 2015). Organizational barriers include: 
• Lack of access to health care or not having health insurance (IOM, 2003; Swanson & 
Ward, 1995; USHHS, CDC, 2011a) 
o After controlling for insurance status, Jimenez et al. (2013) found that after 
controlling for health insurance, African American, Hispanic and Asian 
patients were just as likely as their white counterparts to enroll in an 
advanced-stage cancer clinical trial. However, not all health insurers cover the 
costs of clinical trial participation. After reviewing data from patients 
consented into a cancer clinical trial at the Sidney Kimmel Comprehensive 
Cancer Center over a 3-year period, researchers determined that 13.6% of 
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consented patients were denied coverage by their insurer (Klamerus et al., 
2010). While federal law now requires health insurers to cover routine costs in 
clinical trials under ACA, exceptions to this law may result in coverage gaps. 
For example, health plans that existed when the ACA was enacted are not 
required to cover routine patient costs in clinical trials (USHHS, NIH, NCI, 
2020) 
• Lack of access to research centers: minorities are less likely to have access to research 
centers where clinical trials are commonly offered (Boden-Albala et al., 2015; Diehl 
et al., 2011; Durant et al., 2014)  
• Organizational barriers related to the clinical research sites, including: 
o Lack of access to the study population (Durant et al., 2014; Ejiogu et al., 
2011; Swanson & Ward, 1995; Williams & Corbie-Smith, 2006) 
o Lack of experience in recruiting racial and ethnic minorities (Ejiogu et al., 
2011; Williams & Corbie-Smith, 2006) 
o Researcher beliefs and biases, which influence the effort researchers exert in 
addressing barriers to minority recruitment. For example, a researcher’s 
perception of the potential harm or benefit a trial could have to patients, as 
well as a researcher’s perception of participants’ distrust of research (Ejiogu et 
al., 2011; Ford et al., 2008; Simon et al., 2004; Stone, Mauch, & Steger, 1998; 
Swanson & Ward, 1995; Williams & Corbie-Smith, 2006) 
o Organizational climate, lack of resources and limited funding to support 
minority recruitment efforts (Joseph & Dohan, 2009) 
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• Study design: eligibility criteria precludes minorities from being eligible due to 
disproportionate comorbid conditions (Adams-Campbell et al., 2004; Ford et al., 
2008; Swanson & Ward, 1995) 
o Adams-Campbell et al. (2004) conducted a study to systematically evaluate 
the influence of the study design on the recruitment of African Americans into 
cancer clinical trials being conducted at one large cancer center. Of the 
African American patient population studied, nearly one-fourth was ineligible 
to participate in an existing clinical trial because of comorbidities. Langford et 
al. (2014) also found that being of non-Hispanic black race was significantly 
associated with not meeting eligibility criteria due to existing comorbidities. 
Given that health disparities disproportionately affect racial and ethnic 
minorities (USHHS, CDC, 2011a; USHHS, CDC, 2011b), it is likely 
minorities also have a disproportionate burden of comorbidities excluded by 
study protocols, which results in a lack of opportunity to participate 
• Members of racial and ethnic minority groups are underrepresented in the healthcare 
workforce, leading to a shortage of minority physicians involved in clinical research. 
Ramirez et al. (2008) found that half of the Latino physicians who participated in 
their survey indicated they had never been involved in a clinical trial, compared with 
one-third of white physicians. This is an important finding since the inclusion of 
minority investigators and research staff is associated with successfully recruiting 
minority study participants (Ford et al., 2013; Swanson & Ward, 1995; The Society 
for Women’s Health Research & FDA, 2011; Williams & Corbie-Smith, 2006) 
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Community barriers. Community is not only defined by individuals sharing common 
demographic or geographic characteristics, but also includes mediating structures such as family, 
social networks, churches and neighborhoods, all of which may be sources of social identity. 
Community is also defined by relationships among organizations within a geographical region. 
Community barriers include: 
• Cultural beliefs and attitudes 
o Lack of trust in the healthcare system and clinical research, particularly due to 
past history of unethical conduct in clinical research involving minorities 
(Corbie-Smith, Thomas, Williams, & Moody-Ayers, 1999; Ejiogu et al., 2011; 
Ford et al., 2013; Roberson, 1994; Swanson & Ward, 1995; Williams & 
Corbie-Smith, 2006)  
§ One such example was the Tuskegee Study that started in 1932 with 
the US Public Health Service and the Tuskegee Institute and enrolled 
poor African American men who were told they were being treated for 
‘bad blood.’ The men agreed to be treated for their ‘bad blood’ but 
were never properly informed about the study to provide their 
informed consent. Instead, they had been misled about the study and 
were not informed that they had syphilis in order to allow the 
researchers to record the natural history of syphilis in African 
American men. Furthermore, once penicillin was found to be 
successful in treating syphilis in 1947, it was never offered to the study 
participants. The study lasted until 1972, when the US government 
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deemed the study to be unethical and announced the end of the study 
(USHHS, CDC, 2013b)  
§ Another example is known as the Puerto Rican “Tuskegee.” In the 
1950s to the early 1960s in a remote farming town in Puerto Rico, 
women were given a “magic pill.” They were told the pill would keep 
them from having children they could not support. Unbeknownst to 
these women, they were actually subjects in research testing of the 
world’s first birth control pill. Doctors provided hundreds of women 
among Puerto Rico’s poorest agricultural class with these free pills 
that contained three times as much hormone as the versions currently 
on the market. Although the pills kept the women from getting 
pregnant, they also came with a multitude of side effects and, more 
importantly, without the informed consent of the women taking the pill 
(Quintanilla, 2004). 
o Cultural beliefs about illness and disease, such as distinguishing between 
“hot” and “cold” diseases and preferences for folk healers and herbal remedies 
(Juckett, 2013; Swanson & Ward, 1995) 
• Lack of available public transportation to the research site for attending study visits 
(Ejiogu et al., 2011; Ford et al., 2008; Swanson & Ward, 1995)  
Public policy barriers. Barriers at a public policy level include local, state, and national 
laws and policies, such as: 
• The mandate to include women and members of minority groups as participants in 
clinical research applies to NIH-funded trials only (USHHS, NIH, 2001) 
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• The federal law under the ACA requiring health insurers to cover costs for routine 
procedures in clinical trials grants an exception to Medicaid plans and grandfathered 
health plans that were in existence when the ACA became law (USHHS, NIH, NCI, 
2020) 
A few of these barriers were found to be specific to Hispanics (Martin, Negron, Balbierz, 
Bickell, & Howell, 2013; Roberson, 1994). Roberson (1994) found that ethnic background, lack 
of information and mistrust are perceived barriers specific to recruitment among the Hispanic 
population. Lack of interest and time commitment were cited as the most common barriers to 
recruitment for African American and Hispanic women in a postpartum depression study 
(Martin, Negron, Balbierz, Bickell, & Howell, 2013). Ford et al. (2013) found that Spanish-
speaking clinicians are crucial to the successful recruitment of Hispanic patients, since they are 
more likely to be trusted by their Hispanic patients. Study materials need to be translated into 
Spanish, keeping in mind patients with low literacy levels. Researchers also need to reassure 
patients that immigration status will not be documented (Ford et al., 2013). 
Strategies specific to addressing barriers. Martin, Negron, Balbierz, Bickell, and 
Howell (2013) successfully recruited minority women (African American and Latina) into a 
postpartum depression prevention study by using a feedback-responsive recruitment strategy. 
Their approach involved immediately responding to identified recruitment barriers that evolved 
throughout the enrollment period by revising their recruitment messages. This strategy resulted 
in a decreased refusal rate to participation of 40% to 19%. Lack of interest and time commitment 
were identified as the two most common barriers to participation. The researchers addressed 
concerns for time commitment by offering alternative methods for completing follow-up 
interviews that better fit within the women’s schedules. To help overcome lack of interest, they 
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changed their recruitment message and presented the study to potential participants as a way to 
teach them about postpartum mothers’ health so their input could be used to benefit other 
African American and Latina women in the future. This shared goal of helping others helped 
increase recruitment, which is consistent with research that demonstrates altruism as a main 
reason for participating in clinical trials (Bevan, Chee, McGhee, & McInnis, 1993). A study 
conducted by Smith et al. (2007) found that African American women are motivated by the 
desire to help their community or other people of their color. 
In a study conducted by Ejiogu et al. (2011), barriers that disproportionately affect 
participation in clinical trials by minorities and the socioeconomically disadvantaged were 
targeted in order to overcome recruitment challenges and successfully recruit for a longitudinal 
study. The study examined how race and socioeconomic status influence the development of 
age-related health disparities. They targeted biracial (African American and non-Hispanic white) 
and socioeconomically diverse participants. The researchers identified barriers that were specific 
to this study and its targeted participants by meeting with local stakeholders, health 
professionals, government officials, as well as establishing a community advisory board that 
included church leaders, neighborhood activist leaders and local residents. To address the 
barriers, the researchers created a recruitment and retention plan that included deploying mobile 
medical research vehicles (MRVs) parked in the participants’ neighborhoods in Baltimore, 
Maryland, and offering transportation to the MRVs. They also educated members of the 
community advisory boards about health disparities and the need for research in their 
communities to gain feedback on the study methods and local barriers, as well as to gain 
community support. They coordinated surveillance of the MRVs with the Baltimore Police 
Department and developed a cultural proficiency curriculum for site staff. The investigators also 
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established active community citizenship through their participation in local festivals and 
community social events. Finally, they adapted the study design to include medical benefits as a 
means to motivate participants who didn’t have access to healthcare. Their recruitment strategy 
paid off. Of the 3,722 participants recruited, 2,200 (59%) were African American and 1,522 
(41%) were white (Ejiogu et al., 2011). They designed the study based on the recruitment 
strategy, which is an important consideration because this is typically not common practice since 
recruitment strategies are often an after-thought. Williams and Corbie-Smith (2006) have found 
that recruitment strategies need to be established prior to beginning enrollment in order 
maximize their success. When they are altered during the recruitment period, they are less 
successful in recruiting minority participants.  
Value investigators place on minority recruitment. The literature indicates that 
physicians’ attitudes toward participating in clinical trials directly impacts enrollment in general, 
likely due to the value and importance they place on clinical trials. Further, those physicians who 
have more positive feelings towards clinical trials are more active in enrolling patients (Jacobs et 
al., 2014). However, there is an ethnic disparity among physicians in regard to their attitudes 
toward clinical trials. Twice as many Latino physicians as white physicians disagree that the 
scientific value of clinical research outweighs the risks (18% vs. 9%, respectively) (Ramirez et 
al., 2008). This may contribute to the underrepresentation of Latino researchers, as well as the 
underrepresentation of minority clinical trial participants, since Latino physicians are more likely 
to treat Latino patients. This is important because having Spanish-speaking research staff who 
look like the population they are trying to recruit has been successful in recruiting Hispanic 
women (National Academies of Sciences, Engineering, and Medicine, 2016). Therefore, 
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improving minority physician attitudes towards clinical trials could improve minority 
participation.  
Results of studies have determined that PI attitudes play a significant role in minority 
recruitment. The value investigators place on minority recruitment has been found to be a key 
contributor toward the success or failure of recruiting minority participants into clinical studies 
(Williams & Corbie-Smith, 2006; Wright et al., 2001). For example, Williams and Corbie-Smith 
(2006) found that investigators who valued the inclusion of minority participants in clinical 
research were more successful in recruiting minority participants. In their study, Williams and 
Corbie-Smith (2006) surveyed PIs to gain their perspectives on recruiting minority participants 
into clinical trials to identify factors associated with success in this area. The majority of PI 
respondents (90%) were white but the majority of them reported including minorities on their 
research team. Notably, 73% of the investigators surveyed self-reported success with recruiting 
minority participants into a trial. PIs who considered minority participation in research as 
important, who didn’t need to make midstream modifications to their recruitment strategy and 
who reported fewer recruitment barriers reported being successful in minority recruitment. 
Although including minority recruiters, investigators and/or project managers as part of the site 
staff was associated with reported minority recruitment success, the race of the PI was not 
associated with reported minority recruitment success. Of the sites that didn’t make midstream 
changes to their recruitment strategy, 76% reported success in recruiting minority participants, 
whereas only 59% of those sites that made changes midstream to their recruitment strategy were 
successful in recruiting minorities. 
Durant et al. (2007) conducted a survey of PIs to evaluate the attitudes and experiences of 
those who receive federal funding in recruiting minorities and women in clinical trials. The 
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purpose of their study was to determine the recruitment goals that investigators set for minority 
recruitment, the percentage of PIs that failed to reach their goals, and whether or not PI and study 
characteristics and PIs’ perceptions of minority recruitment were associated with their failure to 
meet minority recruitment goals. The majority of the PIs surveyed were white males with a mean 
age of approximately 50 years. The most common methods of recruitment used among the PI 
respondents were clinic or hospital-based recruitment, word of mouth, flyers and physician 
referral. The authors found that many PIs did not set recruitment goals for individual minority 
groups. Goals were set more frequently for African Americans (91%) and whites (88%); 67% of 
PIs self-reported setting recruitment goals for Hispanics and 55% for Asian Americans. Mean 
recruitment goals were highest for whites (71%), compared with mean recruitment goals of 33% 
for African Americans, 21% for Hispanics and 10% for Asian Americans. Although investigators 
who receive federal funding are required to meet minority enrollment targets, this study 
reinforces the fact that many of these investigators do not set minority recruitment goals. In 
another study that explored researcher strategies to incorporate the NIH’s policy to include a 
representative proportion of minorities in NIH-funded clinical trials, only half of the respondents 
indicated they proactively set recruitment goals for minority inclusion (Boden-Albala et al., 
2015). Durant et al. (2007) also found that PIs were more likely to fail to meet their racial and 
ethnicity demographic-specific recruitment goals set for African Americans (51%), Asian 
Americans (55%) and Hispanics (44%) compared with goals set for whites (30%). Failure rates 
in meeting recruitment goals were significantly higher for African Americans and Asian 
Americans as compared with failure rates in meeting recruitment goals for white participants. 
Many factors were found to be associated with failing to meet recruitment goals, but they were 
varied, and none were consistently associated with failing to meet recruitment goals across 
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different racial and ethnic groups. Sixty percent of PIs had not yet completed study enrollment 
for their most recent federally funded trial, which could contribute to not meeting their minority 
recruitment goals. The factors found to be associated with failing to meet recruitment goals for 
African Americans were related to investigator and study characteristics, as well as PI 
perceptions. These factors included PIs conducting an observational study, completed study 
enrollment, or the perception of PIs that there would be a large number of barriers to minority 
enrollment (Durant et al., 2007). The fact that a perception of recruitment barriers was associated 
with failing to meet recruitment goals corroborates the findings of Williams and Corbie-Smith 
(2006) who reported fewer perceived recruitment barriers were associated with greater success in 
minority recruitment (Willams & Corbie-Smith, 2006).  
Durant et al. (2007) also found that having more than 20 years of funding as a PI was 
associated with a lower chance of failing to meet recruitment goals for African Americans. This 
may be due to greater experience in conducting and recruiting for clinical trials. None of the 
factors that were analyzed were independently associated with failing to meet recruitment goals 
for Hispanics. The value investigators place on minority recruitment plays a role in successfully 
recruiting minority participants (Williams & Corbie-Smith, 2006) but whether or not this value is 
associated with setting individual minority recruitment goals is unknown. 
Interestingly, sites in the ALLHAT with a large African American patient population 
recruited African Americans at the same rate as those sites without a high percentage of African 
American patients. Though the reasons behind these similar recruitment rates were not 
articulated, the authors speculated that they were due to the motivation and training of 
investigators to recruit diverse patients, as well as the existing physician-patient relationship at 
those sites that successfully recruited African American participants (Wright et al., 2001). These 
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findings demonstrate that recruiting minority participants into clinical studies is achievable when 
investigators are motivated and place value on recruiting minorities and suggests that these sites 
were specifically focusing on and actively recruiting minority participants. Since more than half 
of the ALLHAT participants were minorities (Pressel et al., 2001), the research also suggests that 
minorities are willing to participate when given the opportunity, similar to findings from Diehl et 
al. (2011), Jimenez et al. (2013) and Simon et al. (2004). This is also important to recognize 
because of a sponsor’s focus and priority to expedite trial enrollment in order to conduct a study 
in the shortest amount of time possible (Getz, 2012; IMS Health, 2012; USHHS, OIG, 2000). 
The findings from Wright et al. (2001) provide evidence that recruiting minority participants 
when the right sites are involved is not time-consuming.  
African American and Hispanic participants likely will enroll in clinical trials when given 
the opportunity (Diehl et al., 2011) and minorities are interested in learning about clinical trials 
(Markman, Petersen, & Montgomery, 2008). These findings suggest that minority participation 
may increase when value on the importance of including minority participants in clinical 
research is instilled in more investigators. Therefore, if guidance or successful experience with 
minority recruitment is shared among the research community, it may increase the value that 
investigators place on recruiting minority participants and, ultimately, result in an increased 
number of minority participants enrolling in clinical trials.  
Organizational context. Organization contextual factors can impact the enrollment 
success of clinical trials among the general population. Specifically, those organizations that 
provide support and offer incentives to physicians to enroll patients, as well as mandate 
minimum enrollment targets, accrue more patients. While these organizational contextual factors 
increase enrollment, they were not found to directly influence physician attitudes toward clinical 
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trials. Physicians’ positive attitudes toward participating in clinical trials did, however, have a 
direct positive effect on enrollment (Jacobs et al., 2014). McMullen, Griffiths, Leber, and 
Greenhalgh (2015) explored factors related to high-recruiting and low-recruiting practices 
(within the general population) and found that high-recruiting practices were innovative and 
characterized by strong leadership, good managerial relations, dedicated resources and provision 
of staff training. Adams, Caffey, and McKevitt (2015) found that research staff perceived 
organizational factors to contribute more to recruitment success than the study itself (in general). 
These factors included commitment by the research team, the value of research recognized 
within the organization and having sufficient resources. In a systematic literature review 
conducted by Fletcher, Gheorghe, Moore, Wilson, and Damery (2012), the researchers found 
that providing research-dedicated staff, enrollment incentives and additional training led to 
increased recruitment rates. They also found that being part of a practice active in research is 
connected with positive recruitment results. These findings relate to clinical trial recruitment in 
general, and further studies are needed to determine if the same factors apply when recruiting 
minorities. However, there is a small pool of literature on organizational contextual factors 
specific to minority recruitment. 
When exploring organizational barriers to minority participation in cancer clinical trials, 
Joseph and Dohan (2009) found that organizational climate and research infrastructure impacts 
minority recruitment. Specifically, a lack of resources created a climate in which clinical trials 
were made a low priority, such as providers who are already being stretched to see patients and 
having recruitment activities occupying exam rooms that were needed for patient care. Limited 
funding for research left providers with a small research staff and a lack of resources to translate 
patient-facing materials that described studies that were being conducted to patients. 
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Furthermore, the interdisciplinary structure of the clinic was such that patients did not have a 
dedicated provider, which resulted in a lack of continuity of care and limited individual provider 
awareness of specific trials. These factors led to staff having an unfriendly attitude toward 
clinical trials, which shaped the culture of the clinic to prioritize clinical care over research. 
These findings by Joseph and Dohan (2009) support other findings that research center 
infrastructure and experience impact the successful enrollment of minority participants (Etkin, 
Farran, Barnes, & Shah, 2012). PIs’ perceived importance of minority inclusion is also 
associated with minority recruitment success rates (Williams & Corbie-Smith, 2006), which 
would likely impact organizational climate.  
 As previously discussed, factors related to the investigator site that negatively impact 
minority recruitment include lack of access to the study population, lack of experience in 
recruiting racial/ethnic minorities, lack of information about effective strategies and cultural 
differences between research staff and participants (Williams & Corbie-Smith, 2006). On the 
other hand, several studies suggest that characteristics related to specific research sites may have 
contributed to their successful enrollment of minorities into clinical trials. Jimenez et al. (2013) 
found that white race was not a significant predictor of clinical trial enrollment after controlling 
for recruitment site. One recruitment site in particular in this study was a statistically significant 
confounder to predicting enrollment based on race and ethnicity. More than half of the study 
participants in the ALLHAT were African American and those sites with a large African 
American patient base recruited at the same rate as sites that did not have primarily African 
American patients (Wright et al., 2001). These examples suggest that there is something different 
about these sites from the other sites in terms of recruiting minority participants and that, 
perhaps, they are specifically focusing on minority recruitment. In a study conducted by Duda et 
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al. (2011), the lack of consistency with recruitment strategies employed across different research 
sites led the researchers to believe that the success specific sites had with recruiting minority 
patients was related to characteristics of the investigator sites themselves. More research is 
needed in this area to determine the specific organizational characteristics that may contribute to 
successful minority recruitment.  
Health literacy. Health literacy is defined as “the degree to which an individual has the 
capacity to obtain, communicate, process, and understand basic health information and services 
to make appropriate health decisions” (USHHS, CDC, 2019). Although general literacy and 
health literacy are not the same, even people with strong literacy skills and high education levels 
have trouble understanding health information. For instance, 15% of high school graduates have 
limited health literacy (US Department of Education, Institute of Education Sciences, 2006). 
General literacy is defined by the US Department of Education, Institute of Education Sciences 
(2006) as “using printed and written information to function in society, to achieve one’s goals, 
and to develop one’s knowledge and potential.” This includes reading, writing and basic 
mathematical and speech comprehension skills. Thus, general literacy is the foundation for 
health literacy because literacy provides the skills that enable individuals to understand and 
communicate information within a health context (IOM, 2004).  
On average, Hispanic adults have lower health literacy than any other racial or ethnic 
group and white adults have the highest health literacy compared with adults of other races or 
ethnicities. Sixty-six percent of Hispanic adults have either below basic or basic health literacy 
skills, indicating limited health literacy, and 41% do not have the skills to perform simple 
everyday literacy activities. Fifty-eight percent of African American adults have limited health 
literacy, compared with 28% of white adults (US Department of Education, Institute of 
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Education Sciences, 2006). Individuals with limited health literacy have less knowledge about 
their medical conditions and management of their disease (IOM, 2004). For example, Williams, 
Baker, Parker and Nurss (1998) found that functional health literacy levels in patients with a 
chronic disease were correlated with knowledge and management of their disease—patients with 
limited health literacy cannot optimally manage their disease. Patients with limited health 
literacy also are less likely to use preventive services, since they are more likely to enter into the 
healthcare system at a more advanced stage of their disease (IOM, 2004). Paasche-Orlow and 
Wolf (2007) suggest that access and utilization of the healthcare system is decreased in 
individuals with limited health literacy due in part to a limited ability to navigate the complexity 
of the healthcare system. In a systematic literature review conducted by Koskan, Friedman and 
Messias (2010), the researchers found that Hispanics with lower levels of health literacy were 
less likely to be screened for the presence of diseases. It is no surprise that limited health literacy 
is a barrier to clinical trial participation among minorities (Corbie-Smith, Thomas, Williams, & 
Moody-Ayers, 1999; Swanson & Ward, 1995). Barriers with entering the healthcare system as 
indicated by the IOM (2004) and Paasche-Orlow and Wolf (2007), as well as the limited 
knowledge of chronic disease in individuals with lower health literacy levels, may be part of the 
reason behind lower clinical trial participation. Further, Hispanic ethnicity and lower levels of 
education have been found to be independently associated with decreased levels of clinical trial 
awareness (Leiter, Deifenbach, Doucette, Oh, & Galsky, 2015). In a study conducted by Duda et 
al. (2011), the researchers found that the minority participants who enrolled in the National Lung 
Screening Trial were disproportionately less well educated and more economically 
disadvantaged than whites, both of which are factors contributing to limited literacy (IOM, 
2004). Although distinct from general literacy, basic literacy skills are required for health 
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literacy, and the percentage of adults with proficient health literacy increases accordingly with 
each higher level of educational attainment beyond high school (IOM, 2004; US Department of 
Education, Institute of Education Sciences, 2006). In fact, approximately half of US adults lack 
the basic literacy skills required for full participation in American society. Since basic literacy 
skills are a building block for health literacy, a large proportion of the US population, a 
disproportionate amount of which are racial and ethnic minorities, therefore, has limited health 
literacy. Both being a member of a racial and ethnic minority and lower education levels have 
been found to be associated with limited health literacy (IOM, 2004). This poses a problem with 
informed consent when sites need to educate patients with low education or limited health 
literacy on study details and requirements and any potential risks of participating in the study. 
The readability levels of informed consent documents for clinical trials are higher than the 
average reading level of most adults in the United States, and the majority of clinical trial 
participants do not fully understand the study information presented to them during the consent 
process (Cortes, Drainoni, Henault, & Paasche-Orlow, 2010; Flory & Emanuel, 2004; 
Helgesson, Ludvigsson, & Stolt, 2005; IOM, 2004). In fact, after using health literacy principles 
to redesign a surgical consent form, the percentage of patients who actually read the form 
increased from 25% to 91% (Lorenzen, Melby, & Earles, 2008). Even so, following industry 
recommendations for improving comprehension of a consent form for a hypothetical study did 
not always result in comprehension among Spanish-speaking individuals with low literacy or 
lack of familiarity with research. Researchers should incorporate interactive consent discussions 
into their consent processes to better ensure comprehension by all potential research participants 
(Cortes, Drainoni, Henault, & Paasche-Orlow, 2010; Flory & Emanuel, 2004). Additionally, the 
teach-back method can help the researcher determine the patient’s understanding of the 
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information being presented (Lorenzen, Melby, & Earles, 2008). Furthermore, individuals with 
limited health literacy are less likely to ask questions of their provider and admit that they have a 
poor understanding of the discussion. Physicians are often unaware of any misunderstandings 
(IOM, 2004). This could result in patients not taking their study medication or performing any 
at-home study requirements as instructed, since patients with limited health literacy remember 
and understand less than half of what they are told by their physicians (IOM, 2004).  
The skill of healthcare professionals in communicating health information also 
contributes to health literacy (IOM, 2004). The Agency for Healthcare Research and Quality 
(AHRQ) has recognized that in order to address the needs of patients with limited health literacy, 
organizations need to become health literate. Ways to promote health literacy within a healthcare 
practice include improving communication (spoken and written), providing patients with 
empowerment to control their disease and implementing patient support systems (AHRQ, 2010). 
According to the participants of an IOM roundtable on health literacy, a health literate 
organization is “an organization that makes it easier for people to navigate, understand, and use 
information and services to take care of their health” (Brach et al., 2012). Livaudais-Toman, 
Burke, Napoles, and Kaplan (2014) conducted a study to assess the organizational health literacy 
of clinical trial sites and characteristics associated with health literate behaviors, measured by 
communication (written and verbal) and outreach efforts. Less than half of the sites surveyed 
offered supplemental information about clinical trials (such as frequently asked question sheets 
to help potential participants better understand clinical trials), and only 22% of sites offered 
supplemental materials in languages other than English. Only one-fourth of sites offered 
translated materials to facilitate recruitment and patient navigation to trials. The provision of 
translated materials does not, however, solely fulfill health literacy requirements, since 
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individuals with limited English proficiency may have limited health literacy (IOM, 2004). 
Sixty-five percent of sites offered professional interpretation services, a finding that is 
disappointing given the National Standards on Culturally and Linguistically Appropriate 
Services (CLAS) in Health Care policy that healthcare organizations must offer and provide 
language assistance services, at no cost, to each patient with limited English proficiency 
(Livaudais-Toman, Burke, Napoles, and Kaplan; USHHS, Office of Minority Health, 2018). 
Additionally, less than half of the sites engaged in community outreach efforts, a strategy that the 
authors categorized as an organizational health literate characteristic and that others have found 
to be successful in recruiting minority participants (Etkin, Farran, Barnes, & Shah, 2012; 
Livaudais-Toman, Burke, Napoles, and Kaplan). Findings by Livaudais-Toman et al. (2014) 
suggest that clinical research sites are not addressing the health literacy needs of their patients.  
It is also important to note that culture influences how individuals interact with the health 
care system. Cultural differences may have an effect on the communication and understanding of 
health information, and an individual’s ability to make appropriate healthcare decisions is based 
on their cultural beliefs (Ingram, 2012; IOM, 2004). As a result, culture is a component 
influencing the health literacy skills of an individual. As such, cultural competence skills and 
knowledge are required for healthcare professionals to be able to provide care as part of a health 
literate organization (IOM, 2004). 
Cultural competence. Cultural competence is a required skill set among physicians for 
them to deliver high quality care to patients successfully, helping to reduce racial and ethnic 
disparities in healthcare (Betancourt, 2004; Betancourt, Green, Carrillo, & Ananeh-Firempong, 
2003). Cultural competency requires that organizations have a congruent set of values, 
behaviors, attitudes, practices, policies and structures that enable them to adapt to diversity and 
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deliver services in order to work effectively cross-culturally (Cross, Bazron, Dennis, & Isaacs, 
1989). In order to be culturally competent, healthcare professionals must be aware of the values 
and belief systems of different cultures, have knowledge of cultural world views, possess the 
skills to collect health information in a culturally sensitive manner and encounter patients from 
culturally diverse backgrounds with cross-cultural interactions. Lastly, they need to have a desire 
to engage in the process of cultural competence (Campinha-Bacote & Campinha-Bacote, 1999; 
IOM, 2004). A culturally competent healthcare system is one that acknowledges and 
incorporates the importance of culture and adapts services to meet specific cultural needs based 
not only on health beliefs and behaviors but also on social factors (Betancourt et al., 2003). 
Purnell et al. (2011) published guidance for assessing an organization’s cultural competence in 
the delivery of culturally competent healthcare, of which the key components are administration 
and governance, education, language services and staff competencies. For example, a culturally 
competent healthcare organization has a mission statement and philosophy that address diversity; 
they partner with ethnic community agencies to engage the local community in activities, such as 
community health screenings; advertisements and health promotion campaigns are representative 
of the diversity and languages of patients and placed where they will reach patients in the local 
community; resources are allocated to diversity training for all levels within the organization; 
recruitment of staff reflects the diversity of the community; and staff are knowledgeable of their 
patients’ cultures. Further, Brach and Fraserirector (2000) suggest that if an organization exhibits 
cultural competency techniques they could effectively change both physician and patient 
behavior, resulting in improved communication, a better understanding of patients’ cultural 
behaviors, increased trust and improved patient education on their disease and treatment options. 
This would ultimately yield greater access to appropriate healthcare services among minorities. 
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Poor doctor-patient communications, cultural differences between researchers and participants, 
mistrust, lack of patient knowledge about clinical research as a potential treatment option and 
limited access to healthcare services are all barriers to minority recruitment (Baquet, 
Commiskey, Mullins, & Mishra, 2006; Corbie-Smith, Thomas, Williams, & Moody-Ayers, 
1999; Ejiogu et al., 2011; Ford et al., 2008; Ford et al., 2013; IOM, 2003; Leiter, Diefenbach, 
Doucette, Oh, & Galsky, 2015; Roberson, 1994; Simon et al., 2004; Swanson & Ward, 1995; 
USHHS, CDC, 2011a; Williams & Corbie-Smith, 2006). These findings, therefore, suggest that a 
healthcare organization employing cultural competency techniques also would yield greater 
access to clinical trials among minority populations.  
Cultural competence also needs to be prevalent in protocol design and study initiation 
(Diehl et al., 2011). For example, Adams et al. (2004) found that exclusion criteria prohibited the 
eligibility of many African Americans from cancer trials due to the disproportionate incidence of 
comorbidities in that population. Characteristics of African Americans and other minorities must 
be taken into consideration when developing study designs and eligibility criteria. The capacity 
to acquire cultural knowledge about patients is a crucial component of cultural competence 
attributed to recruiting minority populations into clinical trials (O’Brien et al., 2006). Examples 
in the literature describe successful recruitment of diverse patients into clinical trials by 
acquiring cultural knowledge about patients they are targeting and incorporating that knowledge 
into the study design and recruitment plan (Ejiogu et al., 2011; Wallington et al., 2016). 
Wallington et al. (2016) used a cultural competence conceptual framework to integrate culturally 
competent strategies into the study design, such as using diverse staff from the local community, 
ensuring all staff were trained on the elements of cultural competence, as well as reviewing all 
study procedures, consent documents, data collection tools and recruitment materials for health 
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literacy and cultural suitability. Additionally, Ejiogu et al. (2011) found that culturally sensitive 
researchers, support of the local community, and designing their study to overcome known 
barriers to minority participation in clinical research all contributed to the successful recruitment 
of minorities. As part of their recruitment plan, cultural proficiency training was instituted to 
help researchers and site staff recognize how their personal biases could influence their 
interactions with potential patients who were of a different culture. As a result of these 
considerations, the recruitment success in the study was partly credited to the diverse research 
staff and the cultural proficiency training program that provided continuous training to the 
researchers throughout the study.  
Cultural competency also plays an invaluable role in the informed consent process with a 
multicultural audience, as evidenced by Simon and Kodish (2005). In reviewing a series of 
informed consent discussions for participation in clinical trials for pediatric leukemia, Simon and 
Kodish found that information quality and the disclosure process regarding the clinical trial was 
significantly better for white parents than it was for minority parents. This included informing 
parents about the right to withdraw from the trial, details about the benefits and risks, as well as 
details about any expected pain or discomfort that may result from the investigational 
medication. Simon and Kodish attributed the disparity in clinical trial information communicated 
to the parents of minority patients to assumptions made by the researchers about these parents’ 
information needs and preferences based on their race or ethnicity and socioeconomic status. 
The ACA includes provisions for recruiting and thorough training of the healthcare 
professional workforce in an effort to improve access to and delivery of care for all individuals, 
especially those who face healthcare disparities, such as minorities (KFF, 2013a; KFF, 2013b; 
Sultz & Young, 2014). One such provision provides support for cultural competence training of 
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healthcare professionals (KFF, 2013a). However, additional cultural competency training is 
needed as several investigators reported deficiencies in this area (Diehl et al., 2011; O’Brien et 
al., 2006). Lack of researcher training in communication techniques that are culturally 
appropriate is a known barrier to recruitment (Baquet, Commiskey, Mullins, & Mishra, 2006), 
yet Boden-Albala et al. (2015) found that only 36% of investigators required cultural 
competency training for staff as part of their strategy to adhere to the NIH’s minority inclusion 
policy. 
Cultural, community and site-specific recruitment strategies. Direct community 
involvement by researchers who tailor their strategies to align with the culture of the community 
have proven to be successful in recruiting minority participants into clinical trials (Duda et al., 
2011; Ejiogu et al., 2011; Etkin, Farran, Barnes, & Shah, 2012; Germino et al., 2011; Wallington 
et al., 2016). Germino et al. (2011) described a successful recruitment strategy for recruiting 
young African American breast cancer survivors into an interventional study designed to help 
women deal with fears and communication issues around their breast cancer and identify positive 
directions for their lives. The recruitment strategy involved engaging community stakeholders to 
address barriers to recruitment specific to the study population and community. The over-arching 
recruitment objectives were focused on increasing familiarity of the study in the targeted 
communities through community outreach, partnering with African American churches and 
community organizations, increasing the availability and accessibility of study information, and 
using cultural brokers to help accomplish their goals. One of the strategies used for increasing 
the availability and accessibility of study information included using African American recruiters 
who made calls from their homes in the evening so their name appeared on the caller ID rather 
than a private or unknown number. They also collected data in the participants’ homes to help 
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make participation more convenient. Through the implementation of these culturally informed 
strategies by Germino et al. (2011), the recruitment rate of younger African American breast 
cancer survivors increased 373% in just under 1 year, with the steepest rise in recruitment 
occurring after all strategies were in place and operating simultaneously. 
Community involvement by researchers conducting the Telephone Resources and 
Assistance for Caregivers (TRAC) study resulted in an exceeded minority enrollment target of 
30%. Researchers used social marketing and a community-based approach to develop their 
recruitment plan for this interventional study that enrolled sedentary caregivers of patients with 
Alzheimer’s disease in an attempt to increase caregiver physical activity. The researchers 
collaborated with community leaders and organizations and maintained a strong presence at 
community events. They also cast a broad net into the community, making relationships with 
senior centers, faith-based organizations and adult day care programs. They attributed their 
success in recruiting for this study to the infrastructure and experience of the research center, as 
well as the collaborative partnerships and relationships they developed in the community through 
their community engagement and giving in the form of educational programs (Etkin, Farran, 
Barnes, & Shah, 2012). Similarly, Wallington et al. (2016) conducted community advisory 
boards to gain entry into the community and also used the knowledge they gained about the 
patients they were targeting and the community they live in to guide their research design. As a 
result, they experienced a 62% increase in African American participants across the non-
interventional trials they were conducting. 
Interestingly, the African American Study of Kidney Disease and Hypertension (AASK) 
trial utilized community-based screening and outreach strategies as part of their recruitment 
efforts and found it to be ineffective in recruiting African American participants. This may be 
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due to a lack of awareness in the community about the relationship between hypertension and 
renal dysfunction. Additionally, many people were not aware they have the disease that was 
being studied (renal insufficiency due to hypertension) (Phillips et al., 2004). This suggests that 
while community-specific recruitment strategies can be successful, their success is dependent on 
the disease being studied and cannot be generalized as an effective recruitment strategy across all 
studies.  
Duda et al. (2011) conducted a study to determine the impact of targeted recruitment 
strategies on recruiting minority participants into the National Lung Screening Trial. Seven 
institutions from the American College of Radiology Network were selected to be the 
intervention sites, which created their own targeted minority recruitment strategies. These seven 
sites, which were situated in culturally diverse communities, were selected based on their 
performance in overall recruitment and their past success in recruiting minority participants. 
Their site-specific recruitment strategies varied from direct mailing, advertising, printed 
brochures, disseminating information at community events and enlisting cultural insiders. Of the 
18,842 participants enrolled in the study, 1,576 (8.4%) were from racial and ethnic minority 
populations. Of the 1,576 minority participants enrolled, 1,223 (77.6%) were from one of the 
seven sites that had implemented a targeted minority recruitment strategy. These seven sites with 
targeted recruitment strategies enrolled significantly more racial and ethnic minority participants 
than those without targeted minority recruitment strategies. Specifically, they enrolled a higher 
percentage of African American (9.5% vs. 2.0%), Asian (0.9% vs. 0.3%) and Hispanic (1.7% vs. 
0.9%) participants. Duda et al. (2011) found that the rate of minority recruitment increased 
quickly after the targeted recruitment strategies were implemented at those seven sites with 
dedicated strategies, while the rate of minority recruitment was relatively stable across all other 
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sites. Although minority recruitment increased significantly after the targeted recruitment 
strategies were implemented, recruitment methods varied and there wasn’t a common strategy 
that worked consistently well across all seven sites with targeted recruitment. Additionally, these 
seven sites were selected because they were already enrolling minority participants. Therefore, 
the impact of their targeted strategies for boosting minority recruitment is speculative and could 
be due to characteristics of the site itself.  
In a study by Harris et al. (2003), the researchers used both proactive and reactive 
recruitment strategies to enroll African American participants into a smoking-cessation clinical 
trial, which eventually led to successful recruitment due to their flexibility in changing the 
recruitment strategy mid-stream. For the proactive methods, study staff personally recruited 
participants from the existing patients and staff at an African American health center in which 
the study took place. Reactive strategies consisted of community outreach via a targeted media 
campaign and included ads in the form of television, radio and print. Minority recruitment was 
considered prior to study design, and many factors were taken into consideration in developing 
the study design to increase recruitment of African American participants. For example, all staff 
members were African American, the study setting was a health center that was trusted by the 
African American community and incentives and reimbursement were offered. Only proactive 
strategies were implemented at the start of the study, but since recruitment goals were not being 
met, the researchers put reactive strategies in place. Once the reactive strategies were 
implemented, recruitment significantly increased and was found to be more successful in 
recruiting participants (n = 534) over the proactive strategies (n = 66). Just over one-fourth of all 
enrolled participants were recruited on the 5% of screening days in which the media outreach 
took place. Additionally, people screened during the reactive phase were more likely to be 
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eligible and enroll in the study. Presumably, this was due to those who responded to the media 
outreach pre-screening themselves based on their review of the eligibility criteria and who also 
were more likely to be ready to quit smoking. After comparing the demographic information 
between participants recruited using both methods, Harris et al. (2003) found that participants 
recruited in the proactive phase were more socially and economically disadvantaged than those 
recruited in the reactive phase. This is likely because the community health center serves an 
African American population with a 93% rate of incomes below poverty level, compared with 
the metropolitan area surrounding the clinic, in which 28% of the African Americans had 
incomes below the poverty level in that year. From this, it may be assumed that proactive 
strategies may be more successful in studies looking to recruit lower-income African American 
participants. The investigators learned that ensuring the recruitment strategy could remain 
flexible when designing the trial was imperative to successful recruitment. When the proactive 
recruitment strategies were unsuccessful, alternative methods were used via the reactive 
strategies to successfully recruit minority participants (Harris et al., 2003). One difference 
between the success reported by Harris et al., (2003) and Williams and Corbie-Smith (2006) in 
making midstream modifications to the recruitment strategy is that the smoking-cessation trial 
described by Harris et al., (2003) took into consideration a flexible recruitment strategy upfront 
when designing the trial. 
Brown et al. (2012) conducted a recruitment experiment to determine whether sending 
personalized recruitment letters and including ethnic-specific health information in the letter 
increased the response rate of minorities recruited for a weight-management trial for obese 
women. The response rate was 34.4% higher among the women who received letters that 
included health information specific to ethnic minority women than among those women who 
  79	
received generic letters. However, personalized letters did not result in a higher response rate. In 
this weight management trial, 33.7% were minorities. Of the minority women enrolled in the 
trial, 68.9% were recruited using direct mail letters. Of these women, 75.8% were sent a letter 
addressed to them and 24.2% were referred into the trial by a family member or friend who 
received the letter (Brown et al., 2012). This suggests that direct mail letters are a successful 
technique for recruiting minority women into clinical trials.  
A personalized letter containing a statement regarding heart disease statistics for the 
general American population sent along with a recruitment flyer mailed to Hispanic employees 
of Stanford University was found by Kiernan, Phillips, Fair, and King (2000) to result in a 
significantly higher response rate (7.8%) to a dietary intervention study than the Hispanic 
employees who received only the recruitment flyer without the personalized letter (2.1%). This 
study’s findings are in direct conflict with the study findings by Brown et al. (2012) who found 
that a personalized solicitation letter did not result in a higher response rate. Kiernan, Phillips, 
Fair, and King (2000) have found that a personalized approach to minority recruitment was 
successful and employees were four times more likely to respond and be eligible for participation 
if they received a flyer along with a personalized letter than those who only received a flyer. 
Kiernan et al. (2000) also found that the response rate among Hispanic employees who received 
the recruitment flyer in addition to a personalized letter containing heart disease statistics 
specific to Hispanics was higher (9.1%) than those who received the flyer with the personalized 
letter containing statistics pertaining to the general American population (6.5%). Although this 
finding wasn’t significant, it aligns with the finding from Brown et al. (2012) that providing 
ethnic-specific disease information yields a higher response rate from minorities.  
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The examples of successful minority recruitment that were just discussed are very 
specific to the community in which the study was taking place. Additionally, the recruitment 
strategies were not consistent across all sites. As demonstrated by the unsuccessful community 
outreach strategies described by Phillips et al. (2004), these cultural-, site- and community-
specific strategies employed cannot be generalized across all studies. This leads to a discussion 
on the lack of evidence-based minority recruitment strategies.  
Lack of evidence-based minority recruitment strategies. There is still a lack of 
evidence-based strategies for minority recruitment. The successful examples discussed involved 
a combination of several different recruitment strategies. A gap in the evidence remains as to the 
effectiveness of any single strategy (Duda et al., 2011; Ejiogu et al., 2011; Etkin, Farran, Barnes, 
& Shah, 2012; Germino et al., 2011; Harris et al., 2003). For example, Duda et al. (2011) found 
that the site-driven recruitment plans implemented in their study resulted in an increased number 
of minority participants enrolled. However, although minority recruitment increased significantly 
after the targeted recruitment strategies were implemented, there wasn’t a common strategy that 
worked consistently well across all seven sites with targeted recruitment. Additionally, these 
seven sites were selected because they were already enrolling minority participants (Duda et al., 
2011). The success that Duda et al. (2011) found may be due to the investigator sites themselves 
and their experience rather than an individual recruitment strategy. Their targeted strategies also 
required staff to devote a significant amount of time to recruitment efforts, taking away from 
their clinic responsibilities. It is also important to note that these sites received infrastructure 
support by the NIH for disseminating information in minority communities. 
Germino et al. (2011) employed a population-specific approach to recruitment that will 
require systematic testing of the strategies implemented in order to know which individual 
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strategies were successful in recruiting and retaining younger African American breast cancer 
survivors into the study. The researchers’ approach expanded on the existing literature on the 
importance of community engagement in research. Through a combination of factors, such as 
addressing barriers to research participation, taking into account cultural preferences, as well as 
bridging gaps across cultures and communities through the use of cultural brokers, they were 
able to successfully recruit African American women into this study. Although the researchers 
were successful in recruiting minority women participants, the strategies were very specific to 
the community and they can only deduce that the combined strategies were successful. Germino 
et al. (2011) did not evaluate the effectiveness of the strategies on an individual level. The 
strategies employed also required extra time commitment not typically provided by investigator 
sites.  
Similarly, a limitation of the study conducted by Harris et al. (2003) is that they did not 
systematically test the successful recruitment strategies. The majority of enrolled participants 
were recruited through the radio (n = 209), followed by referrals from a friend (n = 152). The 
manner in which participants’ friends found out about the study in order to make the referral is 
unknown. For instance, study staff members may have approached them during the proactive 
stage, or they could have heard about the study through the media campaign. Additionally, 
referral by a friend was found to be similar to the reactive strategies in the ability to recruit a 
population that was eligible for and more likely to enroll in the study. Although Harris et al. 
(2003) demonstrated successful recruitment strategies, it will be important to further test these 
strategies to understand which can be attributed to successful recruitment. 
Ejiogu et al. (2011) demonstrated how recruiting minority and socioeconomically 
disadvantaged participants can be successful by infiltrating the community to better understand 
  82	
the needs of the targeted patient population and gaining the support of community stakeholders. 
However, they used a combination of several strategies that would need to be evaluated in order 
to determine which strategy or strategies were successful in recruiting minority participants. 
Their recruitment efforts were directed towards the specific barriers of the targeted population in 
that particular community. Specific strategies that are successful in one community may not 
work in another because each community and culture has its own unique barriers. Similarly, 
Wallington et al. (2016) successfully recruited African American participants into non-
interventional cancer clinical trials by employing cultural- and community-specific strategies that 
were relevant to a specific population in the Washington, DC metropolitan area. The authors 
recognized that strategies might need to vary when recruiting participants from other racial and 
ethnic groups and in other geographic locations (Wallington et al., 2016).  
While recruitment for the TRAC study was successful in exceeding the minority 
recruitment target, it was largely due to the geographical area in which the study was conducted 
and the inclusion of a research center that was already well established in the local community. 
In fact, the researchers were not successful in recruiting minority participants from communities 
in which the center did not already have established relationships (Etkin, Farran, Barnes, & Shah, 
2012). The extent of community engagement and involvement that was practiced in this study is 
beyond the traditional realm and resources of industry investigators. Likewise, the hands-on 
approach discussed by Ejiogu et al. (2011) that involved direct community engagement by the 
site staff and PIs, including the creation of a community advisory board, is not common practice 
in industry-sponsored studies. Instead, the focus is on reducing R&D costs, while completing a 
trial in the shortest amount of time possible to expedite the drug development process (Kermani 
& Bonacossa, 2003; National Academies of Sciences, Engineering, and Medicine, 2016; 
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USHHS, OIG, 2000). However, this level of involvement greatly contributed to these studies’ 
minority recruitment successes. The sustainability of this approach is yet to be documented 
among industry-funded studies.  
Lack of evidence-based minority recruitment strategies in benchmark trials. There are 
three benchmark trials that focused specifically on ethnic minority populations: AASK, the 
African American Heart Failure Trial (A-HeFT) and ALLHAT (Taylor & Wright, 2005). A brief 
description of each follows, as well as a discussion on the lack of evidence-based minority 
recruitment strategies or lack of sustainable strategies for these benchmark trials. These 
examples provide further evidence of a need to better understand what contributes to 
successfully recruiting minority participants into industry-funded clinical trials. Even with these 
trials that specifically required a large number of minority participants, variability in recruitment 
approaches and success rates among the government-funded trials and lack of information on 
recruitment approaches used in the industry-sponsored trial demonstrates that more research is 
required in this arena. 
AASK. The AASK trial was conducted to compare the effectiveness of different 
treatments in African American patients with renal insufficiency due to hypertension. The AASK 
trial was funded by the National Institute of Diabetes and Digestive and Kidney Disease, as well 
as by NIH grants. Financial support and drug donations were also provided by Pfizer, 
AstraZeneca and King Pharmaceuticals (Phillips et al., 2004). Before beginning enrollment into 
the AASK study, a pilot study was conducted to determine the feasibility of the proposed 
recruitment, retention and data collection procedures. The pilot study enrolled 94 African 
American participants, most of whom were recruited through the primary recruitment strategy of 
clinic-based chart screening and referrals (67%). Four secondary recruitment strategies were also 
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encouraged: mass mailing campaigns, mass media campaigns, community-based screening and 
referrals of relatives and friends of existing patients. The contributions and effectiveness for each 
of the secondary recruitment strategies varied widely by research site. Screening through clinical 
practice provided only 17% of the participants for pre-screening, yet yielded 67% of the 
randomized participants. Mass mailing provided the most interested patients for pre-screen 
(44%), but only 15% of the patients recruited through mass mailings were randomized. Of note, 
75% of the participants were men (Whelton et al., 1996).  
The most-effective recruitment strategy for recruiting patients into the AASK trial was 
the same as in the pilot study—screening patients in clinical practice. This included pre-
identifying prospective patients through chart reviews, as well as primary care provider referrals. 
Eight-three percent of patients were recruited for a screening visit through this method and 
provided 58% of the randomized patients. However, this required a total of 558,295 chart 
reviews to randomize 635 patients, requiring a tremendous amount of resources from the clinics. 
The number of chart reviews per randomized patient varied widely among the 21 clinics, ranging 
from 42 to 6,381 charts reviewed per site, averaging 879 charts reviewed per randomized patient. 
This was a much less effective strategy in the full trial than in the pilot study and also not likely 
to be feasible from a resource perspective in an industry-sponsored study without additional 
support. Similar to the pilot study, there was variability in the use and effectiveness of the other 
recruitment strategies across the 21 clinic sites. As previously discussed, community recruitment 
was not an effective strategy for this study. This was likely because patients with hypertension 
and renal dysfunction are asymptomatic with low awareness of these diseases in the community. 
This suggests that community-based approaches are dependent on the disease being studied and 
cannot be generalized as being effective in all populations, diseases or communities. Recruitment 
  85	
in general proved to be challenging and the recruitment period was extended by 1 year in order 
to meet the recruitment goal (Phillips et al., 2004). 
The African American Heart Failure Trial (A-HeFT). Another benchmark trial focusing 
on minorities was A-HeFT. A-HeFT was sponsored by NitroMed, Inc., a privately held 
pharmaceutical company that is no longer in existence (businesswire, 2008; Mitchell et al., 
2011). Amid much controversy, the first race-specific drug, BiDil, was approved by the FDA in 
2005 based on the results of A-HeFT. BiDil was approved for the treatment of heart failure in 
African American patients when added to standard therapy. It was approved after demonstrating 
effectiveness and showing a mortality benefit in African American patients during A-HeFT, 
which recruited over 1,000 African American participants (Brody & Hunt, 2006). The decision 
to conduct the study only in African American participants was justified by both NitroMed and 
the FDA due to the fact that the post hoc subgroup analyses from two similar studies conducted 
previously indicated that African American and white patients had a different response to BiDil. 
There was an effect in treatment in African American patients, yet little or no effect in white 
patients using the fixed-dose combination of two generic drugs to study the effects against 
placebo and an existing treatment. Based on this fact, the FDA had reason to believe that a large 
study that included both African American and white participants wouldn’t detect a treatment 
effect in white patients. Coupled with the well-known disparities in heart failure rates that 
African American patients suffer from more so their white counterparts and the infeasibility of a 
mixed-race study that would be too large and take too long to conduct (from a cost and time 
perspective to get a needed drug to market), the decision to only include African American 
participants was made (Temple & Stockbridge, 2007). An abundance of literature discusses A-
HEFT, including the controversy the study sparked over the rationale for including only African 
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American participants and using race and ethnicity to categorize participants to test response to 
drugs. However, no literature discussed the recruitment strategies employed to recruit the 1,050 
African American participants. This is likely due to the fact that this was an industry-sponsored 
study and not supported by NIH grants. However, this important study provides more evidence 
on the genetic differences in response to different treatments and, therefore, reinforces the 
importance of clinical trial participation parity. 
ALLHAT. The third benchmark trial, ALLHAT, was funded by the NHLBI. Financial 
support was also provided by Pfizer to provide additional recruitment resources to study sites. 
The study medications were supplied by three pharmaceutical manufacturers: Pfizer, 
AstraZeneca, and Bristol-Myers Squibb (Wright et al., 2001). The primary goal of ALLHAT was 
to evaluate different treatment regimens to examine the reduction of CVD incidence between the 
different treatment arms in 40,000 patients with hypertension aged 55 or older in a racially 
diverse group, 55% of which needed to be African American (Wright et al., 2001). Initial 
recruitment strategies implemented by the Recruitment and Eligibility Subcommittee included 
mass mailings, as well as encouraging sites to conduct chart reviews, obtain physician referrals 
and conduct community screening activities. Some sites also advertised locally. Enrollment into 
ALLHAT was slower than projected, which resulted in several study design and recruitment 
strategy changes being implemented in an effort to recruit the required 40,000 patients. These 
changes included increasing the number of sites from 270 to 600, including expanding the 
geographic region to Canada and Puerto Rico; extending the recruitment period by 1½ years 
(which resulted in extending the follow-up period by an additional year in order to achieve 
sufficient power); opening up the eligibility criteria to also include smokers and reducing the 
minimum age requirement from 60 to 55 years; increasing site reimbursement for patient 
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enrollment; providing funding for additional site resources; and instituting a national advertising 
campaign (radio, print and direct mail letters). Similar to what was reported by Harris et al. 
(2003), a flexible approach is sometimes required. These changes all ultimately led to the 
successful recruitment of 42,419 participants, 54% of whom were minorities. African Americans 
represented 36% of the study participants; however, the goal of recruiting at least 55% African 
American participants was not achieved. As demonstrated by Durant et al. (2007), recruitment 
goals set for African Americans are not likely to be achieved.  
Minority participation in ALLHAT is still considerably higher than most studies, but, 
unfortunately, an analysis of effective strategies specific to recruiting minority participants was 
not conducted. Since it was a practice-based study and nearly all of the participating patients 
were from the practices that were involved in the study, it is expected that the minority 
participants primarily were recruited because sites with a large minority patient group were 
selected. For example, the addition of Puerto Rican sites also yielded a high number of minority 
participants (Pressel et al., 2001). However, the ALLHAT sites with a high African American 
patient population recruited at the same rate as those sites recruiting other populations. Wright et 
al. (2001) contributed the parity in recruitment rates to investigator motivation, training and 
existence of a trusting relationship between investigators and their patients, instead of on the 
diverse demographic patient population of these sites. While this is promising, it contributes to 
the fact that not only is there a lack of understanding of evidence-based minority recruitment 
strategies, but also a lack of understanding of the interacting components and characteristics that 
may contribute to an investigator site successfully enrolling minority participants.  
Lack of evidence-based minority recruitment strategies summary. In summary, many 
studies in the literature focus on the barriers to minority participation in clinical trials and not the 
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successful strategies. The successful examples of minority recruitment discussed in the literature 
involved government-funded studies and employed strategies that not only would be costly and 
difficult for industry to adopt without a system change but also vary across different studies, 
sites, patient populations and communities. Even the benchmark studies that specifically required 
minority participation reinforce the fact that there is a lack of evidence-based minority 
recruitment strategies. 
Summary of the Literature 
Disparities exist in clinical trial participation, with racial and ethnic minority populations 
underrepresented in most studies (Diehl et al., 2011; Duda et al., 2011; Killien et al., 2000; 
Martin, Negron, Balbierz, Bickell, & Howell, 2013; Murthy, Krumholz, & Gross, 2004; The 
Society for Women’s Health Research & FDA, 2011). There are many reasons for this disparity 
as many barriers have been identified that preclude minorities from participating in clinical 
research studies. Some of these barriers include individual patient beliefs and concerns about 
participating in research; lack of awareness of clinical trials; lack of trust in the healthcare 
system; cultural differences between researchers and patients; as well as doctor-patient 
communication barriers (Ejiogu et al., 2011; Ford et al., 2012; Ford et al., 2013; Swanson & 
Ward, 1995; Williams & Corbie-Smith, 2006). However, minorities are interested in learning 
about clinical trials and tend to enroll when they are given the opportunity (Diehl et al., 2011; 
Jimenez et al., 2013; Markman, Petersen, & Montgomery, 2008; Simon et al., 2004; Wendler et 
al., 2006). Research sites may be better equipped to provide greater access to clinical trials to 
minority populations when they follow guidance suggested for delivering culturally competent 
healthcare services and exhibit culturally competent techniques (Brach and Fraserirector, 2000; 
Purnell et al., 2011). 
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Based on findings from a prior study, another area that could help to improve access and 
provide minorities with opportunities to enroll is working toward increasing the value 
investigators place on minority clinical trial participation, since this has been found to play a role 
in the success of recruiting minority participants into clinical trials (Williams & Corbie-Smith, 
2006). This is important because minorities are less likely to be offered a clinical trial than their 
white counterparts (Baquet, Commiskey, Mullins, & Mishra, 2006; Diehl et al., 2011; Simon et 
al., 2004). It has been found by some researchers that PIs’ perceptions of minority patients being 
ineligible, noncompliant or disinterested provide explanation for this disparity in recruitment 
practices (Durant et al., 2007; Eggly, Barton, Winckles, Penner, & Albrecht, 2015; Howerton et 
al., 2007; Simon et al., 2004). Furthermore, many PIs, including those receiving NIH-funding, do 
not set minority recruitment goals (Boden-Albala et al., 2015; Durant et al., 2007). While the 
literature describes PI attitudes and perceptions in relation to minority recruitment, it is also 
important to understand characteristics and perceptions of other research site staff members who 
often play a critical role in clinical trial recruitment. This is an area in which there is an 
opportunity for contribution to the literature. 
Research center infrastructure and experience has also been found to impact the 
successful enrollment of minority participants (Etkin, Farran, Barnes, & Shah, 2012; Joseph & 
Dohan, 2009). For example, study site staff inexperience with the recruitment of minorities is a 
barrier to minority recruitment, as is clinical research sites inability to address the health literacy 
needs of patients (Ejiogu et al., 2011; Livaudais-Toman et al., 2014; Williams & Corbie-Smith, 
2006). Many organizations, even those receiving NIH-funding, are limited in their focus on 
minority recruitment because of infrastructure barriers and the additional cost of translating 
materials (Durant et al., 2014; Joseph & Dohan, 2009). 
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Existing literature suggests that characteristics related to both specific research sites and 
individual investigators may have contributed to their successful enrollment of minorities into 
clinical trials (Boden-Albala, 2015; Duda et al., 2011; Jimenez et al., 2013; Joseph & Dohan, 
2009; Williams & Corbie-Smith, 2006; Wright et al., 2001). More research is needed in this area 
to determine what those specific characteristics may be, including site staff perspectives and 
characteristics and how they may play a role in minority recruitment. For example, cultural, 
community and site-specific minority recruitment strategies have proven successful in NIH-
funded trials (Duda et al., 2011; Ejiogu et al., 2011; Etkin, Farran, Barnes, & Shah, 2012; 
Germino et al., 2011; Wallington et al., 2016). There still remains a lack of evidence on what 
specifically contributes to successful minority recruitment because while success has been 
experienced, it was the result of a combination of several strategies. These strategies were also 
specific to the local communities in which the studies were being conducted and may or may not 
be generalizable to other geographic areas. Success also may have been due to characteristics of 
specific research sites and/or researchers themselves, leading to an unclear explanation as to 
what the specific elements are that led to their success (Duda et al., 2011; Ejiogu et al., 2011; 
Etkin, Farran, Barnes, & Shah, 2012; Germino et al., 2011; Harris et al., 2003; Wallington et al., 
2016). Additionally, as the examples discussed were from NIH-funded studies, they have a 
minimum requirement for enrolling racial and ethnic minority participants as a stipulation of 
receiving funding (USHHS, NIH, 2001). Hence, these successful examples discussed could be 
due to additional funding and support sites received to amplify their recruitment efforts. 
Exploring environmental elements that may be involved with minority recruitment 
holistically, including research site staff perceptions and organizational characteristics, among 
other factors from an ecological perspective, will contribute to filling these gaps in the literature 
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and facilitate a more comprehensive understanding of what specific elements are involved in the 
active recruitment of minority participants into industry-funded clinical trials. This will also 
provide a significant contribution to the literature since the existing peer-reviewed literature 
describing minority clinical trial recruitment is solely related to NIH-funded trials. Additionally, 
it offers a wide view for understanding environmental factors more wholly from the perspective 
of healthcare professionals involved in clinical research. Once these factors are better 
understood, industry stakeholders involved with clinical research can better support minority 
recruitment initiatives.  
  92	
Chapter III
 
METHODOLOGY 
 
 
The purpose of this study was to understand the socio-ecological elements that are 
involved in the active implementation of racial and ethnic minority recruitment practices for 
biopharmaceutical-funded trials in the United States. A qualitative design was selected utilizing 
semi-structured, in-depth interviews in order to allow participants to “express their own 
understandings in their own terms” to appropriately capture their perceptions and experiences 
(Patton, 2002, p. 348).  
Study Design 
  The study design is a descriptive, exploratory, general qualitative study. A general 
qualitative study “involves collection of data in an effort to characterize human experience as it 
occurs naturally” to capture participants’ perspectives (Portney & Watkins, 2000, pp. 14-15). 
When conducting qualitative research, the researcher is the key instrument and attempts to 
identify the complex interactions of factors within the context of the data to gain an in-depth 
understanding of how a phenomenon is experienced by individuals (Creswell, 2013). The study 
is descriptive in that it involves describing what is prevalent regarding a phenomenon as it 
naturally occurs to create a better understanding (Bickman & Rog, 2008; Kumar, 2011; Portney 
& Watkins, 2000). This research is also exploratory as it involves examining a phenomenon in 
which little is known and “explores its dimensions, including how it relates to other factors” 
(Kumar, 2011; Patton, 2002; Portney & Watkins, 2000, p. 14). This design was selected to study 
this topic because of the gap in the literature on the specific elements involved when a research 
site is actively focused on minority recruitment, including site staff member and organizational 
characteristics. This understanding is best achieved when participants are allowed to express 
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their own perspectives and experiences rather than fitting them into the researcher’s pre-defined 
categories (Patton, 2002). This study design allowed for gaining insight into the personal 
perceptions, experiences and behaviors of individuals who work at a clinical research site 
regarding trial recruitment and what factors play a role in their actions regarding minority 
recruitment. Semi-structured, in-depth interviews were conducted to achieve this. 
  Research questions. Since this research study utilized a qualitative design, there are no 
hypotheses accompanying the research questions. One overarching research question guided the 
study:  
• What are the socio-ecological elements that are involved in the active implementation of 
racial and ethnic minority recruitment practices for biopharmaceutical-funded trials in the 
United States? 
This research question is important because it addresses the gap in the literature on what specific 
elements contribute to successfully recruiting minority participants into industry-funded clinical 
trials from a socio-ecological perspective. To support the overarching research question, five 
primary research questions guided the study: 
1. How are intrapersonal site staff elements involved in the active implementation of 
minority recruitment practices for biopharmaceutical-funded trials in the United States?  
2. How are interpersonal site staff elements involved in the active implementation of 
minority recruitment practices for biopharmaceutical-funded trials in the United States?  
3. How are organizational elements involved in the active implementation of minority 
recruitment practices for biopharmaceutical-funded trials in the United States?  
4. How are community elements involved in the active implementation of minority 
recruitment practices for biopharmaceutical-funded trials in the United States?  
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5. How are policy elements involved in the active implementation of minority recruitment 
practices for biopharmaceutical-funded trials in the United States?  
These five primary research questions address different components of the socio-ecological 
model, the conceptual framework that guides this study. The exploratory and descriptive nature 
of the overarching research question fit the exploratory and descriptive study design and the 
qualitative data analysis methodology as discussed in the literature and that was utilized to 
analyze the data in this study. 
Sample Selection 
  Purposive sampling was used to identify potential participants based on the inclusion and 
exclusion criteria. In qualitative research, information-rich samples are typically selected 
purposefully by the researcher on the basis of specific criteria that will allow for studying this 
topic in-depth to learn about issues of central importance to the purpose of the study (Patton, 
2002; Portney & Watkins, 2000). Snowball sampling was also utilized. It was suggested that 
those individuals contacted may pass along the study solicitation to other potential candidates 
who are involved with minority recruitment for clinical trials (Patton, 2002; Portney & Watkins, 
2000). In this research study, participants were involved with actively recruiting racial or ethnic 
minorities for biopharmaceutical-sponsored clinical trials. As this study was bound to be US-
specific, participants needed to reside in the United States. Other inclusion criteria included 
being 18 years of age or above and having the ability to understand and speak English.  
  The sample frame from which to recruit was established from publicly available data that 
identifies clinical trial research staff based on the medical conditions in which they specialize, as 
well as geographic location. The PI used the publicly available data to create a targeted 
recruitment list inclusive of clinical trial research staff located in geographic areas of the United 
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States with a large ethnically diverse population, as well as those involved with clinical trials in 
disease areas that disproportionately affect racial and ethnic minority populations.  
Sample size. The study required a sample size of 15 individuals who provided their 
insights on and experiences with recruiting minority participants into clinical trials. These 15 
individuals provided adequate information to “elucidate the particular” in reaching an 
understanding (Creswell, 2013, p. 157). G*Power is not used to calculate sample size in 
qualitative studies. Instead, data are collected until the categories and themes become saturated, 
meaning that fresh data no longer gleans new insights (Creswell, 2014). As such, there are no 
sample size limitations in qualitative inquiry and, instead, participants should be selected to 
provide information-richness to the study findings (Patton, 2002). Patton (2002) recommends 
specifying minimum samples “based on expected reasonable coverage of the phenomenon” (p. 
246). The goal is to fulfill the intent of qualitative research to explain the particular in depth, and 
not to generalize (Creswell, 2013; Merriam, 1998). Typically, a sample size between 10 and 15 
individuals provides in-depth coverage of the phenomenon to reach redundancy in qualitative 
research (Creswell, 2013; Lincoln & Guba, 1985). According to Guest, Bunce and Johnson 
(2006), interviewing 12 participants is sufficient when it is a relatively homogeneous group and 
the goal is to describe a shared perception or behavior. Therefore, as this was a qualitative study 
utilizing interviews, inclusion of 15 participants is in accordance with guidance that has been 
established by qualitative experts. Additionally, data saturation was achieved during this study as 
these 15 individuals provided adequate information to reasonably describe the elements of 
actively implementing minority recruitment practices in order to reach an understanding. 
  Sampling Procedure. As previously mentioned, the PI used publicly available data to 
create a targeted recruitment list. Upon Institutional Review Board approval, the PI emailed the 
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Study Solicitation to individuals on the target recruitment list. The Study Solicitation provided 
instructions for individuals interested in participating to confirm their interest, as well as offer 
the opportunity to pass along the invitation to other individuals who may qualify for 
participation. Individuals confirmed their interest in participating by clicking on a hyperlink that 
was provided in the Study Solicitation that directed interested individuals to a registration form 
for them to indicate that they would like to be contacted by the PI for study participation, provide 
preferred contact details and answer an eligibility screening question. If interested individuals 
met the online eligibility criteria, they were contacted by the PI to further confirm eligibility and 
to schedule a date and time to participate in a telephone interview. The PI re-contacted 
individuals who did not respond to the Study Solicitation after 1 week by sending a solicitation 
reminder via email and/or placing a telephone call. A last reminder for any remaining individuals 
who did not respond took place 3 weeks following the initial Study Solicitation. Prior to the 
telephone interview taking place, the PI emailed the participant the Informed Consent Form (see 
Appendix B) and provided a personal fax number for returning the signed consent form prior to 
the start of the interview. 
  The recruitment period was 5 months in duration, during which time a total of 165 
individuals were invited for study participation. Of those 165 individuals, 25 declined 
participation; three accepted and then were no longer reachable; six had incorrect contact details 
listed in the publicly available data and were not reachable; two accepted but were ineligible; 94 
did not respond; and the maximum number of follow-up attempts were reached for 20 
individuals. Following this recruitment process, 15 individuals participated in this study. 
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Data Collection 
  Data was collected using semi-structured, in-depth telephone interviews. A semi-
structured interview format was used to allow respondents to more freely share their perceptions 
and experiences, while still allowing flexibility for probing for additional information as needed. 
Specific interview questions were used as a guide to interview the participants (see Appendix A). 
While the development of the interview guide was informed by the socio-ecological model, the 
questions were constructed to be broad to allow for more freedom of response by the 
participants. Certain steps were taken for the conduct of the interviews, as described next. 
  Interview process—before the interview. In qualitative research, the researcher is the 
instrument. Therefore, it is important that the researcher is attentive to and discloses his or her 
personal perspectives and experiences with the phenomenon under study that may affect data 
collection, analysis and interpretation (Lincoln & Guba, 1985; Merriam, 1998; Patton, 2002). In 
this study, the credibility of the researcher was substantiated through the PI’s 
reflexivity/positioning statement (see Appendix C) indicating her position in terms of her 
experiences with the topic being explored in this study prior to conducting any interviews. 
Reflexivity is when qualitative researchers position themselves by becoming self-aware of the 
origin of their perspective. This involves becoming conscious of the biases, values and 
experiences that they bring with them, including how that shapes data collection and 
interpretations of the data (Creswell, 2013; Patton, 2002). Prior to conducting each telephone 
interview, the PI assigned the individual a participant number to be used to identify the 
participant during the transcription and data analysis phase to maintain confidentiality. As 
previously mentioned, the PI obtained a signed informed consent from each participant prior to 
the start of the interview.  
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  Immediately before the interview started, the PI explained the goals of the research, 
assured the interviewee that responses would remain confidential and asked for permission to 
audio record the interview.  
  Interview process—during the interview. Upon permission, the telephone interviews 
were recorded utilizing the audio recording functionality from freeconferencecall.com. An 
Olympus Digital Voice Recorder model number WS-853 was used to serve as a back-up 
recording mechanism. Interview questions were asked one at a time using the interview guide, 
asking probing questions as relevant and providing transitions between major topics. The PI tried 
to remain neutral and unbiased and took brief notes during each interview. Each interview was 
approximately 1 hour in duration. 
  Interview process—after the interview. Due to the nature of the topic being studied, 
questions related to the study participant’s demographic characteristics, as well as characteristics 
related the organization in which he or she worked at the time of the interview, were asked at the 
end of the interview (see Appendix A). After the interview, the researcher took notes regarding 
the interview.  
Data Analysis 
  While data collection and data analysis are simultaneous processes in qualitative 
research, formal data analysis commenced once data saturation had been reached (Creswell, 
2014; Merriam, 1998). Data analysis for this study was conducted as follows. 
  Transcription. Each recorded interview was transcribed verbatim, increasing reliability. 
A transcription key was used to capture voice inflection and emphasis participants placed on 
their words. All personally identifiable information was removed and confidentiality of the 
participants was maintained by referring to each participant only by his or her participant 
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number. After transcription, the transcripts were checked to make sure no obvious mistakes were 
made during the transcription by playing the recording back and ensuring that it matched the 
transcription. 
  Organizing the Data. The raw data was organized by creating a “database” in which to 
store all information collected. This included interview transcripts, participant demographic 
information and any researcher notes or reflections on the interviews (Creswell, 2013; Merriam, 
1998). Atlas.ti data analysis software was utilized for this purpose (Friese, 2019).  
  Reading and Memoing. The PI immersed in the data by reading transcripts in their 
entirety and reviewing all data collected, writing notes in the margins as applicable (Creswell, 
2013; Merriam, 1998; Patton, 2002). This process allows the researcher to get a general sense of 
the information collected and reflect on the overall meaning (Creswell, 2014).  
  Coding and Categorizing. The next step was coding and categorizing. First, the PI 
formed codes by assigning a label to meaningful, recurrent segments of data (Patton, 2002). 
Codes were formed inductively based on information that emerged from the data (Creswell, 
2013; Patton, 2002). The socio-ecological model was then used to categorize codes by each level 
of the model. All of the data for three interview transcripts were coded initially in order to 
develop a preliminary codebook that included definitions and examples for all of the codes 
created. A codebook is a set of codes with accompanying definitions and examples in order to 
guide data analysis and maintain consistency when coding the data (DeCuir-Gunby, Marshall, & 
McCulloch, 2011; Miles & Huberman, 1994). According to Creswell (2013), it is recommended 
to develop a codebook from three interview transcripts prior to obtaining inter-coder agreement. 
Prior to obtaining inter-coder agreement, intra-coder agreement was achieved by the PI re-coding 
a portion of an interview transcript and comparing it with the previously coded portion to assess 
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the level of consistency in coding (Miles & Huberman, 1994). Inter-coder agreement was then 
established by having an independent reviewer with expertise in qualitative data analysis audit 
the codes by coding data from a portion of a transcript independently, using the preliminary 
codebook that was developed. The independent reviewer and PI met to compare their analyses, 
discuss discrepancies and come to a consensus (Miles & Huberman, 1994). Both intra- and inter-
coder agreements were achieved within the recommended ranges, which are between 80% and 
90% (Creswell, 2013; Miles & Huberman, 2014). The codebook was refined based on the inter-
coder review process and was then used as a guide for assigning codes to the data for the 
remaining transcripts (Creswell, 2013). The codes were continuously reviewed and defined 
throughout the coding process (Miles & Huberman, 1994). After all of the data were coded, 
major categories were developed based on patterns that emerged from the coded data (Creswell, 
2013). As with the codes, the categories were classified by the socio-ecological model levels. 
  Establish Themes. Overarching themes were developed by further classifying several 
categories that formed a common idea and analyzing them to look for consistency and repetition 
in order to establish patterns and create the overarching themes (Creswell, 2013). The themes 
were categorized by each of the socio-ecological model levels.  
  Interpretation. Lastly, the PI interpreted, or made sense of, the data using themes to 
explain findings (Taylor-Powell & Renner, 2003). The socio-ecological model was used as a lens 
to interpret findings and explain the results. The interpretation was grounded in the larger 
research literature on this topic (Creswell, 2013).  
Trustworthiness 
  Validity and reliability are specific to quantitative studies. As this is a qualitative study, 
trustworthiness standards need to be achieved instead. Trustworthiness demonstrates rigorous 
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methods were used for doing fieldwork in an attempt to assess the accuracy of findings as best 
described by the researcher and participants (Creswell, 2013; Patton, 2002). In other words, 
trustworthiness demonstrates that the researcher followed protocol and standards for conducting 
qualitative research such that the findings reported by the researcher accurately describe what the 
participants shared. According to Lincoln and Guba (1985), the criteria for establishing 
trustworthiness in qualitative studies are through establishing credibility, transferability, 
dependability and confirmability. Each of these concepts is described next.  
  Credibility. Credibility in qualitative research is the equivalent to internal validity in 
quantitative research and demonstrates that findings are worth paying attention to, based on 
establishing confidence in the truth of the findings (Lincoln & Guba, 1985). Credibility was 
achieved in this study through the following courses of action: 
• Member checking was used during the telephone interviews to ensure the PI accurately 
interpreted the interviewee’s statements (Creswell, 2013; Lincoln & Guba, 1985; 
Merriam, 1998) 
• Independent reviewer examination was conducted to audit findings (Merriam, 1998)  
• In addition to the themes that were formed, discrepant information that ran counter to the 
themes was also presented (Creswell, 2014) 
  Transferability. Transferability in qualitative research is the equivalent to external 
validity in quantitative research and refers to the extent to which findings have applicability in 
other contexts (Lincoln & Guba, 1985). Transferability was achieved in this study through the 
following course of action: 
• Rich, thick description was provided when conveying the findings in order to make 
transferability judgments possible for the reader (Creswell, 2013; Lincoln & Guba, 1985). 
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Direct quotations from the interview data have been shared in Chapter IV to provide 
context to the themes that were derived from the data.  
Dependability. Dependability in qualitative research is the equivalent to  
reliability in quantitative research and demonstrates that findings would be repeated if the 
inquiry were replicated (Lincoln & Guba, 1985). Dependability was achieved in this study 
through the following courses of action: 
• Data collection procedures were guided by the study design, research questions and 
interview guide 
• The interviews were recorded and transcribed verbatim (Creswell, 2013) 
• Findings and interpretations were supported by the data collected (Lincoln & Guba, 
1985; Merriam, 1998) 
• A study database was developed to store all raw data (Creswell, 2013; Merriam, 1998) 
• An audit trail maintained a chain of evidence that demonstrated how data were collected, 
how categories were derived and how decisions were made in deriving study findings 
(Lincoln & Guba, 1985; Merriam, 1998) 
• A codebook was created to maintain consistency when coding the data (Creswell, 2014; 
Miles & Huberman, 1994) 
• Inter-coder agreement was established by using an independent reviewer to analyze and 
code transcripts, as well as to audit the creation of categories (Creswell, 2013) 
  Confirmability. Confirmability in qualitative research is the equivalent to objectivity in 
quantitative research and refers to the degree to which findings are determined by the 
respondent’s and not the researcher’s biases (Lincoln & Guba, 1985). Confirmability was 
achieved in this study through the following courses of action: 
  103	
• An audit trail maintained a chain of evidence that allowed data to be traced back to its 
original source (Lincoln & Guba, 1985; Merriam, 1998) 
• Credibility of the researcher was maintained through reflexivity/positioning, becoming 
self-aware of personal bias (Creswell, 2013; Lincoln & Guba, 1985; Merriam, 1998; 
Patton, 2002) 
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Chapter IV
 
RESULTS 
 
 
The results will be presented in two sections. At the end of each interview, several 
demographic questions related to characteristics of the interview participants, as well as the 
organization in which he or she worked at the time of the interview, were asked. Those results 
will be shared first. Second, the themes involved with active minority recruitment practices that 
emerged for each level of the socio-ecological model will be shared. 
Demographics 
The participants in this study were asked 19 demographic questions following the 
telephone interview. Table 1 provides a summary of the results related to characteristics of the 
interview participants.  
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Table 1  
Interview Participant Demographics  
Participant Characteristics n % 
Clinical Research Experience 
 
  
     1-5 years 1 7% 
     6-10 years 2 13% 
     11-15 years 5 33% 
     16-20 years 3 20% 
     Over 20 years 4 27% 
Minority Recruitment Experience 
 
  
     1-5 years 4 27% 
     6-10 years 1 7% 
     11-15 years 6 40% 
     16-20 years 4 27% 
     Over 20 years 0 0% 
Duration at Site 
 
  
     1-5 years 3 20% 
     6-10 years 4 27% 
     11-15 years 6 40% 
     16-20 years 1 7% 
     Over 20 years 1 7% 
Current Role 
 
  
     Ownera 3 20% 
     Principal Investigatora 3 20% 
     Research/Recruitment Lead 10 67% 
     Executive Director 1 7% 
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Interview Participant Demographics    
Participant Characteristics n % 
Patient-Facing Role 
 
  
     Yes 14 93% 
     No 1 7% 
Spoken Language other than English 
 
  
     Yes 6 40% 
     No 9 60% 
Spoken Language Other than English 
 
  
     Spanish 2 13% 
     French 1 7% 
     Russian 1 7% 
     Chinese 1 7% 
     German 3 20% 
Gender 
 
  
     Male 8 53% 
     Female 7 47% 
Ethnicity 
 
  
     Hispanic, Latino or Spanish origin 2 13% 
     Not Hispanic, Latino or Spanish origin 13 87% 
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Interview Participant Demographics    
Participant Characteristics n % 
Race 
 
  
     White 9 60% 
     Black or African American 3 20% 
     Asian 2 13% 
     Native Hawaiian or Other Pacific Islander 0 0% 
     American Indian or Alaska Native 0 0% 
     Mixed 1 7% 
 aSome participants indicated they are both an owner and Principal Investigator. 
 
The majority of participants (33%) have between 11 and 15 years of clinical research 
experience, as well as minority recruitment experience (40%). Forty percent of participants also 
indicated that they have been with their current organization between 11 and 15 years. However, 
it is important to note that of the participants who responded that his or her clinical research 
experience, minority recruitment experience or duration at his or her organization was between 
11 and 15 years, it was not consistently 11-15 years across all three responses. Some participants 
focused on minority recruitment for longer than they have been with their current organization, 
for example. 
The current role of the interview participants is as follows:  
• Three participants own their organization that they opened specifically to improve 
access to clinical trials to minority patients—two own dedicated research institutions 
and one owns a community physician practice 
• Three are PIs, two of which are also owners  
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• The majority of participants (10 out of 15) are responsible for overseeing recruitment 
activities within their organizations 
• One participant is an executive director  
Only one participant is not in a patient-facing role. During analysis, it became evident 
that this participant’s responses did not consistently fit with the themes emerging for the other 
roles. 
Six participants speak a language other than English fluently. These languages include 
Spanish, French, Russian, Chinese and German.  
There were nearly as many female participants (47%) as male participants (53%), which 
is the exact same overall percentage of trial participants by gender in industry-funded trials 
reported by CISCRP (2017). 
Participants were also asked if they consider themselves to be of Hispanic ethnicity, as 
well as which racial designation best describes them. Questions were asked in alignment with the 
FDA’s guidance for industry on collecting race and ethnicity information in clinical trials 
(USHHS, FDA, 2016). Since respondents were asked to respond to both the race and ethnicity 
questions, some respondents indicated that they are of Hispanic ethnicity and white race. Figure 
2 provides an overall representation of race and ethnicity in the study. Minority representation is 
53%, considerably higher than the minority population in the United States, as well as 
representation in clinical trials (CISCRP, 2017; US Census Bureau, 2019). This may be 
explained by the fact that participants are researchers themselves focusing on minority 
recruitment and, therefore, likely interested in the topic of this study.  
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Figure 2. This bar chart illustrates the representation of race and ethnicity in the study. 
Participants were asked to provide a response to both race and ethnicity questions.  
 
Table 2 provides a summary of the results related to characteristics of the organizations in 
which interview participants worked at the time of the interview.  
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Table 2  
Organizational Demographics 
Organizational Characteristics n % 
Type of Organization 
 
  
     Dedicated research institution 8 53% 
     Academic medical center 2 13% 
     Community physician/medical practice 3 20% 
     Public hospital 2 13% 
Geographical Area of Clinical Trial Setting 
 
  
     Urban 8 53% 
     Suburban 7 47% 
     Rural 0 0% 
Trial Fundinga 
 
  
     Biopharmaceutical Sponsors 15 100% 
     NIH 3 20% 
Therapeutic Area/Disease State of Trialsa 
 
  
     Cardiovascular 6 40% 
     Diabetes 7 47% 
     Neurology 5 33% 
     Oncology 5 33% 
     Urology 3 20% 
     Multi-therapeutic 4 27% 
Racial/Ethnic Minorities Included on Research Teama,b 
 
  
     Principal Investigator 10 67% 
     Sub-Investigator 10 67% 
     Recruiter 14 93% 
     Study Coordinator 11 73% 
     Study Nurse 9 60% 
Minority Recruitment Goal Setting 
 
  
     Yes 6 40% 
     No 7 47% 
Cultural Competency Training Required 
 
  
     Yes 6 40% 
     No 8 53% 
% Minority Participation in Trials 
 
  
     10% or less 3 20% 
     11-25% 2 13% 
     26-40% 3 20% 
     41-55% 1 7% 
     56-70% 2 13% 
     71-85% 0 0% 
     86-100% 3 20% 
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Organizational Demographics 
  
Organizational Characteristics n % 
   
% Minority Participation Representation of  
Community Demographics    
     Less 4 27% 
     Same 6 40% 
     More 4 27% 
Note. Due to missing responses, n values may not sum to 15 and percentages may not equal 100.  
aDue to multiple responses per participant, n values may exceed 15 and percentages may exceed 
100. 
bRecruiter, Study Coordinator and Study Nurse are the same role in some organizations. 
 
More than half of the interview participants (53%) work for dedicated research 
institutions, 20% of participants work for a community physician/medical practice, 13% of 
participants work for an academic medical center and 13% work for a public hospital. This 
reflects the trend with the investigator site landscape for industry-sponsored studies, which has 
shifted away from academic medical centers toward private practice or dedicated research sites 
used exclusively for research (USHHS, OIG, 2000; IOM, 2012). Private-practice community 
physicians and research institutes have replaced academic medical centers as the majority of 
industry-sponsored sites, increasing from 37% in 1994 to 74% in 2004 (Steinbrook, 2005). 
Increasingly, however, there has become a significant shortage of community physicians 
conducting clinical trials since 2009, moving towards an ever-increasing number of research 
institutions conducting industry-sponsored clinical trials. Part of the reason for this is the 
increasing complexity of procedures included in trial design, making conducting the study within 
the trial infrastructure a burden for community physicians and academic medical centers (IOM, 
2012). 
 The geographic area of each organization’s clinical trial setting is either urban (53%) or 
suburban (47%). None of the participants reported having a clinical trial setting in a rural area. 
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As part of the eligibility criteria, all participants need to be recruiting racial or ethnic 
minorities for clinical trials in which biopharmaceutical sponsors are the funding source. Three 
participants work for organizations that also receive NIH funding in addition to 
biopharmaceutical funding for the trials that their organizations conduct.  
The therapeutic areas and/or disease states of trials that the participating organizations 
conduct include cardiovascular, diabetes, neurology, oncology, urology and multi-therapeutic, 
meaning that they conduct trials across a multitude of indications. The clinical trial experience of 
participating organizations in these disease areas is to be expected since minority patients are 
disproportionately affected by CVD, diabetes, Alzheimer’s disease, cancer and urologic 
conditions, such as prostate cancer (Alzheimer’s Association, 2020; USHHS, CDC, 2013a; 
USHHS, NIH, NCI, 2019).  
The majority of study sites (93%) have included members of racial and ethnic minorities 
as part of their research teams. Only one participant responded that minority staff are not part of 
the research team; however, minority staff are part of the regular practice at that organization. 
Recommendations from the literature indicate that important components for overcoming distrust 
are ensuring research staff are the same race or ethnicity and speak the same language as the 
patients they are trying to recruit (Germino et al., 2011; Ford et al., 2013; Hinton et al., 2010). 
While 93% of the participants reported their organizations have minority recruiters, a lower 
number reported having minority PIs or Sub-Investigators (67%). Although some minority 
patients prefer to be treated by physicians of similar racial or ethnic backgrounds, minority 
recruiters also have been found to contribute to the successful enrollment of minority participants 
(Cook, Kosoko-Lasaki, & O’Brien, 2005; Ejiogu et al., 2011; Germino et al., 2011). In fact, 
Williams and Corbie-Smith (2006) found that the inclusion of minority recruiters, not PIs, was 
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associated with reported success of minority recruitment. This suggests that while including 
racial and ethnic diversity on the research team is important, the race of the PI alone may not be 
an essential component.  
Nearly half of the organizations that participants work for do not set recruitment goals for 
racial and ethnic minority groups (47%), a finding that corroborates with the existing literature. 
In fact, recruitment goals for individual minority groups are not often set, even for NIH-funded 
studies (Boden-Albala et al., 2015; Durant et al., 2007). 
More than half of the organizations (53%) do not require staff to take cultural 
competency training. Ensuring researchers are culturally sensitive has been found to be a 
contributing factor in the successful recruitment of minorities (Ejiogu et al., 2011). Although 
cultural competency is not often instituted as a training requirement among PIs conducting NIH-
funded trials, it has been recommended as a best practice for minority recruitment by these 
researchers (Boden-Albala et al., 2015). When asked if staff members are required to take 
cultural competency training, a couple of study participants indicated that may be something they 
may incorporate in the future. Participant #3 said: 
No but that’s something I would like to do… that’s a good question…as of today – no but 
that is something that I have considered to incorporate into my research uh process and 
it’s a good question actually… 
Participant #13 also shared: 
No? No, it’s a good idea though. That’s not really been um an issue that’s arisen but that 
would be a good idea ‘cuz I never I mean I understand my competency on to other 
backgrounds but I haven’t really evaluated any others. There’s never really been a reason 
to…but it makes sense. Ya, I’m gonna write that down. 
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Eight participants reported that the percentage of minorities who participate in trials 
conducted by their organizations is 40% or above. This is unique among industry-funded 
research sites in that minority recruitment is on par with minority representation in the US 
population, which is currently 39% (US Census Bureau, 2019). This finding indicates that these 
participants recruit considerably more minorities than other organizations conducting industry-
funded trials, since overall only 17% of trial participants in industry-sponsored studies are 
minorities (CISCRP, 2017). Four of these participants went on to report that they recruit more 
minority participants in their studies on average than the population demographics of their 
nearby community. This could be another indicator that researcher and organizational 
characteristics may play a role in recruiting minorities.  
Themes 
The second part of the results that will be discussed are the themes involved with active 
minority recruitment practices that emerged for each level of the socio-ecological model during 
the data analysis process.  
First, the application of the socio-ecological model used for this study is explained. 
Because the study explored how the behavior and practices of individuals involved in clinical 
research who actively recruit minority participants are influenced by and influence 
environmental elements, this puts the research site staff at the intrapersonal level of the model. 
Therefore, the intrapersonal level encompasses characteristics of the study participants only, 
including their knowledge, attitudes, perceptions, behavior and demographics.  
The interpersonal level is related to the interpersonal relationships of the  
study participants. The interpersonal level includes characteristics or interactions related to the 
interview participants’ co-workers, colleagues and social networks. 
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The organizational level is defined as the research sites in which the study  
participants belong. This includes organizational characteristics such as policies, culture, 
processes, structure and mission. 
Community is related to the community surrounding the study participants’ research 
sites. The community level encompasses information related to patients; patients’ social 
networks; local community stakeholders or organizations; and any outreach efforts conducted by 
the study participant or his or her research site that took place in the community. 
Policy is related to national, state or local laws, as well as clinical trial policies. The 
policy level includes items such as government regulations on clinical trials; federal guidance 
related to clinical trial conduct; regulations, policies or expectations set forth by the trial funder 
(i.e. NIH or pharmaceutical sponsor); and the healthcare system. 
In addition, because the study was designed to better understand perceptions and 
experiences of research site staff, most of the discussions and subsequent themes from data 
analysis were related to the intrapersonal and organizational levels of the socio-ecological model. 
Therefore, results are presented in the order of the socio-ecological model levels in which more 
themes emerged. First, findings in response to Research Question #1 are shared related to 
intrapersonal site staff elements involved in the active implementation of minority recruitment 
practices for biopharmaceutical-funded trials in the United States. Second, organizational 
findings related to Research Question #3 at the organizational level of the socio-ecological 
model are discussed. Next, community elements in response to Research Question #4 related to 
the community level of the socio-ecological model are discussed. Research Question #2 related 
to interpersonal site staff elements at the interpersonal level of the socio-ecological model is 
addressed next. Lastly, policy elements related to Research Question #5 are discussed. 
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There are 20 overarching themes that emerged from the interview data during the data 
analysis process. Table 3 provides an overview of these themes involved with active minority 
recruitment practices, along with corresponding levels of the socio-ecological model and 
corresponding research questions that are addressed. 
Table 3 
20 Themes Involved with the Active Implementation of Minority Recruitment Practices Emerged 
During Data Analysis that Represent Each Level of the Socio-Ecological Model  
 
Research 
Question 
Socio-Ecological 
Model Level 
Theme 
#1 Intrapersonal Research is important 
#1 Intrapersonal Important to increase minority participation in 
clinical trials 
 
#1 Intrapersonal Frustration with barriers to recruiting minority 
participants 
 
#1 Intrapersonal Personal commitment to recruiting minority 
participants 
 
#1 Intrapersonal Satisfying work 
#1 Intrapersonal Evolving personally 
#3 Organizational Mission related to improving healthcare through 
clinical research 
 
#3 Organizational Mission guides recruitment efforts 
#3 Organizational Organizational commitment to minority 
recruitment related to providing community 
education 
 
#3 Organizational Organizational commitment to minority 
recruitment related to organizational structure 
 
#3 Organizational Culture of inclusion 
#3 Organizational Minority recruitment practices evolving based 
on learning 
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20 Themes Involved with the Active Implementation of Minority Recruitment Practices 
Emerged During Data Analysis that Represent Each Level of the Socio-Ecological Model  
 
Research 
Question 
Socio-Ecological 
Model Level 
Theme 
#4 Community Should have access but don’t: not just about 
location 
 
#4 Community Efforts to instill trust 
#4 Community Cultural sensitivity 
#4 Community Encouraging active role in healthcare and trial 
participation 
 
#2 Interpersonal Teamwork 
#2 Interpersonal No peer influence 
#5 Policy Lack of diversity emphasis 
#5 Policy Diversity emphasis attempts 
 
Six intrapersonal themes that are involved with the active implementation of 
minority recruitment practices. 
Research is important. The first theme at the intrapersonal level is research is important. 
Participants shared their personal point of view related to his or her perspective that clinical 
research is important. As participant #16 said: 
… if research is done well it it’s a win-win-win for everybody. It’s a win for the patient, 
it’s a win for the research team, and it’s a win for...the pharmaceutical company that’s 
sponsoring it and for the public in general. 
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In addition, participant #12 shared, “I think it’s a positive thing. I encourage everyone to do a 
research study…I really do, I think you get great…care…you’re helping out society…it’s all 
good.” 
 Participants also discussed how research is important in the context of believing what 
they do is important. Participant #3 shared, “I think what…I do is important. You know I think 
it’s important for the value of…the scientific validity of new drugs and uh new drug 
development…” 
Important to increase minority participation in clinical trials. The second theme at the 
intrapersonal level is that participants not only believe that research is important, but they also 
believe that it is important to increase minority participation in clinical trials. Participants 
discussed this in relation to why they feel minority inclusion is important, including for 
generating generalizable knowledge in understanding if a drug is safe and effective in different 
populations. Participant #1 said: 
Research for me is that you know we’re here to seek generalizable knowledge that’s what 
we’re trying to learn how this medication or medications or device works and we need 
more you know minorities to participate. 
In addition, participant #3 shared:  
…it’s important to understand…if we can extrapolate the data to… the general practice I 
think as a physician and I don’t think a lot of physicians think about this but you know I 
thought about it for a long time…when I’m looking at a drug you know for example 
when I’m looking at a blood thinner right an anticoagulant you know I’m looking at the 
studies that were done and you know that only had a few if any minority participation, 
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how can I say that this drug is safe? How can I say it’s effective? You can’t say that until 
the only way that’s going to change is to to get more representation in trials. 
Participant #2 expanded on this by sharing: 
... like I said we wanna start looking at precision medicine and how medication helps a 
person, people with the same indication but of different genders, races, age groups, you 
know it’s very, very important that we include all people… in those studies... 
Having equitable access to treatment options available in clinical research was also 
discussed as a reason why participants feel it is important to increase minority participation in 
trials. Participant #2 went on to say, “I also think it’s extremely important for the patients in our 
health system to have access to the clinical innovations, the research innovations that are there.” 
Frustration with barriers to recruiting minority participants. The next theme is 
frustration with barriers to recruiting minority participants. Participant #7 said:  
I really wanna see um basically effort at the end of the day…we are smaller companies 
and… we really wanna see industry-wide more…towards this and giving more help and 
support to encourage minority…group to participate in…pharmaceutical trials…but it 
just I feels like it’s more frustration from my end… I wanna encourage them but I don’t 
have the enough energy and effort…I’m too small… to change the whole 
big…picture…so that’s just my frustration…I feel personally it’s important to cover…all 
the diversity group, majority or minority, but um big picture wise, industry wise, it seems 
that they all ignore that part. 
Frustration with barriers related to study design or lack of supportive materials that 
prevent access were also discussed. Participant #14 shared: 
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…this is a big issue, all of our trial materials need to be translated into different 
languages. And the fact that these consents for the most part are not translated routinely 
into Spanish, into other languages, is ridiculous…it should be a knee-jerk thing. You 
have a Spanish version, you have an English version, you have a Spanish version, you 
have an English and it’s really only based on a lot of the sites depending where they are, 
maybe you know we’ll we’ll only do it then. Well if you know you have a… urban site 
like Chicago where you want to go ahead and do a trial and you have nothing translated 
in Spanish, you’re not gonna do it because…you’re then asking only for English 
speakers, ok and I think this is something that we have to really understand. You are 
excluding people because you will not…go ahead and translate a consent into the 
language and/or the study materials and/or the study questions... 
Additionally, participants discussed communication barriers with patients, as well as 
expressed frustration with barriers preventing appropriate communication with patients. 
Participant #14 shared: 
I think there’s a lack of understanding from the investigators um to understand the culture 
and the community itself and you know I have I have heard investigators say that’s not 
my job that is my study team’s job, that’s the nurse’s job, it’s the social worker’s job, it’s 
the researcher’s assistant’s job, and I would argue and say no, actually it’s your job. Um 
you are the PI and you are the person conducting the trial and if you have no interest or to 
even understand how the community operates - what are some of the barriers they face, 
um what their world looks like then you really shouldn’t be doing a lot of these trials um 
that require um you know you actively recruiting… and I see this consistently where the 
community feels this. And the community is very smart and the community will say you 
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know the investigator never even came over here. You know, the study team only came. 
Or the investigator didn’t have time to talk about results or midway…or…anything about 
the disease that’s being studied and I think that’s really sad and I think that’s the reason 
why a lot of our minority recruitment is hurting. Um because the investigators itself and 
again I mean the PI um needs to be much more engaged in understanding his or her 
community in a real way, not just from what his people tell him or her about the 
community. 
Personal commitment to recruiting minority participants. The fourth theme at the 
intrapersonal level is personal commitment to recruiting minority participants. Participants in this 
study demonstrated having a personal commitment to minority recruitment by initiating self-
directed action for this purpose. Participant #3 said: 
…about 14 years ago I went out in private practice and started my own research company 
and…I was focused primarily on recruiting uh patients from…racial minority ethnic 
communities uh then trying to improve outcomes in clinical research, participation of 
research… 
In addition to initiating self-directed action, participants also demonstrated commitment 
by displaying determination or dedication towards recruiting minority participants. Participant 
#10 said: 
I believe in medicine that works for everyone…I’ve made a commitment to…try and 
make that happen by hiring um people A) who are from the communities that we’re 
trying to reach and B) who have a real desire to work in those communities and get those 
individuals engaged with science. 
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Participant #5 also discussed this idea: 
A lot of people the moment I tell them um I’m in clinical research they say “oh how 
many people died in a study?” At the beginning it was for me shocking that people would 
even ask because for me it was a given that everybody out there knows that nobody 
actually nobody should die in a clinical trial, right? Uh and that’s why we have all those 
regulatory authorities and all of this but guess what? People do not know and there is still 
this mentality in particular uh nowadays with… technology and social media if 
something bad happens it’s immediately spread all over the world but all the good things 
that happened are not out there so therefore we have to fight against this myth that 
clinical research is something very bad… there are people that abuse the system and then 
its it’s a slap in the face for the entire clinical research community trying to do our best 
because they did not play by the rules so we go back to the starting point and have to 
explain that the moment it’s it’s properly done the entire system tries to keep everybody 
volunteering in the system as safe as we can. We are not careless in this industry and this 
is something we have to explain there. And I will not give up doing this. 
Satisfying work. The fifth theme at the intrapersonal level is satisfying work. Participant 
#15 shared: 
I mean, it’s kinda funny um maybe I’m telling you too much but… I’m 65 and I um 
everybody says to me “are you, when are you gonna retire?” …I’m not ready to retire, yet 
I think about it because you know of course it’s I can think about it but…I enjoy research 
and I enjoy this job… 
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Participants shared their job satisfaction in relation to having positive feelings from 
helping patients. For example, participant #16 said, “…you know the whole idea is to help 
people. I mean I love what I do.” 
In addition to being satisfied with their jobs, participants feel rewarded by their efforts 
that help patients. Participant #13 said: 
I think it’s very exciting…because it’s something that you’re actually able to possibly 
help somebody with as well as help a lot of other people with it. You know it’s really 
rewarding experience just to be part of that. Um especially whenever you can talk to 
somebody who you know that could possibly benefit from this trial ‘cuz…it’d be better 
for them ….. I’ve met this fellow...he was supposed to be taking metformin every day 
twice a day. He was taking it once a week, he was borrowing it from his neighbor….I 
said listen, you need to come in and meet this doctor. Also I have some trials you might 
be good for. He didn’t qualify for the trials ‘cuz of his his hemoglobin A1c was way too 
high ‘cuz he wasn’t treated. Uh but the doctor was actually able to get him samples of 
the..medicine he needed uh to the point to where he was to actually able to get in to the 
the threshold of what the study fit... What if I wasn’t out there that day?...I’m not saying 
I’m the direct…reason but…the rewarding part of it is is I know because I had the 
opportunity to talk with him, he was actually able to take some action…and find a way to 
help himself… 
Participant #3 also shared: 
…it always makes me happy to you know I see a patient who may have had some 
reservations earlier on who have come in for their study visits, who are interested, who 
want to know the laboratory data, want to know how they’re doing in the research 
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program... it makes me smile, it makes me happy that uh that we have not only educated 
a patient, patient who is had some reservations now patient is engaged, fully 
engaged…they’re joining their follow-up visits uh and and you know at the end of the 
day I can sit down at my desk and say well I think we’ve made…a significant impact on 
this patient life…and just it’s a good feeling for me. 
Evolving personally. The sixth theme at the intrapersonal level is evolving personally. As 
previously mentioned, the responses for the one participant in the non–patient-facing role did not 
consistently fit with all of the themes that emerged from the data at the intrapersonal level. This 
is one example in which that participant’s responses did not align. Aside from that individual, 
personal growth was a common theme that was discussed, with participant #3 saying: 
…my feeling when I in participating in trials has made it really I think has made me a 
better physician, uh it’s made me a better physician for my patients…in understanding 
their disease process, what they go through and how we can impact that in in clinical 
trials… 
Evolving by changing perspectives was discussed in relation to becoming more sensitive to other 
cultures and cultural preferences. Participant #16 said: 
I think I’ve um become just a little bit more knowledgeable and sensitive to the situations 
that different uh minority populations are in. Um I think over time I’ve learned more and 
so I think I’m just a little bit more sensitive to it now than I I was previously. I think 
that’s kind of a continuous process. 
In addition to changing perspectives, participants also discussed behaviors they have adapted in 
order to develop skills for interacting across cultures. Participant #5 shared:  
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I can give you a very real example. I needed to be exposed I’m a Caucasian through and 
through…so I have never dealt with the African American community besides having 
some friends and coworkers. So I personally even started…mingling this um community 
in a completely different way in my private time simply to learn more about the thinking 
and the culture of this particular group so I ended up line dancing sounds weird 
now…with a group of black women at the church. Why did I do this? I want to learn 
more about their culture and what kind of triggers them and what what they think about 
certain things. That’s why I um even made the step into my private life um investing and 
learning and it’s actually it it embraces my life. 
Six organizational themes that are involved with the active implementation of 
minority recruitment practices. 
Mission related to improving healthcare through clinical research. The first theme at 
the organizational level is having an organizational mission related to improving healthcare 
through clinical research. This includes healthcare for overall society, as well as at an individual 
patient level, by improving access to treatment options available in clinical trials. When asked to 
share his organization’s mission, Participant #10 said, “to…treat and prevent Alzheimer’s 
basically…we’re being seen as a brand uh in the community that can deliver care…at a high-
level and provide research opportunities at a high-level.” Participant #3 also shared: 
…when I developed it many years ago…my mission was to… recruit and to improve 
minority participation in clinical trials uh with the ideal to dispel misconceptions, to 
dispel myths, to improve outcomes in healthcare through participation in community–
based research... 
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Mission guides recruitment efforts. The next theme at the organizational level is that the 
organization’s mission guides recruitment efforts. Participant #10 said: 
So…that idea that we have a mission to prevent and treat is is part of what we market and 
what we for lack of a better word sell to people that that being active in research is part of 
that ongoing process of treatment or prevention…whether you get better…or not it’s part 
of the hope and the… intrinsic value…as a human being that…if you…have dementia for 
example being part of the solution ultimately. 
In addition, participant #3 shared the following when asked about team members, indicating that 
the organization’s mission is prevalent in the ways of working across the organization: 
… they’re engaged…they understand what our mission is and they’re engaged… as 
engaged and as I am in in getting patients involved in studies, getting the patients 
engaged…” 
Organizational commitment to minority recruitment related to providing community 
education. The third theme at the organizational level is organizational commitment to minority 
recruitment related to providing community education. Disease and general clinical trial 
education needs to be provided to minority communities prior to presenting a specific trial 
opportunity. As participant #14 said: 
We’ve always talked about wellness first and we’ve always talked about how do we 
maintain where we’re at so we so the decline that we know can happen can be lessened. 
So it’s educating first. That then is built on, once we have that established, then we build 
on discussing recruitment into trials for specific…trials. This trial is for memory decline, 
this trial is for Alzheimer’s, this trial is for stroke, this trial is for Parkinson’s. Then we 
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start to build on that but the foundation always is how do we understand aging, how do 
we prevent the declines that we know can happen… 
Additionally, the education needs to be culturally appropriate. Participant #10 shared:  
...somewhere along the way we decided we needed to make that much more culturally 
appropriate um it had been uh developed basically with a bunch of rich older white um 
folks…in these sort of relatively affluent…retirement communities. And when we were 
talking with various community groups and other people we were realizing this didn’t 
make any sense for um other groups and we wanted to ask those groups…what they 
wanted to learn about and how-what was the best way to deliver that? So we started… to 
try this in some black churches um and we…asked them, “…what of these pieces of 
[[Alzheimer’s Disease prevention disease education]] do you want to learn, are there 
anything different?” um and then we also went into uh a couple of Latino serving 
organizations and asked them to help us refine it as well. And we got very different 
answers from each group... So we we took [[Alzheimer’s Disease prevention disease 
education]] and we modified it to meet those um different demands…and then um uh 
started delivering that in those communities um as a first entry point to get people to 
know us as a center and build a little bit of trust by delivering some um education and 
service maybe connecting people with um resources in that area um off-line or things like 
that. So it was it was very little about recruitment and very much about exposure in the 
community.  
 Building on the needs to provide culturally appropriate disease and general clinical trial 
education prior to presenting a specific study opportunity, this requires a long-term investment. 
As participant #6 said:  
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…and this is where many people make a mistake you know how do you recruit patients 
for a trial? You recruit patients for a trial, this…particular demographic by first educating 
them. By offering them something valuable that they can use without the pressure of or 
without the you know the pressure or the um the need to even have to discuss a study. 
You know…when you do this in in an effective manner, it means that you have to put up 
a lot of resources and quite honestly, many businesses are not willing to invest over the 
long term and this is where they go wrong. People want to see numbers on a spreadsheet 
and that’s just not the case…when you’re dealing with a certain demographic you cannot 
be there for that trial for just that study, your investment has to go beyond that, beyond 
the study number one and then before the study even starts, … there’s an initial 
investment that you have to make long before that so you can’t look at numbers on a 
spreadsheet to determine that you know that that piece of advertisement worked – it 
doesn’t work that way. Not…for the kinds of patients that we see. 
Organizational commitment to minority recruitment related to organizational 
structure. The fourth theme at the organizational level is organizational commitment to minority 
recruitment related to organizational structure, which needs to be made conducive for recruiting 
minority participants. This includes hiring diverse staff from the local community, ensuring that 
staff members are able to speak the same language of the patients that are being recruited and 
adjusting hours of operation. Participant #10 said: 
…we do make an effort to have people um who uh have comfort and knowledge uh of 
the communities we’re trying to…recruit from um so you know for lack of a better way 
to say it this is sort of how the field says it - you want to have people in your organization 
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who look like the people you’re trying to recruit right and who sound like the people 
you’re trying to recruit and who grew up in the neighborhoods and…places. 
While participants discussed their organization’s commitment to creating an 
organizational structure in order to be better at recruiting minority participants, they also 
recognized room for improvement. Participant #10 went on to say:  
…who could uh provide the full infrastructure that’s needed it’s not just recruitment I’ve 
gotta have um a a doctor to do physical exams who um can speak Spanish for 
example,…a Study Coordinator who uh can explain all of the procedures and do help 
with all the scheduling um who speak Spanish if that’s the only language… I can make 
small investments for recruitment but to really fully get people into trials it is a very 
there’s a critical mass…of investment…the center has to make um across the board in in 
all aspects of what we do…I can’t just piece meal it 10% here, 10% there, for a 10% 
Latino population. I’ve gotta have a full-time person who can do uh who can do that, 
multiple full-time people who can serve that whenever we need it. And that’s that’s hard. 
Surprisingly, participants discussed their organization’s commitment towards overcoming 
barriers to making structural changes just as often as discussing barriers that prevent their 
organizations making structural enhancements. Participant #6 said: 
And so a couple of years ago you know we made the investment of opening up our clinic 
on Saturday, which was a hard thing for us to do because you know from a business 
perspective it’s an expensive thing to do Saturdays. You know additional staffing, 
physician time, you know you have limitations in terms of how…late you can see 
patients because of courier issues, I mean there’s just a multitude of things and so it 
requires an up-front investment and a continued sustained approach… 
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Culture of inclusion. The fifth theme at the organizational level is culture of inclusion 
with regards to diverse inclusivity in clinical research, as participant #5 said: 
So you know living in an area here where we have um a population heavily mixed with 
minority groups we have all of those people here and the kind of uh communication we 
have even on our lunch breaks or whatever now, it’s different. We are listening to each 
other to learn about each other and our cultural backgrounds. That hopefully helps us to 
understand the motivation of minority groups better um to possibly being a part of 
clinical research. 
Some participants discussed having a culture of inclusion derived from leadership support or 
directive. Participant #2 shared: 
I think one of the more important things the aspects of how we recruit is that everyone is 
should have access to clinical research within our health system. It is imperative that 
everyone have an opportunity to take advantage of health alternatives and that’s just a 
thought from um the top of the administration down to you know the clinical research 
program. 
Additionally, participant #15 shared: 
…our hospital system I mean…their whole mission is to serve anyone that comes 
through the doors…that kinda drives how you know research mindset is that everybody 
qualifies for a study and we don’t care you know. 
Minority recruitment practices evolving based on learning. The final theme at the 
organizational level is minority recruitment practices evolving based on learning. Participants 
discussed how their research organization’s approach to minority recruitment evolves based on 
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lessons learned. Participant #3 said, “…you know we’re continually evolving and uh trying to 
get understanding of what would help more…” Participant #6 also discussed this idea: 
Well it’s changed over time. You know, it’s evolved over time and part of…that is 
because you know we don’t have um how can I explain it – it’s changed over time 
because as you start to gain the confidence and you start to to learn more about you know 
what what people want and what they respond to, you have to kind of customize as you 
go along. 
Past experiences shape future recruitment approaches. As participant #5 said: 
We were supposed as many other sites worldwide this year to enroll in a 
pharmaceutical…study uh to enroll people with a different uh ethnical background so um 
we were looking for Hispanics, for Asians and for African Americans. Um we thought 
living in a hot spot of a very mixed culture here um around San Diego would make it 
easier and boy did we learn that it has nothing to do with the statistics of the population 
but it has more to do with I come back to the basis with trust. Cuz people of different um 
ethnical backgrounds have a different culture and they trust their own but not so much the 
rest of the world and therefore if you are not deeply rooted and have have earned your 
trust in this community already before you are looking for um volunteers for a clinical 
trial um you might not be successful and uh unfortunately this entire project has been 
pulled by the by the uh pharmaceutical sponsor because uh the entire world suffered the 
same. So what we learned as a team is uh the entire clinical research industry invested in 
some education of the public over the last four decades but this education was mainly 
targeting Caucasian people – nobody else. And that bites us a little bit in our behind now 
because uh we dropped all those other people uh and they need to be educated now that 
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we we go to the same level of trust and have a chance to attract them volunteering in 
clinical research. So we adjust. So our work now with uh ethnical different communities 
changed dramatically so we reprioritized our efforts... 
Four community themes that are involved with the active implementation of 
minority recruitment practices. 
Should have access but don’t: not just about location. The first theme at the community 
level is should have access but don’t: not just about location. Clinical research sites do not 
always have access to minority patients for trials, despite having physical access based on 
geography. As participant #4 said, “…but if you start the trial just because uh doctor say yes yes 
yes I have the patient population – 80% of the time uh that means failure.” This is because of the 
multitude of barriers to minority participation, which were previously discussed. Participant #2 
said: 
…and then when I got this position here where our demographic is 88% you know 
African American little bit easier to have – ‘cuz you have that population but the 
difficulties are still the same because you still have more opportunities for education, 
more opportunities for…well more opportunities for continuous education. 
Mistrust of research among minority patients was prominent in the discussions during the 
telephone interviews, as shared by participant #12: 
…minority you just really have to I mean they still have I can’t tell you how many 
minority men have you know come have mentioned the [Tuskegee] um incident and you 
know “are you using me as a guinea pig?”... probably like one out of every three brings 
that up to me. 
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Also mentioned earlier as a past experience shaping recruitment approaches, Participant #5 
expanded on mistrust as a learning experience that demonstrates it takes much more to being 
successful with recruiting minority populations than just having physical access: 
We were supposed as many other sites worldwide this year to enroll  
in a pharmaceutical…study uh to enroll people with a different uh ethnical background so 
um we were looking for Hispanics, for Asians and for African Americans. Um we 
thought living in a hot spot of a very mixed culture here um around San Diego would 
make it easier and boy did we learn that it has nothing to do with the statistics of the 
population but it has more to do with I come back to the basis with trust. ‘Cuz people of 
different um ethnical backgrounds have a different culture and they trust their own but 
not so much the rest of the world… 
Efforts to instill trust. The second theme at the community level is efforts to instill trust. 
Many efforts are taken by the study participants and their organizations to establish trust with 
minority patients. These efforts are divided into two subthemes: site staff interpersonal 
interactions with patients and leveraging a patient’s social network. 
Site staff interpersonal interactions with patients. There are several different ways in 
which trust is developed with minority patients that relate to research site staff interpersonal 
interactions with those patients. First of all, it’s important to give back to the community without 
asking for anything in return. As participant #6 said: 
We have more traction in terms of recruitment just from word of mouth because we’re 
not seen as somebody who just takes. You know if you just take, take, take, it’s gonna 
become apparent. You can’t just target people for a study. You know you don’t, you 
don’t build trust that way. And so we’ve had to give, give, give, and our return quite 
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honestly has been ten-fold. But we haven’t changed that. We put an investment into the 
give, give, give, first. 
A way to give back to the community and establish trust is to provide personalized education to 
help patients understand their disease and how to manage it. Participant #6 shared: 
So many of the things that we did to gain their trust first of all you know revolved around 
more um humanitarian kind of services so you know one of the things that um that I 
learned early on is that um you know people…have a sense and a fear of of the unknown 
and when it comes to their…own condition or disease um many of them just don’t have 
an understanding. So one of the things that we decided early on is you know rather than 
to approach um people with you know with studies why don’t we just dedicate the time 
and resources to be able to educate people on what it is that they have… 
Having personal interactions with minority patients is important for instilling trust. As 
shared by participant #5 
…the direct face to face contact with those who might to be impacted by themselves or 
take care of somebody who is affected. The face to face um opportunity to meet people 
and discuss things is the most important thing um to build the trust for sure… 
Another important component for developing trust is for research staff to have a 
commonality with patients. This helps with making patients feel comfortable, as well as indicates 
to them that the trial is important, when there is someone from the same racial or ethnic 
background as part of the study team. Participant #3 shared: 
…you know patients trust me and uh that’s important…they’re able to to look at me, I’m 
African American and I’m coming from an African American population…so you know 
in contrast to an academic center where they’re looking at an Investigator who may not 
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reflect um you know their racial or social sensitivities where I may and and so there’s 
some commonality and that that helps a lot in terms of recruiting… 
Communication techniques are also important for developing trusting relationships. As 
Participant #12 said: 
…being a good listener…taking our time - if we have to repeat things multiple times, we 
repeat them. Um you know just really um if you say you’re gonna call them back, even if 
you don’t have the answer yet, you call them back. You have to…you have to build trust 
you have to…you just have to do that…and once they start trusting you then it’s great. 
You know, there’s no hiding. Like you just gotta make sure they know that nothing, 
there’s nothing hidden – there’s no hidden agenda, there’s no we are here for you, and 
you know and I think once they meet us and they realize all the stuff we do for them… 
In fact, participant #12 went on to share, “…these people become like family. Our 
patients, I mean I have so many um you know to be able to help them and you know I’m part of 
their lives.” 
Developing trust occurs over time and needs to be nurtured. It is also crucial that the PI is 
engaged. As participant #14 said:  
…the last piece is um you know there has to be a (community) involved with in some 
way to ask people to come into a trial and if you don’t give the education and the results 
back of what previous trials have shown and explain it, you’re not going to get continued 
people to even consider coming in a trial. And that’s very big in our minority populations 
where you know it’s you you continue to see it. You know, investigators have come in 
and done some work and then they the community never hears from them again…, they 
don’t talk about the results, whatever’s been gleaned, and it’s just moving on to the next 
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project. And the community’s like wondering well what happened. So I think that’s really 
key um especially in our minority populations. 
Patient interpersonal influence: social network. There are a couple of ways in which trust 
is developed with minority patients by leveraging their social networks. First, participants 
discussed how patients’ social networks, such as friends or family members, may refer them for 
a trial if they themselves are supportive or had a good experience with a trial. Some participants 
discussed the importance of engaging the family in recruitment and consent discussions. 
Participant #12 said: 
…we really encourage um the wives a lot of times are very mistrusting of us…and uh so 
getting um getting them to come in…when their husbands are there with us and actually 
talking it out all of us together um helps a lot… 
Second, partnering with community stakeholders that serve as existing trusted sources of patients 
is a critical component for establishing trust and gaining access to minority communities. As 
participant #6 said: 
You know…it evolved over time and really what looking back now it was a process of 
gaining trust…if I could target those people that were most influential – pastors,…priests 
within congregations, if I could get gain their trust and they in turn could introduce me to 
people and if I could gain their trust, then I was kind of one step closer to to being able 
to…draw them in... 
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Cultural sensitivity. The third theme at the community level is cultural sensitivity. Being 
aware of and respectful that cultural differences may exist is an important component when 
recruiting diverse populations. Participant #16 shared: 
…every population is different and you have to really understand what their concerns are, 
and and their culture, and and try to…bridge the gap in an individual manner. I mean first 
of all, I I think you’ve just gotta respect each individual first of all. First you can’t draw 
any conclusions you deal with that person directly and individually. Then if you’re gonna 
try to reach out to African Americans or to Hispanics then you you have to understand 
how they typically view research… 
Participant #14 discussed the negative impact of not recognizing or addressing the 
specific needs of cultural groups by stating: 
…the other issue we’re facing is because we are trying to recruit ethnically diverse 
people, and it goes back to understanding the community but it’s really going back to 
understanding the culture. And I have seen this multiple times…if you’re a PI and if you 
do not understand the culture and the history of this ethnic group and racial group either 
in the city you’re in, the town you’re in, or from the native country about some of the 
things that are very important to the group and some of the medical issues that may have 
happened with the group, then you’re in trouble and um people sense it and they 
understand that…you don’t know of this atrocity that may have happened to to 
my…people. That you know typically is said – my people. You don’t know about this 
therefore why would…I let you do something to me if you don’t even know that this 
happened to our group in this trial… 
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It goes beyond recognizing the existence of cultural differences to also understanding 
cultural preferences in order to effectively communicate with patients across cultures. As 
participant #5 said: 
That hopefully helps us to understand the motivation of minority groups better um to 
possibly being a part of clinical research. The moment we we understand minority groups 
better we have a chance to target and approach them in a different way because we are 
thinking more out of their head then out of our head. And that makes a difference... 
Participant #4 expanded on this by discussing how everyone who works for him must 
learn to work with different cultures: 
…forget about your belief um because this trial is not about you…let’s concentrate on the 
belief of that minority, let’s try to understand their needs, let’s try let’s try to understand 
their culture…let’s try to understand how can we make it better for them… let’s try to to 
be educative as possible, let’s try to find new ways to send a very strong message to 
them, um let’s learn about them, that’s my message um if you if you work for me…you 
have to to learn how to um work with different cultures…and leave your perception out 
because it’s not about you. It’s about the patients, it’s about the different cultures. 
Encouraging active role in healthcare and trial participation. The fourth theme at the 
community level is encouraging an active role in healthcare and trial participation. Participants 
discussed how they encourage patients to be engaged and take an active role in managing their 
health by educating them so they understand their disease and how to manage treatment options.  
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Participant #6 said,  
…take for example a diabetic, what we found is that people…could have been diabetic 
for 20 years but they really do not understand what is occurring within their own bodies. 
And so the first challenge is to really help them understand… 
In addition, encouraging patients to take an active role in trial participation is also important, as 
stated by participant #1: 
…I believe what works for me is give the patient enough time to go over the informed 
consent, let them read it, tell the patient, “look you know I need you to ask questions. I 
don’t just want you to sign a document, I want you to ask me questions about particular 
adverse events. Would this happen? What is the likelihood? What’s the percentage? What 
happened?” I mean I need this information because it keeps ME fresh as well too so I like 
to have the patient ENGAGED in terms of the studies that they may or may not 
participate in. 
Participants in this study also shared how minority patients are interested in receiving 
disease and general trial education and understanding what it means to them, as shared by 
participant #14: 
…the foundation always is how do we understand aging, how do we prevent the declines 
that we know can happen, and of late we have been focusing on racial differences that we 
see…and trying to understand what those racial differences are between Blacks and 
Whites and uh Hispanics and hopefully soon Asians…this kind of discussion is very 
important in the community. People want to hear it and people are very interested and 
wanting to know why are these differences there, what are you thinking, and how are you 
designing trials to address those differences… 
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Two interpersonal themes that are involved with the active implementation of 
minority recruitment practices. 
Teamwork. The first theme at the interpersonal level is teamwork. Participants discussed 
working together as a team as a standard way of working. Participant #15 said: 
I have various teams and…one person comes in…in the morning, also you have to set 
your roles and your schedule so that everybody’s agreeable. But one person comes in in 
the morning and starts recruitment um starts screening every morning. Um and when she 
gets aggravated by doing all that, then you know then I say to the other person, “well, you 
know either get in a little bit earlier or as soon as you get here start doing it so that the 
other person the first person could do the regulatory today or do something else.” Um so I 
think the team effort… 
Several different aspects of teamwork were discussed, including taking a proactive, team 
approach to recruitment planning as well as involving the PI in recruitment discussions with 
team members. Participant #2 discussed both of these ideas: 
…ya so it’s it’s developing a recruitment plan uh before we even start we sit down with 
the Principal Investigator, develop a recruitment plan on um how we’re gonna chart 
review in our electronic medical records, the…physician’s schedule um they are really 
involved in looking at their schedule to see if the patients…fit inclusion exclusion 
criteria… 
Participants described learning as a team within their organizations, as shared by 
participant #9, “…well the first few times that we go through the process everybody learns, we 
definitely learn something...” 
Problem solving as a team was also discussed, as shared by participant #16: 
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…if things aren’t going well…we’re just trying to work together to solve the problem so 
um I would say I other than maybe some disappointment when things don’t go exactly 
according to plan we we’re really just troubleshooting. 
Effective communication across teams and between team members is important in order 
to be effective at recruitment, as mentioned by participant #16, “…we’re very much a team 
and…we’re all in the same room so…there’s really kinda no barriers to conversation between 
us.” 
Participants also discussed having a team spirit, or camaraderie, as shared by participant 
#14: 
Assuming you have people that like what they do, love being out there…have a team 
supporting them and then you know it’s a very enjoyable experience…for everybody 
involved but for especially for them they feel a sense of accomplishment. They feel a 
sense of the giving back. They feel that this project is not just let’s say your project, it’s 
the team’s project. It’s a win-win. 
No peer influence. The second theme at the interpersonal level is no peer influence. 
Participants indicated that their colleagues or peers do not influence them with regard to minority 
recruitment when asked one of these two questions during the interview, “what types of 
discussions are happening among your colleagues with regards to minority recruitment?” or 
“Can you share an example of when one of your colleagues encouraged you to focus on minority 
recruitment?” Participant #16 responded, “Hmmmm. You know most of my… physician 
colleagues are…White, mostly male…” Participant #13 provided a similar response: 
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…not a lot to be honest with you…I do talk with other people in the country – I’ve a 
friend over in California, I have some friends down in South Florida…they run research 
sites and um there’s not really a lot of talk about that… 
 In fact, some participants shared how they are the ones actively attempting to influence 
others with regards to minority recruitment, as mentioned by participant #14, “…um I’m trying 
to think I mean it’s often the opposite…It’s me telling somebody else that they better you know 
get this thing going here…” 
Two policy themes that are involved with the active implementation of minority 
recruitment practices. 
Lack of diversity emphasis. The first theme at the policy level is lack of diversity 
emphasis by the trial sponsor or governing body. Participant #7 shared: 
…I feel horrible…because for years I still don’t see…I was always curious as a 
researcher background before, I…always ask questions…why uh does no one see it? Is 
this really doesn’t matter or it’s like it does matter it’s also difficult for organization like 
FDA you know or like pharmaceutical company perspective is this really hard for them to 
encourage minority group to participate uh that’s why they just ignore it, they don’t even 
put a policy on it or any do anything about it, give any…additional support to the site to 
cover it? 
Participant #2 expanded on this by stating: 
… pharma companies allow too…much control from the individual sites meaning that 
hey if I don’t get minorities I don’t get minorities but I…fulfilled my recruitment goal. 
You know, in the long run that looks great on the site and it may look great for the 
pharmaceutical company but actually is that the best medicine that could be provided 
  143	
for…the patient…for the population? … there’s an area of…opportunity there that I 
believe um the pharma company can can kind of control a little bit more um you know 
they can put regulations… 
Participants in this study discussed how either they themselves, their colleagues and/or 
organizations are motivated to meet the enrollment goal commitment made to the study sponsor. 
This essentially results in a lack of diversity focus, as participant #10 shared: 
But at the end of the day, I am judged by how many what my n is…not my n solely of 
you know well you you needed 20 and you only got four, but all four were African-
American…that’s okay but that means I only got paid for four people. Not 20 people.  
There was one participant who was an outlier regarding this topic. Participant #3 was 
motivated by making a difference to a patient’s life and not necessarily by the numbers: 
...these are lives that it’s I think its very powerful…you may have one patient you know 
we’ve had trials where I only had one patient and involved in the trial but that one 
patient did well. That one patient had a positive outcome and a that one patient had a 
positive experience and that one patient comes back and and asks us if there’s other trials 
that that she can participate in. You know so you know that that you know that for a 
physician I I think that’s important a lot of times we get you know we get sort of bogged 
down in in you know even in research we look at the numbers… 
Some participants also discussed the lack of diversity focus during site selection, as 
participant #3 said, “…when I go to…Investigator Meetings… if there are a hundred 
investigators at the meeting there may be 2 or 3 minority investigators…in a clinical trial…”  
Surprisingly, participants in the study who work for organizations that also receive NIH 
funding shared examples demonstrating a lack of diversity focus that still occurs at the NIH 
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level, despite the policy that has been instituted as part of the NIH Revitalization Act of 1993 
(USHHS, NIH, 2001; USHHS, NHLBI, 2011). Participant #10 shared: 
I’ve never heard of a trial being pulled ‘cuz you didn’t meet your underrepresented 
minority uh goal, right? Um nobody ever pulls a trial or scolds you or holds you 
accountable to those things. 
Diversity emphasis attempts. The second theme at the policy level is diversity emphasis 
attempts made by either the trial sponsor or governing body. Participants discussed a recent shift 
in the trial landscape with the trial sponsor or FDA emphasizing diversity. This was discussed in 
relation to both the NIH and pharmaceutical organizations as the trial sponsor, as shared by 
participant #10: 
I don’t know if…that’s gonna continue over the next five years. I really feel like at least 
at the NIH level there is beginning to be a, “this is not lip service this is important” um 
kind of sense…to what I’m hearing. I also think that Pharma truly has an interest in 
having their drug um tested in in all types… but…I don’t know if they’re gonna start you 
know really holding people accountable…I think there might be…a shift 
in…accountability uh beginning just now…just in the last maybe year or so. 
Participant #4 discussed this recent shift to a diversity emphasis solely in the context of 
pharmaceutical sponsors: 
I think right now there’s a small uh shift and I think they’re realizing this now and we’re 
seeing more and more feasibility questionnaires um, “hey where is your access to this 
specific population or ethnicity group?” um I’m seeing this more on the uh mid-size, 
small biopharma companies but in the huge pharma companies I still haven’t seen that 
yet…  
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When requirements or expectations related to diversity are put in place, this influences 
research sites to focus on diverse recruitment, as described by participant #5: 
…from a researcher point of view and knowing that the treatment in in the indication we 
are operating is heavily impacted by ethnical background, so by genes, the FDA, they 
started already requiring not only certain age groups but certain minority groups as well 
because the simply the treatment of the same condition is different for different ethnical 
groups so therefore…there is no way around this there will be more and more protocols 
that will require this targeted population. It’s a requirement so and therefore we have to 
be prepared that we have access to those uh minority groups. 
Summary of Findings 
In summary, several themes emerged during the data analysis process that answered the 
research questions, providing an explanation for the elements involved with active minority 
recruitment practices. Each research question represented a different component of the socio-
ecological model.  
  Research question one: how are intrapersonal site staff elements involved in the 
active implementation of minority recruitment practices for biopharmaceutical-funded 
trials in the United States?  Individuals who participated in this study believe that research is 
important. They also believe that it is important to increase minority participation in clinical 
trials and shared their frustration with barriers preventing that from happening. Participants in 
this study are personally committed to providing access to clinical trials to minority participants, 
which may be fueled by the satisfaction they receive from their recruitment efforts and their 
personal beliefs. Finally, participants discussed examples in which they have personally evolved 
through these efforts. 
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  Research question two: how are interpersonal site staff elements involved in the 
active implementation of minority recruitment practices for biopharmaceutical-funded 
trials in the United States? At the interpersonal level, participants discussed several aspects of 
working as a team towards their recruitment goals. While participants in this study are not 
influenced by their colleagues to focus on minority recruitment, there is a social norm within 
their organizations of working as a team on their minority recruitment initiatives.   
  Research question three: how are organizational elements involved in the active 
implementation of minority recruitment practices for biopharmaceutical-funded trials in 
the United States? Participants work for organizations that have a strong sense of mission 
related to improving healthcare through clinical research. A commitment to minority inclusion is 
demonstrated by efforts made to provide culturally appropriate, general disease and clinical trial 
education to the community with an organizational structure conducive for minority recruitment. 
Participants represent organizations that demonstrate a culture of inclusion and continued 
learning for further refinement of minority recruitment practices based on learning. 
  Research question four: how are community elements involved in the active 
implementation of minority recruitment practices for biopharmaceutical-funded trials in 
the United States? Participants also discussed community elements related to how although they 
may have physical access to minority populations to recruit into clinical trials, factors such as 
mistrust and lack of awareness come into play that hinder participation. As such, several efforts 
are taken by participants and their co-workers to instill trust in the research process and between 
patients and site staff, including being sensitive to and understanding cultural preferences, as 
well as empowering patients to take an active role in managing their disease through education. 
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  Research question five: how are policy elements involved in the active 
implementation of minority recruitment practices for biopharmaceutical-funded trials in 
the United States? Participants in this study are not often influenced by public policy or 
expectations of pharmaceutical sponsors to focus on minority recruitment. A strong sense of 
commitment to meeting enrollment goals contributes to a study-level focus in expediting 
recruitment. At the same time, participants are making long-term preparations for improving 
access to minority groups, which also prepares them for the cohort-specific expectations from the 
FDA and/or pharmaceutical sponsors that participants discussed are becoming more prevalent. 
The next chapter will discuss the meaning of these findings by first comparing and 
contrasting with existing literature, then by using the socio-ecological model as a lens to interpret 
these findings, and lastly by suggesting recommendations for practice based on these findings 
from the data analysis. 
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Chapter V
 
DISCUSSION, RECOMMENDATIONS AND CONCLUSIONS 
 
 
This qualitative study was designed to understand the socio-ecological elements involved 
in the active implementation of minority recruitment practices for biopharmaceutical-sponsored 
clinical trials. The socio-ecological model guided this study, and 20 themes emerged from the 
data analysis and were categorized across the socio-ecological model levels.  
The following section interprets the emerging themes in relation to the literature. The 
meaning of these findings is then discussed in relation to the socio-ecological model. 
Implications for practice that have been guided by an ecological perspective and derived from 
the findings are provided to offer guidance and suggestions for enabling clinical research sites to 
effectively create an environment for recruiting minority participants. In conclusion, suggestions 
for future research are provided. 
The literature on the topic of minority recruitment in clinical trials is in the context of 
NIH-funded trials, so these findings offer a new contribution to the literature related to industry-
funded trials. In addition, it is important to differentiate between the support and resources that 
are provided to sites conducting NIH-funded studies versus those provided to industry-funded 
studies. In addition to individual study support, the NIH oftentimes provides funding for research 
activity infrastructure at sites. This includes providing strategic guidance, placing resources at 
sites or providing funding for hiring and training minority staff to support recruitment and 
educational activities (Duda et al., 2011; Cook et al., 2005; Hinton et al., 2010). The discussion 
that follows will focus on areas in which the study findings are similar and divergent from 
existing literature, outside of these differences discussed relating to the literature and support 
provided for NIH-funded trials.  
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Themes Interpreted with Literature 
As previously discussed, the themes that emerged have been categorized across the socio-
ecological model levels, with themes representing the “intrapersonal” and “organizational” levels 
found to be more prominent in this study. A reason why these two levels were more prevalent in 
this study is likely a result of the study design and interview questions that captured a better 
understanding of research site staffs’ perceptions and experiences within their organizations 
related to minority recruitment. Interestingly, attitudes and other intrapersonal elements 
regarding minority inclusion in clinical trials from a healthcare professional perspective are not 
widely explored in the existing literature and are limited to PI and physician attitudes, perception 
of barriers and extent of or lack of focus by virtue of setting and measuring progress toward 
minority enrollment targets (Boden-Albala et al., 2015; Durant et al., 2007; Eggly, Barton, 
Winckles, Penner, & Albrecht, 2015; Howerton et al., 2007; Simon et al., 2004; Williams & 
Corbie-Smith, 2006).  
From an organizational perspective, infrastructure barriers to minority recruitment, such 
as inexperience and limited funding, are discussed in the literature (Durant et al., 2014; Joseph & 
Dohan, 2009; Williams & Corbie-Smith, 2006). However, outside of the importance of hiring a 
diverse research staff, organizational contextual characteristics in relation to successful minority 
recruitment practices are not widely described in the literature (Etkin, Farran, Barnes, & Shah, 
2012; Ford et al., 2013; The Society for Women’s Health Research & FDA, 2011; Williams & 
Corbie-Smith, 2006). Existing literature suggests that characteristics related to research sites may 
have contributed to the successful enrollment of minorities into clinical trials (Duda et al., 2011; 
Jimenez et al., 2013; Wright et al., 2001). Participants in this study have provided context for 
specific organizational characteristics that contribute toward the active implementation of 
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minority recruitment practices, including incorporating improving access to clinical research in 
an organization’s mission statement and nurturing a culture of inclusion.  
Although the data that emerged from this study were not as prominent on the community 
level as the intrapersonal and organizational levels, there was still an abundance of data 
representing the community level of the socio-ecological model. These data were provided from 
the perspective of the individuals who participated in this study and was primarily related to 
efforts they take to engage with their local communities in efforts to build trust. Most of the 
literature related to minority recruitment is specific to the community level of the socio-
ecological model. Many of the examples discussed in the literature share cultural or community-
specific recruitment strategies that involved engaging with the local community and building 
trust (Ejiogu et al., 2011; Etkin, Farran, Barnes, & Shah, 2012; Germino et al., 2011; Wallington 
et al., 2016). The literature also provides minority patient perspectives, including motivators and 
barriers to clinical trial participation (Ejiogu et al., 2011; Ford et al., 2012; Ford et al., 2013; 
Markman, Petersen, & Montgomery, 2008; Salihu, Wilson, King, Marty, & Whiteman, 2015; 
Wells & Zebrack, 2008). In this study, participants discussed patient motivators and barriers to 
trial participation. Although this information was not collected directly from patients, the 
perceptions shared by this study’s participants corroborates with existing literature describing 
minority patient perspectives regarding clinical trials. In addition to information reported in the 
literature, the participants in this study provided context surrounding minority patient interest in 
receiving disease education and learning about clinical trials. Participants discussed building 
long-term trusting relationships with minority communities by providing education and 
empowering patients to take an active role in managing their disease. Study participants also 
shared their experiences related to learning about other cultures through face-to-face interactions.   
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At the interpersonal level, only two themes emerged from this study – teamwork and no 
peer influence. The existing literature related to minority recruitment in clinical trials is not 
inclusive of the interpersonal level of the socio-ecological model from a research provider 
perspective. Instead, the socio-ecological model has been used in the literature for categorizing 
barriers to minority participation in clinical trials and describes influencers of patients’ 
interpersonal relationships as opposed to researchers’ interpersonal relationships (Salihu, Wilson, 
King, Marty, & Whiteman, 2015; Wells & Zebrack, 2008). Thus, the themes at the interpersonal 
level provide new contributions to the literature. 
Similarly, two themes emerged that represent the policy level of the socio-ecological 
model. These two themes are lack of diversity emphasis and diversity emphasis attempts made 
by either the trial sponsor or governing body. Due to the application of the socio-ecological 
model for this study, the policy level was defined to represent both public policy and clinical trial 
policy or expectations set forth by trial sponsors. Therefore, any expectations or lack of 
expectations regarding minority enrollment on behalf of the pharmaceutical sponsor was 
categorized under the policy level, which broadened the opportunity for representation of this 
level. The clinical trial literature is not heavily saturated with policy-level representation related 
to minority recruitment. An abundance of literature discusses minority recruitment strategies 
utilized for NIH-funded studies; however, the focus of the literature is on describing the 
strategies used and not policy implications related to these studies having a minimum 
requirement for enrolling racial and ethnic minority participants as a stipulation of receiving 
funding (USHHS, NIH, 2001). However, some of the strategies utilized in the literature that were 
discussed may have been made possible due to additional funding and support. There is also 
literature regarding the low uptake of planning for the NIH’s mandate for minority inclusion with 
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regards to setting minority enrollment goals, requiring cultural competency training and 
translating study materials (Boden-Albala et al., 2015; Durant et al., 2007; Durant et al., 2014; 
USHHS, NIH, 2001). Finally, lack of access to healthcare or not having health insurance are 
discussed as barriers to minority participation in clinical trials (IOM, 2003; Swanson & Ward, 
1995; USHHS, CDC, 2011a). While not a dominant theme, participants in this study discussed 
lack of access to healthcare as being both a barrier and an enabling factor toward minority 
participation in clinical trials.  
Intrapersonal themes interpreted with literature. Participants in this study 
demonstrated their personal commitment to minority recruitment by initiating self-directed 
action for this purpose. Based on the literature, underlying factors contribute to active minority 
recruitment efforts, specifically actively offering a trial to minority patients. For example, 
researcher perception of barriers influence whether or not minorities are offered trial 
participation (Durant et al., 2007; Simon et al., 2004; Stone, Mauch, & Steger, 1998; Williams & 
Corbie-Smith, 2006). PI motivation also is believed to play a role in successfully recruiting 
minority participants (Wright et al., 2001). Researcher attitudes influence success with minority 
recruitment, likely because those with positive attitudes toward minority inclusion are more 
active in enrolling patients (Williams & Corbie-Smith, 2006). Participants in this study not only 
believe that clinical research is important, but also that it is important to increase minority 
participation in clinical trials. Participants discussed their frustration with barriers to recruiting 
minority participants. Based on the findings of this study, participants’ positive attitudes toward 
minority inclusion are fueled by their desire to ensure equitable access to treatment options 
available in clinical research and their frustration with barriers. These factors likely contribute to 
participants in this study taking an active role in minority recruitment. In addition, participants 
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shared their experiences that go beyond merely offering a trial and shared examples detailing 
ways in which they are personally committed and determined to improve minority participation 
in clinical trials. Participants discussed feeling satisfied with and rewarded by their jobs, more so 
than the industry trends reporting job satisfaction levels of clinical research professionals 
(Korieth and Anderson, 2015). The participants also discussed personal growth as they undergo a 
continuous process of learning through their recruitment efforts. By better understanding their 
patients’ needs and perspectives, participants are better able to be effective at communicating 
cross-culturally. Existing literature does not discuss personal growth or change among clinical 
research staff. For participants in this study, continuous learning is important to being more 
effective in minority recruitment. 
The limited literature discussing intrapersonal elements from a research professional 
perspective is confined to PI and physician attitudes and perceptions regarding clinical research 
or minority inclusion in clinical research. This study offers perspectives from other research 
professionals related to minority inclusion in clinical trials, outside of PIs. The majority of 
participants in this study have responsibility for recruitment within their organizations. They 
have positive perceptions regarding the importance of diversity inclusion in clinical research and 
are personally committed to actively implementing minority recruitment efforts. For research 
organizations focusing on minority recruitment, taking perspectives regarding diversity inclusion 
into account is an important consideration when making hiring decisions. When organizations 
focus on minority recruitment, hiring considerations for recruitment staff should include those 
who believe minority inclusion to be important and thus contribute to a culture of inclusivity 
within the organization. 
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Organizational themes interpreted with literature. One of the key elements to 
successfully recruiting minority participants, which is supported by the literature, is education of 
minority communities through providing disease and general clinical trial education prior to 
presenting a specific trial opportunity (Etkin, Farran, Barnes, & Shah, 2012; Regnante et al., 
2019; The Society for Women’s Health Research & FDA, 2011). Despite recognition of the 
importance of minority community education prior to study-level recruitment activities, such 
action is not being taken ahead of study recruitment activities nor is providing community 
education a common practice at the site level (Livaudais-Toman, Burke, Napoles, & Kaplan, 
2014). Those research sites that are engaged in educating their local communities are providing 
education at the same time as trial recruitment, even when receiving NIH funding or resources 
(Aponte-Rivera et al., 2014; Cook et al., 2005; Germino et al., 2011; Hinton et al., 2010; 
Sturgeon et al., 2018). The success and sustainability of this approach to providing education to 
minority communities is yet to be documented among industry-funded studies. However, NIH 
National Institute on Aging Alzheimer’s Disease Research Centers (ADRCs) and NCI-
designated comprehensive cancer centers provide community education to minority communities 
prior to introducing a clinical trial opportunity in partial fulfillment of the requirements for being 
recognized as a federally designated center and maintaining federal designation status (American 
Cancer Society, 2014; Etkin, Farran, Barnes, & Shah, 2012; USHHS, NIH, 2018, January; 
Regnante et al., 2019).  
Surprisingly, participants in this study discussed how their organizations have made the 
commitment to invest in providing general disease education to minority communities prior to 
discussing a study, despite the fact that this is not common practice even for NIH-funded 
institutions (other than the federally designed ADRCs and NCI comprehensive cancer centers 
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that are stipulated to do so). Educational events are costly and they yield few participants 
(Sturgeon et al., 2018). Additionally, pharmaceutical sponsors are focusing on expediting trial 
enrollment (USHHS, OIG, 2000). Sponsors provide centralized recruitment support on a study-
by-study basis, leaving it up to the research sites to establish a long-term commitment to 
community education, should they wish to do so. The extent of community education being 
provided by sites that conduct industry-sponsored trials is unknown, though presumed scarce or 
non-existent based on the literature that depicts NIH-funded research institutions as not initiating 
community education at all, let alone as a long-term investment (Livaudais-Toman, Burke, 
Napoles, & Kaplan, 2014). This clearly differentiates the participants in this study from research 
staff in both NIH and industry-sponsored sites. Industry stakeholders who attended a recent 
workshop acknowledged that although recommended, community education prior to focusing on 
study recruitment is not occurring with industry-sponsored studies (The Society for Women’s 
Health Research & FDA, 2011). Some interview respondents discussed how this concept was 
fairly new to them as they recently learned about the importance of community education when 
they started focusing on minority recruitment. They ultimately made that change to overcome 
barriers and commit to investing in a long-term commitment to educating their local 
communities and empowering patients to understand their disease and its potential treatment 
options and to be comfortable with the concept of participation in a clinical trial prior to 
presenting a specific trial opportunity. 
Individuals in this study also discussed how their organization demonstrates its 
commitment to minority recruitment by investing in structural enhancements. As described in the 
literature, research center infrastructure impacts the successful enrollment of minority 
participants, including having the appropriate dedicated staff, resources and structure for 
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conducting research activities (Etkin, Farran, Barnes, & Shah, 2012; Ford et al., 2013; Joseph & 
Dohan, 2009; Williams & Corbie-Smith, 2006). Even with these investments and having 
leadership supportive of clinical research initiatives within their organizations, participants 
discussed continuing barriers. Many expressed the need for additional research staff members 
and more language capabilities, which are also discussed in the literature as limiting factors for 
minority recruitment (Durant et al., 2014; Joseph & Dohan, 2009). However, participants also 
shared examples of how their organizations have overcome barriers to improving their research 
infrastructures and have enhanced their capabilities to better meet the needs of diverse patients.  
Participants also discussed organizational contextual characteristics in relation to 
implementation of minority recruitment practices, which are not widely described in the 
literature. Participants in this study work for organizations with a mission related to improving 
healthcare through clinical research, a finding that is to be expected since these organizations 
conduct clinical research. Improving access to clinical research is a component of the 
organizational mission for many of the participants’ organizations. While the literature does not 
discuss the organizational mission statements of clinical research sites, the authors of one study 
reported that research activities are not sufficiently supported when clinical research is not 
incorporated into a research organization’s mission statement (Joseph & Dohan, 2009). Findings 
from this study suggest that both incorporating clinical research and providing access to clinical 
research within a research site’s mission statement are components that promote active minority 
recruitment efforts. This finding is supported by the fact that participants in this study discussed 
recruitment activities being driven by their mission. Believing in the mission was an important 
aspect leading to principles of working in support of carrying out their organization’s mission. 
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Regnante et al. (2019) reported that cancer research centers recruiting a high percentage 
of minority clinical trial participants demonstrate an inclusive organizational culture by 
dedicating leadership roles to diversity and hiring minority staff. In addition to leadership 
support deriving a culture of inclusion, the organizational cultures related to this study’s 
participants also portray an importance and focus on minority recruitment based on co-worker 
attitudes and interactions. Participants’ co-workers help to create an inclusive organizational 
culture that is prevalent across the organization. 
Another characteristic unique about the participating organizations is that they have 
processes that are flexible. This allows their minority recruitment approaches to change based on 
learnings from past experience, as individuals and their co-workers gain a better understanding 
of the patients being recruited and how to better adapt to those patients’ cultural preferences and 
needs. Crosson, Lane, and White (1999) discussed how organizational learning provides a 
competitive advantage. Individuals who participated in this study discussed the enhancements 
that were made based on organizational learning that improved their organizations’ competencies 
and allowed them to improve their recruitment of minority trial participants. 
Community themes interpreted with literature. Although organizations conducting 
clinical research may be located in diverse communities or have a high percentage of diverse 
patients they manage in clinical practice, this does not equate to having access to these diverse 
patients for clinical research. While physical access based on geography may be apparent, many 
barriers preclude research organizations from the successful enrollment of minority patients into 
clinical trials. For example, according to one study, organizational structural barriers prevented 
minority enrollment into clinical research within a safety net hospital that serves a high 
percentage of minority patients (Joseph & Dohan, 2009). Mistrust in the healthcare system 
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and/or clinical research also has prevented clinical research organizations from enrolling 
minority patients into trials (Corbie-Smith, Thomas, Williams, & Moody-Ayers, 1999; Durant et 
al., 2014; Ejiogu et al., 2011; Ford et al., 2013; Roberson, 1994; Swanson & Ward, 1995). 
Similarly, individuals in this study discussed how factors such as mistrust or a lack of 
understanding related to clinical trials come into play that prevent them from enrolling minority 
patients into trials, despite having physical access to patients based on geography. Despite 
geographical location, it still takes time and a concerted effort to overcome the multitude of 
barriers that prevent successful enrollment of minority participants into clinical trials.  
As mistrust is a prominent barrier, participants in this study discussed the many efforts 
they have taken to instill trust in clinical research, as well as a relationship of trust between 
research staff and minority patients. Participants discussed the need for developing and fostering 
long-term, trusting community relationships that start prior to and extend beyond a specific study 
opportunity, and this is facilitated through education. Participants and their research 
organizations engage in these activities despite existing literature indicating that building trusting 
relationships through community education is not common practice outside of the federally 
designated ADRCs and NCI comprehensive cancer centers, as discussed previously (Etkin, 
Farran, Barnes, & Shah, 2012; Livaudais-Toman, Burke, Napoles, & Kaplan, 2014; National 
Academies of Sciences, Engineering, and Medicine, 2016; Regnante et al., 2019). Providing 
general and personalized disease education, coupled with health screenings, is a way to establish 
trust by giving back to the community without asking for anything in return. Participants 
discussed how their immediate motivation behind community education efforts is related to 
developing trust. Recruitment may be their ultimate goal in the future, but their immediate goal 
is to build trust with minority communities. This concept is not widely practiced and is one area 
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in which the participants in this study display an exceptional practice that is unique compared 
with other clinical research sites.  
Research stakeholders have indicated that disease education is important to minority 
patients (The Society for Women’s Health Research & FDA, 2011). Participants in this study 
further validated this and shared that their efforts to empower patients with knowledge and self-
efficacy for managing their diseases was of interest to minority patients. In fact, when discussing 
patient factors that impact access to clinical trials, participants discussed how patients’ 
engagement with managing their health positively impacts their access to trials more than being 
disengaged negatively impacts access. Participants rarely discussed minority patient interest in 
trials in relation to personal benefit, which may suggest that patients aren’t as motivated by 
financial incentives as by becoming engaged with managing their disease. However, one of the 
barriers is access to information. Patients have to first be made aware of details about their 
disease and clinical trials as a potential option to be able to benefit from participation.  
Participants also discussed the role a commonality between research staff and patients 
plays in developing trust. Ensuring research staff are the same race or ethnicity and speak the 
same language as the patients being recruited is recommended for building trust and has been 
successful for enrolling minorities in past studies (Germino et al., 2011; Ford, 2013; Hinton et 
al., 2010; National Academies of Sciences, Engineering, and Medicine, 2016). Also, participants 
emphasized that the PI needs to be involved with recruitment activities. Regnante et al. (2019) 
reported that a physician’s role is important in influencing a patient’s willingness to participate in 
clinical research. Further, trusting relationships between a physician and a patient, as well as 
between a physician and the patient’s family members, contribute toward successfully enrolling 
minority patients in clinical research (Regnante et al., 2019; Wright et al., 2001). Leveraging a 
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patient’s social network is a tactic participants discussed that helps instill trust in clinical 
research. Many of the successful examples of recruiting minorities that have been discussed in 
the literature involve developing community partnerships with key stakeholders as a necessary 
component for building trust among minority communities (Germino et al., 2011; Ejiogu et al., 
2011; Regnante et al., 2019). Participants in this study shared that they partner with community 
stakeholders that have already been established as trusted sources within minority communities, 
such as pastors and minority association leaders. Some participants discussed this approach as 
being their first step in gaining access to minority communities. Interestingly, while this was 
discussed as an important component among participants in this study, as well as reported by 
some of the literature reporting on NIH-funded studies, this approach does not appear to be 
prevalent among industry-funded clinical research sites. According to a white paper published by 
a trade organization representing clinical research sites, the Society for Clinical Research Sites, 
only half of individuals representing research sites that responded to a survey related to success 
factors in recruiting diverse patient populations in clinical studies indicated that they had 
community connections. Yet, individuals representing sites with more community connections 
self-reported more success with enrolling diverse patients into clinical trials than the individuals 
from sites without community connections (Pierre, 2018). Mistrust or disapproval of clinical 
research by a patient’s social network is a known barrier to minority recruitment (Ford et al., 
2008; Swanson & Ward, 1995). Therefore, it would be prudent for researchers to educate and 
build trust among a patient’s social network, including leveraging already trusted sources. One 
way participants mentioned that this is achieved is by including family members in recruitment 
and consent discussions.  
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Finally, culturally sensitive researchers provide a valuable role in the successful 
enrollment of minorities in clinical trials, especially since cultural differences have an effect on 
the communication and understanding of health information (Ejiogu et al., 2011; Ingram, 2012; 
IOM, 2004). However, formalized cultural sensitivity or cultural competency training is not 
always instituted (Boden-Albala et al., 2015). Only six of the 15 participants in this study 
reported having formal cultural competency training requirements at their organizations. 
Participants, however, discussed their personal and organizational commitments to actively 
implementing minority recruitment practices regardless of whether or not formal cultural 
competency training was a requirement within their organizations. Furthermore, formalized 
cultural competency training was not a factor in recruiting minorities in equal or greater 
proportion to the US population in this study. This is in discordance with the findings of the 
author of a recent industry white paper who reported that cultural competency training was a 
contributing factor that enabled sites to have more success with enrolling diverse participants. 
The author also reported that those research sites in which none to most of the staff were 
culturally competent had less success with recruiting diverse patient populations (Pierre, 2018). 
As a measure of ensuring that staff members are culturally competent, research sites may want to 
consider integrating cultural brokers into their research teams. Serving as a connecting link 
between research staff and the communities they serve, this strategy has been found to enhance 
trust, promote cultural understanding among team members and ultimately improve access to 
minority populations (Germino et al., 2011). Rather than discussing formalized cultural 
competency training, participants in this study discussed how understanding and being sensitive 
to other cultures does not necessarily come from institutionalized training. Instead, they 
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discussed the importance of face-to-face interaction with community members and being 
immersed in their culture.  
Interpersonal themes interpreted with literature. Ejiogu et al. (2011) described 
empowering research staff members to take an active role in study-related decision-making by 
soliciting opinions from staff members to inform strategy decisions. This way of working that 
was implemented by the study’s PIs motivated research staff to engage in study activities and 
also promoted staff retention. It was one of many components that led to the successful 
implementation of this longitudinal study in which racially and socioeconomically diverse 
participants were recruited. While not an overarching theme, some participants in this study 
discussed team member satisfaction in relation to being provided autonomy in decision-making. 
The importance of working as a team was a key theme that was divergent from the existing 
literature. Many different aspects of teamwork were discussed, including proactive team 
planning, involving the PI in recruitment activities, learning and problem solving as a team, 
having effective communication across and among teams, as well as having team camaraderie. 
These characteristics of participants’ interpersonal relationships and interactions among their co-
workers provided insight into their organizational cultures and the high regard placed on working 
as a team. Teamwork was important for informing the implementation and refinement of 
minority recruitment practices in this study.  
Individuals in this study conveyed their personal beliefs in the importance of increasing 
minority participation in clinical trials. Through the efforts they take, they also demonstrate a 
personal commitment to providing minority populations with greater access to clinical trials. 
Peer influence is not a factor in these actions that individuals in this study take to promote 
diverse inclusion in clinical trials. This finding is unique in that the clinical trial literature related 
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to minority recruitment does not discuss social influence on minority recruitment efforts. 
Additionally, the clinical trial literature related to the socio-ecological model is primarily 
categorizing motivators and barriers to minority recruitment by providing insights related to a 
patient’s intrapersonal perspectives and interpersonal influences, and not perspectives and 
interpersonal influences among research staff (Frew et al., 2014; Salihu, Wilson, King, Marty, & 
Whiteman, 2015; Wells & Zebrack, 2008). The finding that individuals in this study are not 
influenced by their peers with regard to their efforts taken to actively recruit minority trial 
participants demonstrates that the commitment of these individuals may be due to personal 
attitudes and enabled by organizational contextual factors and teamwork. Although social 
influence related to colleagues external from participants’ organizations was not prevalent, 
participants’ co-workers within their research organizations contribute to a culture of inclusion. 
A combination of the study participant’s attitudes and their co-worker attitudes contribute to a 
social norm within their organization of focusing on minority recruitment.  
While external social influence is not a factor in promoting active minority recruitment 
efforts, participants with a role of PI and/or owner of a research site instead discussed actions 
they take in attempts to encourage their peers in relation to minority recruitment. Interestingly, 
these individuals discussed providing education to their colleagues on clinical research and the 
importance of having diverse representation in clinical trials. Education is also a key practice 
among study participants in their efforts to improve minority participation in trials and build 
trust. As previously mentioned, the clinical trial literature does not cover social influence on 
minority recruitment efforts, so this finding suggests a new contribution to the literature as an 
area for future research with a larger sample size.  
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Given the lack of influence or even discussions taking place among the participants’ 
peers, it is evident that clinical research professionals are not widely focusing on minority 
recruitment. Additionally, according to the literature, many minority physicians do not view 
clinical research as beneficial (Ramirez et al., 2008). PIs and/or owners of a research site 
initiated individual efforts to educate colleagues. This finding provides an opportunity by 
leveraging the finding that social relationships affect behavior (McLeroy, Bibeau, Stecker, & 
Glanz, 1988). Clinical trial stakeholders, such as sponsors, clinical research organizations and 
federal agencies, may want to consider attempting to influence social norms by launching 
education programs targeted toward the healthcare provider community to raise awareness of the 
critical need to improve access to clinical trials among minority populations and to enhance the 
belief in the research process among potential referring physicians.  
Policy themes interpreted with literature. There was a strong sense of obligation 
within participants’ organizations to meet their committed enrollment goals. Participants 
discussed minority enrollment expectations only in the context of study-specific racial or ethnic 
subgroup enrollment numbers required by either the study sponsor or the FDA. In this study, the 
intermittent minority enrollment requirements discussed by participants is to be expected 
because of the focus on expediting trial recruitment and lack of policy mandating enrollment of 
clinically relevant populations in industry-funded trials (USHHS, FDA, 2014; USHHS, FDA, 
2016; USHHS, OIG, 2000). These findings result in a reduced focus on inclusion of diverse 
populations that for some trickles down to the site’s activities where striving to meet enrollment 
targets on a study level becomes a top priority. Rather than enact federal policy, pharmaceutical 
sponsors could start to hold research sites accountable or incorporate minority enrollment targets 
into site contracts that are based on disease prevalence in those populations. This may encourage 
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research sites to focus more on minority recruitment, especially since participants in this study 
discussed the need to meet established enrollment goals as motivation behind fulfilling this 
commitment. In addition, the pressure to meet enrollment goals shifts priorities within 
participating organizations. Although they still engage in actively pursuing efforts to increase 
access to clinical trials among minorities, at a study level, they may need to shift focus to fulfill 
the study requirements. This may also be partly due to the paradigm described by study 
participants in that they take broader efforts to provide education and build trust to encourage 
minority participation, while their goals on a study level are to fulfill the need for enrollment in 
the trial. A shortage of educational campaigns nationwide also may contribute to the efforts 
taken by participants in this study to raise general awareness of clinical trials within minority 
communities. Various resources are available, such as the free “AWARE for All” clinical 
research educational programs held by the non-profit organization “The Center for Information 
and Study on Clinical Research Participation (CISCRP)” (CISCRP, 2020). It is apparent there is 
a need to increase these efforts since lack of awareness of clinical research is a known barrier to 
minority participation in clinical trials (Ejiogu et al., 2011; Ford et al., 2008; Leiter, Diefenbach, 
Doucette, Oh, & Galsky, 2015; Ramirez et al., 2008; Roberson, 1994; Simon et al., 2004).  
On an ad hoc level, expectations and requirements set forth by the trial sponsor or FDA 
to recruit a certain proportion of diverse participants for specific studies influenced minority 
recruitment practices within the participants’ research organizations in this study. If trial 
sponsors expand these expectations beyond select protocols, it may motivate more research sites 
to enhance their capabilities and efforts in recruiting diverse participants. Participants discussed a 
recent shift in the trial landscape with more emphasis being placed on diversity in areas such as 
site selection and expanding the number of protocols with minority enrollment requirements, for 
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example. However, the fact that the participants in this study actively recruit minorities already 
could partially explain the increased focus they reported seeing with trial sponsors.  
Participants discussed barriers to access related to location of research sites and lack of 
diverse healthcare professionals conducting research. Efforts to promote a diverse workforce 
with the skills and interest in conducting clinical research may improve minority participation, as 
a known barrier to minority recruitment is a disparity of minority physicians involved in clinical 
research (Ramirez et al., 2008). This also may contribute towards the availability of known 
research sites with patient demographic populations that represent the prevalence of a disease. 
In spite of strides the NIH has taken to enhance the diversity of clinical trial populations, 
it is evident that more work is required, since disparities in trial participation still exist for NIH-
funded studies (National Academies of Sciences, Engineering, and Medicine, 2016). While the 
sample size was small, participants in this study working for research organizations that also 
receive NIH funding provided examples that support this. Surprisingly, for example, informed 
consent forms are not always translated into Spanish, despite conducting a trial in locations with 
a large Spanish-speaking population. The literature supports that there is still a lack of focus in 
that recruitment goals for individual minority groups are not always set, consent forms and 
recruitment materials often are not translated and cultural competency training is not often 
required for site staff conducting NIH-funded studies (Boden-Albala et al., 2015; Durant et al., 
2007; Durant et al., 2014). It is evident that the NIH may need to provide additional funding and 
support to research sites to enable adherence to and accountability for their policy on achieving 
proportionate trial representation (USHHS, NIH, 2001).  
Unfortunately, the participants discussed that some of the attempts made by trial sponsors 
to stipulate demographic cohort requirements failed. For example, several participants discussed 
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trials with mandated minority cohort enrollment requirements that were canceled because none 
of the sites could recruit the needed numbers. One participant mentioned minority lack of trust 
and a need for education as barriers to recruitment, while another participant discussed study 
design barriers. These examples demonstrate that a concerted effort is needed to enhance 
understanding of successful minority recruitment practices that can be shared with research 
stakeholders across the nation. Pharmaceutical sponsors and contract research organizations need 
to plan for diversity upfront in considering the target demographic representative of the disease 
prevalence and then design the protocol and select research sites in accordance with the target 
patient population. They then need to develop a diversity recruitment strategy and provide 
funding to support these initiatives. Research sites implement minority recruitment practices at a 
local level, and it is critical that they are equipped with the skills and resources to be able to do 
so effectively.  
Consideration of the Socio-Ecological Model  
 As discussed, the socio-ecological model guided this study and themes emerged at each 
level of the model that provided explanation for elements involved in the active implementation 
of minority recruitment practices. When reviewing the findings that represent each level of the 
model, more themes emerged for the intrapersonal and organizational levels of the model. A 
substantial number of findings emerged for the community level of the model. Fewer findings 
emerged that relate to the interpersonal and policy levels of the model. There are two points to 
note in relation to the model and its utility for providing a lens to answer the research questions. 
First, participants in this study represented the intrapersonal level of the model and spoke mainly 
to intrapersonal and organizational components. That is to be expected given the design of the 
study and the interview guide. Had other stakeholders, such as minority patients, participants’ 
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co-workers and pharmaceutical sponsor representatives, also been included in this study, then it 
is anticipated that a substantial amount of additional information would have emerged at the 
community, interpersonal and policy levels. The information shared by participants offered 
unique contributions to the literature at each level of the socio-ecological model, even though 
data were collected from an intrapersonal perspective. Second, while looking at the findings that 
emerged at each level of the socio-ecological model individually offers unique insights, this 
approach also provides a fragmented view of elements involved in active minority recruitment 
practices. Instead, a comprehensive and holistic view facilitating the understanding of effective 
minority recruitment practices is offered when considering the findings at multiple levels in 
relation to one another. This is further explained in the next section discussing the theoretical 
implications for the utilization of the socio-ecological model for this study.  
Theoretical Implication: Interaction of Socio-Ecological Elements Explain the Active 
Implementation of Minority Recruitment Practices 
The socio-ecological model was used as a conceptual framework guiding this study. 
Themes emerged at each level of the model that helped to identify and explain the components 
contributing to the active implementation of minority recruitment practices. The premise of the 
model is environmental change based on interactions between individuals and their environment 
(Bronfenbrenner, 1977; McLeroy, Bibeau, Stecker, & Glanz, 1988). The model further supports 
this study’s findings in that the environment plays a role in influencing behavior and vice versa, 
behavior influences the environment as it relates to minority recruitment. For example, 
participants in this study feel satisfied with their work and rewarded by the positive impact they 
make on patients, indicative of a reciprocal relationship with their environment. At an 
interpersonal level there is a sense of team spirit. They work for organizations that have an 
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inclusive culture. There is a scarcity of efforts at a sponsor or national policy level to educate 
minority communities on clinical trials, and study participants recognize a need to overcome 
barriers such as mistrust. All of these factors play a role in the commitment and actions 
participants take to provide minority patients with access to clinical trials. These results also 
suggest that we need to consider the interaction of components at all levels of the socio-
ecological model for minority recruitment. Although more findings emerged for some levels of 
the model over others due to the nature of obtaining information from an individual perspective, 
it was evident that findings at all levels of the model in combination with each other offer a more 
comprehensive explanation of the elements involved in active minority recruitment practices. 
Thus, these multi-faceted findings reveal that an ecological perspective offers insight into 
improving access to clinical trials and the socio-ecological model provides an opportunity for 
improving minority recruitment practices in the future. This is illustrated graphically in Figure 3.  
 
Figure 3. This figure illustrates the interaction of socio-ecological elements in explaining the 
active implementation of minority recruitment practices for improving access to clinical trials. 
Adapted from McLeroy, K., Bibeau, D., Steckler, A., & Glanz, K. (1988). An ecological 
perspective on health promotion programs. Health Education Quarterly, 15(4), 351-377.  
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Similar to other health promotion interventions, the socio-ecological model only works 
when put into practice. As a means to help facilitate application of findings derived from the 
execution of a socio-ecological model, solutions emerged for improving minority recruitment 
practices that were guided by the implementation of an ecological perspective. Specifically, a 
model for research sites to use to inform the application of minority recruitment practices 
emerged from this study’s findings, which demonstrates how a combination of recommendations 
interacting at multiple levels of the socio-ecological model can be applied practically. 
Practice Implications: Site Action Plan for Making Minority Recruitment a Core 
Competency 
The model that emerged from this study may provide a more comprehensive guide to 
help organizations that conduct clinical research improve their capabilities by creating an 
environment effective for recruiting minority study participants. This model was derived from an 
ecological perspective, and thus by making minority recruitment a site’s core competency, the 
focus is on environmental system change with the ultimate goal of improving minority access to 
clinical trials. This model, the “E3 Model”, consists of three components: 
• Establish: Commit to prepare the foundation 
• Engage: Invest in partnering with the community  
• Execute: Prepare to deliver, refine, repeat 
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Figure 4. This figure illustrates the E3 Model site action plan for making  
minority recruitment a core competency. 
 
Establish: Commit to prepare the foundation. 
Commitment. First, it became evident that sites need to establish themselves internally. 
They need to make the commitment to prepare a foundation for minority recruitment within their 
organizations. For example, they need to articulate and gain buy-in for the value proposition 
across the board from leadership to front-line staff. It cannot just be the top executives who 
believe that minority recruitment is important. Research and diversity need to be incorporated 
into the organization’s mission and the ways of working need to support that mission, including 
recruiting people who believe in and can help foster a culture of inclusivity. Appropriate training 
measures need to be in place to promote effective communication with patients, as well as with 
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other staff members internally. An illustration depicting the required measures for establishing 
the foundation is represented in Figure 5. 
 
 
 
Figure 5. This figure illustrates the “Establish” component of the E3 Model site action plan  
for making minority recruitment a core competency. 
 
Only after the foundation is established will sites be ready to engage with the community.  
Engage: Invest in partnering with the community. 
Long-term investment with developing community relationships. The next component 
of the E3 Model is to engage in investing in partnerships with the community. This requires two 
main actions. First, listen and understand and second, educate and build trust. Figure 6 illustrates 
the engagement component of the E3 Model. 
  173	
 
 
Figure 6. This figure illustrates the “Engage” component of the E3 Model site action  
plan for making minority recruitment a core competency. 
 
Listen and understand. The first step in partnering with the community to develop long-
term relationships is to obtain an understanding of the preferences and culture of the local 
community. This is done by being immersed in an attempt to appreciate and learn other cultures, 
as well as by soliciting input directly from community members.  
Educate and build trust. Once an understanding has been established, the second step in 
partnering with the community to develop long-term relationships is to start building trust and 
forming relationships by providing education, leveraging existing trusted sources as a catalyst for 
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delivery. This education needs to be personalized. For example, high blood pressure and diabetes 
are asymptomatic diseases and people with these conditions may be asymptomatic. The first step 
should be to educate people on the importance of screening and what each individual’s results 
mean and tie it back to the importance of why that should matter to each individual. One critical 
success factor for this component is that recruitment is not the primary focus at this stage. The 
primary focus is empowering patients and their families with the knowledge and self-efficacy to 
understand and manage their disease and treatment options, including clinical trials as a potential 
option.  
Execute: Prepare to deliver, refine, repeat.  
Putting preparation to work. The next component of the E3 Model is to execute and 
prepare to deliver, refine and repeat. Once the foundational core has been established and 
research sites are actively engaged in developing relationships with the community, only at this 
point is it time to put preparations to work and focus on recruitment for a specific study. At this 
point, when research professionals are out in the community educating on management for a 
specific disease, the notion of a clinical trial has already been discussed as a potential option for 
consideration. For example, the assessments that are required have been discussed and 
community member feedback and questions have already been solicited and responded to. At 
this point, a relationship and basic understanding has been established and discussions about the 
potential for enrollment in a specific trial can be offered. It’s also important that an ongoing 
communication across teams and with the community is maintained in order to refine and 
leverage learning for future success as an ongoing process. Figure 7 illustrates the components 
for the execution phase of the E3 Model. 
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Figure 7. This figure illustrates the “Execute” component of the E3 Model site action  
plan for making minority recruitment a core competency. 
 
While future research is required to assess the impact of the E3 Model, the shared goals 
with successfully implementing the E3 Model into practice include site staff satisfaction and 
growth, improved sponsor success, improved community and population health, greater trial 
generalizability, business growth and future funding.  
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Figure 8. This figure illustrates the E3 Model site action plan for making minority  
recruitment a core competency. 
 
Limitations 
 There are limitations to this study. First, the sample is a convenience sample, identified 
from publicly available data. For this reason, there is a potential for self-selection bias from 
participants interested in this topic. Also, data collected from the interviews reflect self-reported 
perceptions regarding organizational, community, interpersonal and policy elements. Finally, as 
this is a qualitative study, the results are not generalizable and an assumption was made that 
study participants honestly conveyed their experiences and perspectives. Participants did 
represent various roles across the full spectrum of clinical research organizational settings in 
both rural and urban areas, offered trials across a variety of therapeutic areas and had differing 
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historical performance in minority enrollment. This allowed for obtaining a broad range of 
perspectives from research stakeholders who were able to provide their first-hand experiences in 
recruiting minorities. However, the small sample size selected through purposeful sampling 
limits transferability of findings. Instead, readers will be able to apply findings to their own 
unique situations to make transferability judgments on their own.  
Future Research 
 There are several opportunities for future research that emerged during data analysis. 
While not a dominant theme, participants discussed the importance of recruiters having certain 
personality characteristics in relation to minority recruitment. They also discussed being 
passionate about what they do and going “above and beyond.” Future research could be designed 
to better understand how personality characteristics contribute to recruitment efforts and job 
satisfaction as an implication for future hiring decisions.  
 As the findings in this study are based solely on the interview respondent’s perceptions, 
future research could involve additional stakeholders to represent direct perspectives at each of 
the socio-ecological model levels. For example, minority patient preferences were conveyed as 
experienced by the interview respondents. Although perspectives shared, such as mistrust of 
research and interest in learning about clinical trials, are similarly documented in the literature, 
obtaining direct input from minority community members would offer a more comprehensive 
view of community factors, for example.  
 The themes presented at the intrapersonal level were consistent across the participants 
that represented various roles within their organizations, except for several occurrences in which 
the responses from the participant in a non-patient role varied. However, there was also an 
apparent difference in responses between roles with regards to other information shared at the 
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intrapersonal level that was not considered an overarching theme. The PIs’ and owners’ 
responses were consistent with one another, yet varied with the recruitment leads’ responses in 
some areas. This also occurred at the interpersonal level as it relates to peer influence regarding 
minority recruitment with the PIs and owners actively encouraging others. Future research could 
explore these differences in responses between roles.  
 This study was bound by recruitment practices and, therefore, retention of minority 
participants was not incorporated into the interview guide and thus not a main focus for the 
study. As these participants shared their gainful knowledge and perspectives related to minority 
recruitment, future research could be conducted to understand how these participants promote 
retention.  
 Finally, while many participants in this study recruit a high percentage of minority 
clinical trial participants, this was not a specification in the eligibility criteria for study 
participation. Participants representing organizations with lower historical minority recruitment 
performance still offered indistinguishable insights related to their minority recruitment 
commitment and practices. For this reason, future research could focus on success not by 
excluding individuals that have not historically recruited a high number of minority trial 
participants and instead conduct a focus group or survey with these same participants to establish 
the E3 Model as a model for success. 
Conclusion 
 In conclusion, guided by the socio-ecological model, the results of this research 
demonstrate that environmental change can provide a premise for improving access to clinical 
trials among minority populations. This research also provides practical guidance for research 
sites to implement minority recruitment practices by implementing the E3 Model. To effectively 
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implement the E3 Model will require a shift in the standard approach to recruitment by moving 
from a study-level recruitment focus to empowering patients and developing trust as the core 
focus, which will require environmental change. The participants in this study demonstrated that 
it is possible, even with their current resources, to create an environment conducive for 
improving minority access to clinical trials.  
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APPENDIX A 
 
INTERVIEW GUIDE 
 
 
1. Tell me about yourself. 
a. How did you get into clinical trials? 
 
Transition: First, I want to get a general sense of the wider picture related to recruitment in 
terms of the societal and environmental landscape. Please answer this next question considering 
this broader aspect.  
 
2. What do you see playing a role in your recruitment efforts? 
a. How about with minority recruitment? 
b. What concerns do you have with what is happening with healthcare in this 
country right now and how that could impact recruitment? 
 
3. Talk to me about your organization’s mission.  
 
4. Walk me through your organization’s approach to recruitment (in general).  
a. What’s working? Not working? 
b. If your organization had unlimited resources, what would you do differently to 
make your organization the best it could possibly be with regards to minority 
recruitment? 
c. How does your organization engage with the community?  
i. How responsive do patients seem to be with your outreach efforts? 
ii. How have you changed what you do based on what you’ve learned? 
 
5. What types of discussions are happening amongst your colleagues with regards to minority 
recruitment? 
a. Can you share an example of when one of your colleagues encouraged you to 
focus on minority recruitment?  
 
6. When tasked with recruiting for a new study, what is it like for you? 
a. How do you react personally?  
b. What about others on the team – what’s it like for them?  
 
7. What are your perceptions with recruiting for clinical trials (in general)?  
a. What about with minority recruitment? 
 
8. What additional ideas do you have that we haven’t discussed that will help me better 
understand what is involved when you specifically focus on minority recruitment? 
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Demographic Information 
  
1. How many years of clinical research experience do you have?   
2. How long have you been involved with promoting minority recruitment? 
3. How long have you been with your current organization? 
4. What is your current title?  
a. In your role, do you speak directly with potential clinical trial participants? 
5. [If answered ‘yes’ to question 4a only] Do you speak a language fluently other than English?    
6. [If answered ‘yes’ to question 5 only] What other languages do you speak? 
7. What is your gender? 
8. From an ethnicity perspective, would you categorize yourself as Hispanic, Latino or Spanish 
origin?  
9. Which of the following racial designations best describes you? You can select one or more: 
a. White 
b. Black or African American 
c. Asian 
d. Native Hawaiian or Other Pacific Islander 
e. American Indian or Alaska Native 
10. What type of organization do you currently work for: 
a. Dedicated research institution 
b. Academic medical center/University hospital 
c. Community physician/medical practice 
11. Which of the following best describes the geographical area of your clinical trial setting? 
a. Urban [within city limits of a metropolitan area’s central city] 
b. Suburban [part of a metropolitan area that is not in that metropolitan area’s central 
city] 
c. Rural [not part of a metropolitan area] 
12. What other funding outside of biopharmaceutical sponsors do you receive for conducting 
clinical trials? 
13. What are the therapeutic areas of the trials that you typically conduct? 
14. Are racial/ethnic minorities included on your research team, specifically in the following 
roles: 
[Minority defined as a race and ethnicity other than non-Hispanic White] 
a. Principal Investigator 
b. Sub Investigator 
c. Recruiter 
d. Study coordinator 
e. Study nurse 
15. Is it common practice for minority recruitment goals to be set within your organization? 
16. Are staff members required to take cultural competency training? 
17. Approximately what percentage of your patients who participate in clinical trials are 
minorities? 
18. Does this reflect the population demographics in your community? 
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INFORMED CONSENT FORM 
 
 
 
 
  203	
 
 
  
  204	
  
  205	
APPENDIX C 
 
RESEARCHER POSITIONING STATEMENT 
 
 
Researchers recognize that their own background shapes their interpretation, and they 
“position themselves” in the research to acknowledge how their interpretation flows from 
their own personal, cultural, and historical experiences. Thus the researchers make an 
interpretation of what they find, an interpretation shaped by their own experiences and 
background. The researchers intent, then, is to make sense of the meanings others have 
about the world (Creswell, 2013, p. 25). 
As a result of being responsible for providing strategic direction or implementation 
oversight of patient recruitment programs for pharmaceutical-sponsored clinical trials for more 
than 10 years, I have first-hand experience and understanding of the pressures related to meeting 
and exceeding recruitment timelines. These pressures are understandable, given the financial 
impact tied to recruitment performance for sponsors, contract research organizations and 
research sites. In my experience, considerations for inclusion of clinically relevant populations 
related to race or ethnicity have historically been limited to a handful of studies in which 
demographic-specific cohorts were the result of a mandate by the Food and Drug Administration.   
The vast majority of trial participants are non-Hispanic white, even though industry 
stakeholders and governmental agencies have recognized a need for greater diversity in 
recruitment. More recently, I have engaged in discussions with diversity and inclusion leaders 
whose roles are to improve diversity in the pharmaceutical-sponsored clinical trials in which they 
participate. Unfortunately, they face some of the same barriers I have encountered when 
attempting to implement a diversity strategy plan on a trial level. While they are in alignment on 
the necessity of diversity inclusion, there is hesitation regarding the return on investment and the 
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potential impact of time and cost on a trial. While that can be frustrating, I have an appreciation 
for the difficulties of operationalizing diversity inclusion on a trial level.  
I grew up in a non-diverse area and did not appreciate social injustice until becoming an 
adult. In addition, my first-hand experiences with people in my life who have different values 
and beliefs regarding utilization of the healthcare system from mine opened my eyes to 
recognizing cultural and socio-economic differences that may impact their beliefs and attitudes 
about healthcare. That is when I began developing a strong interest in how different cultures 
assimilate healthcare information, healthcare disparities among minority cultures, and how to 
address these disparities by providing culturally relevant education through multi-cultural 
marketing initiatives. My professional background in clinical trial recruitment led to combining 
my interest in multi-cultural marketing with opportunities for addressing inequalities by focusing 
on improving access to clinical trials within diverse populations.  
After reading the literature regarding minority recruitment in clinical trials, I was curious 
about what motivates researchers who conduct industry-sponsored trials and who actively focus 
on recruiting minority trial participants, since these researchers are not mandated to do so. I 
assumed that it is not just one reason, but that many different factors could be at play, and the 
socio-ecological model allowed for observing many elements in this regard. I did not want to 
incorporate my preconceived thoughts into the study as to what the motivation or other elements 
may be that are involved when researchers actively recruit minorities when not mandated to do 
so. Therefore, the interview guide was carefully designed to be very broad to allow participants 
to provide a wide view of their perceptions and experiences on this topic.  
My professional background has afforded me experience with developing recruitment 
strategies, including strategies specific to recruiting minority populations. I do not have 
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experience working at a research site and hope that discussing the practical minority recruitment 
experiences of individuals who work at research sites will deepen my knowledge in this area and 
give me a better understanding of related activities that take place at a research site level. I would 
like to be able to be a part of moving the needle from recognizing the problem, to discussing and 
planning for change, to actually implementing a successful change initiative that will result in a 
more proportionate demographic representation in biopharmaceutical-sponsored research.  
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